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                  The human apolipoprotein B mRNA editing enzyme catalytic peptide-like 3 
(APOBEC3; A3) family of proteins are a family of seven cytidine deaminases (A3A, A3B, A3C, 
A3D, A3F, A3G and A3H) that restrict certain viral infections. These innate defense factors are 
best known for their ability to restrict the replication of human immunodeficiency virus type 1 
(HIV-1) lacking a functional Vif protein (HIV-1Δvif) through the deamination of cytidine 
residues to uridines during reverse transcription, ultimately leading to lethal G-to-A changes in 
the viral genome. The best studied of the A3 proteins has been A3G because of its potent activity 
against HIV-1Δvif. However, one member of this family, A3A, has biological properties that 
make it unique among the A3 proteins. 
                 Despite potent restriction activity when expressed in myeloid cells, human A3A 
(hA3A) is generally known lacking inhibitory function towards HIV-1Δvif. Previous studies in 
our laboratory have shown that rhesus macaque A3A (rhA3A) is capable of restricting both 
simian–human immunodeficiency virus lacking vif gene (SHIVΔvif) and human 
immunodeficiency virus lacking vif gene (HIV-1Δvif) to a greater extent than hA3A. Chimeric 
studies by substituting amino acids 25–33 (AC loop 1 region) from rhA3A into hA3A showed 
that this region is critical in determining the restriction pattern against lentiviruses. 
                 Further studies identified three Old World Monkey A3As that were able to restrict 
HIV-1 replication. Restriction assays with various A3As from hominids, New World monkeys, 
and Old World monkeys found that agmA3A and colA3A restricted the replication of SHIVΔvif 
and that all three Old World monkey A3A proteins (agmA3A, colA3A, and rhA3A) restricted 
HIV-1Δvif to some extent. More impressively, it is also showed that the A3A protein from the 
black and white colobus monkey (mantled guereza; Colobus guereza; colA3A) potently inhibited 
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not only HIV-1Δvif replication but also wild-type HIV- 1 in producer cells. Since previous 
studies indicated the importance of AC loop 1 region in determining the restriction ability and 
our sequence alignment analysis showed that A3A proteins from Mandrillus sphinx (mndA3A) 
and Cercopithecus neglectus (debA3A) had an AC-loop1 region that was almost identical to 
colA3A, we tested the restriction ability of mndA3A and debA3A. The restriction assay showed 
that both debA3A and mndA3A restricted HIV-1 similar as colA3A. 
                 Next, we used chimeric protein and amino acid deletion studies to show that AC loop 
1 region, especially the 27WVS29 motif, is the key determinant for HIV-1 and AAV-2 restriction. 
First, by fusing the first 100 amino acids of colA3A and the C-terminal region of hA3A (h1–100 
colA3A), or the first 100 amino acids of hA3A and the C-terminal region of colA3A (col1–
100hA3A), we found that the N-terminal domain of colA3A contains the determinants for HIV-1 
restriction. To further confirm that, we truncated the C-terminal off and constructed the mutant 
proteins that expressed only the N-terminal 100 amino acids (colA3A1–100, mndA3A1–100, 
debA3A1–100). The truncated colA3A, mndA3A and debA3A proteins were all able to restrict 
HIV-1 replication. We then narrowed the region down by examining chimeric proteins with the 
N-terminal 75, 50 and 33 amino acids of colA3A fused to hA3A (col1–75hA3A, col1–50hA3A, and 
col1–33hA3A). The results indicated that the first 33 amino acids harbor the critical determinants 
for HIV-1 restriction. As previous experiments indicate the importance of the AC loop 1 region, 
a chimeric hA3A containing the AC Loop1 region of mndA3A (mnd25–33hA3A) was made.  
Restriction assays revealed that the mnd25–33hA3A chimera was able to restrict HIV-1, indicating 
that the AC Loop1 region of mndA3A was critical to its restriction properties. As the hominids 
have a three amino acid deletion in this region of A3A, we constructed a chimeric hA3A with the 
WVS motif and found that this insertion completely restored the antiviral activity of hA3A. In 
v 
addition, insertion of “WVS” or AC Loop-1 region into hA3A also changed the restriction 
pattern of adeno-associated virus 2 (AAV-2). Therefore, we conclude that this WVS motif is the 
key for both retrovirus and parvovirus restriction.  
                 As we found that the WVS motif in the AC loop 1 region plays a key role in HIV-1 
restriction, we determined the role of each of these three amino acids in inhibiting HIV-1 
replication. We constructed a series of single amino acid substitutions and single/double deletion 
mutants in this region and performed restriction assays on these mutants. The results suggested 
that the nature (charge and hydrophobicity) of the three amino acids was not as important as the 
length for restriction of HIV-1. Finally, we confirmed this by substituting the WVS motif with 
either AAA or GGG, and found that both hA3A[27AAA29] and hA3A[27GGG29] were able to 
inhibit HIV to the level similar as hA3A[27WVS29]. 
                 Finally, we explored the mechanism of hA3A[27WVS29] restriction of HIV-1 
replication. First, we examined the viral replication in producer cells. We determined the viral 
protein synthesis in producer cells, using p24 and pulse-chase analysis, were similar in controls 
and cells expressing hA3A[27WVS29]. Next, we excluded the possibility of subcellular 
localization contributing to defective viruses production as hA3A and hA3A[27WVS29] were 
both expressed in cytoplasm and the nucleus at similar level in producer cells. Further, we 
examined the viral RNA packaging and found that viral RNA was packaged at similar levels in 
in progeny viruses from both control and hA3A[27WVS29]  expressing cells. In addition, we 
showed that the viral reverse transcriptase enzyme activity of the progeny viruses was not 
affected by the presence of hA3A[27WVS29]. We next examined restriction in target cells. We 
first confirmed that the viral replication was inhibited in target cells by showing that the viral 
protein biosynthesis was significantly lower in target cells using pulse-chase experiments. We 
vi 
also excluded that canonical hypermutation contributed to the restriction. We found the levels of 
early and late reverse transcription products were decreased approximately 10-fold in the 
presence of hA3A[27WVS29]. This was also reflected in decreased viral integration and viral 
transcripts in the target cell. Thus, we concluded that the restriction of HIV-1 by 
hA3A[27WVS29] occurred at the level of reverse transcription in the target cells. 
                 In summary, we were able to restore the ability of hA3A to restrict HIV-1 and abolish 
the ability of hA3A to restrict AAV-2 by inserting only three amino acids in the AC loop 1 
region. This reveals that the AC loop 1 region harbors key determinants for both retrovirus and 
parvovirus restriction, and provides promising preliminary data for further translational 
application such as gene therapy.  
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Chapter I : Introduction 
A HIV-1   
    1. HIV-1 epidemic  
                 Human immunodeficiency virus type 1 (HIV-1) infection of humans, which causes 
acquired immunodeficiency syndrome (AIDS), has been one of the most devastating pandemics 
and remains a global challenge (Douek, Roederer, & Koup, 2009; Weiss, 1993). The UNAIDS 
Global AIDS update 2015 from the World Health Organization (WHO) states that there are 
approximately 36.7 million [34.0 million–39.8 million] people currently living with HIV-1 with 
70% of infected individuals residing in Sub-Saharan Africa. The global adult HIV prevalence up 
to 2015 is shown in Figure 1. This number has gradually increased due to emerging new 
infections and longer life spans of HIV-1 patients. Despite decades of global efforts in 
controlling this disease, 35 millions people have died of AIDS since the first case reported in 
1981 (UNAIDS, 2015a, 2015b, 2016). HIV-1 remains leading cause of death worldwide and the 
number one killer in Sub-Saharan Africa. It also continues to be a major challenge in United 
States (U.S.), with approximately 1.2 million people living with HIV-1 in the U.S., with 
approximately 40,000 new infections per year, and roughly 18,000 deaths from AIDS related 
complications in 2015 (CDC, 2016).  HIV-1 epidemic in US is shown in Figure 2. It has been 
estimated that about 16% of the HIV-1 positive people (17.1 million) worldwide are not aware of 
their infection due the asymptomatic early stage of the disease, which contributes to the 
dissemination of this disease.  
 








Figure 1. Global adult HIV prevalence, 2015. UNAIDS Global AIDS update 2015 from the 
World Health Organization (WHO) states that there are approximately 36.7 million [34.0 
million–39.8 million] people currently living with HIV-1 with 70% of infected individuals 
















Figure 2. HIV diagnoses in US. Approximately 1.2 million people are currently living with HIV-
1 in the U.S., with nearly 40,000 new infections per year, and 13,000 deaths from AIDS-related 























                 HIV-1 is a single-stranded, positive-sense, enveloped RNA lentivirus. There are two 
types of HIV that have been characterized: HIV-1 and HIV-2. HIV-1 can be subdivided into four  
groups: M (main), O (outlier), N (non-M/non-O), and P (pending the identification of further 
human cases). HIV-1 group M was initially discovered and is the cause of the majority of HIV-1 
deaths globally. The HIV-1 group M viruses predominate and are responsible for the AIDS 
pandemic (more than 90% of HIV/AIDS cases) and they can be further subdivided into subtypes 
A, B, C, D, F, G, H, J and K based on genetic sequence data (Gilbert et al., 2003). Group O is 
usually found in West-central Africa. It is mostly found in Cameroon, where 2% of HIV-positive 
samples were from Group O (Peeters et al., 1997). Group N was isolated from a dead patient in 
1998. This variant stood out since it reacted with an envelope antigen from SIVcpz rather than 
with those of Group M or Group O (Mourez, Simon, & Plantier, 2013). Group P is the most 
recently identified HIV-1 subtype that has greater similarity to a simian immunodeficiency virus 
recently discovered in wild gorillas (SIVgor). The patient shows no signs of AIDS and remains 
untreated (News, 2009). HIV-2 is less virulent and transmissible. It can be further subdivided 
into A to H. The global distribution of HIV subtypes prevalence is shown in Figure 3.  
                 HIV-1 infects various cellular components of the immune system that are central to 
many immune responses, including CD4+ T cells, macrophages, and dendritic cells. Figure 4 is 
an artificially colored scanning electron micrograph of an HIV-1 particle (in green) budding 
from a cultured lymphocyte. 
                 The clinical course of HIV-1 infected typical progressor can be divided into three 
distinct phases as shown in Figure 5. These include the acute seroconversion (primary stage of 
infection), asymptomatic stage of infection (clinical latency), and finally AIDS phase of disease. 









Figure 3. Global prevalence of all HIV-1 genetic subtypes and recombinants. Subtype C is the 



















1/26/17, 10:18 AMHiv+subtype+image.png 1,045×745 pixels











Figure 4. An artificially colored scanning electron micrograph of an HIV-1 particle (in green) 

























Figure 5. The clinical course of HIV-1 infection. A typical progressor (untreated) includs the 
acute seroconversion (primary stage of infection), asymptomatic stage of infection (clinical 
latency), and finally AIDS phase of disease (Adapted from Pantaleo, G et al. 1993 New England 

















infection. During this period, virus undergoes exponential replication and the number of CD4+ T 
cells declines. Concurrently, virus circulates via the bloodstream to different tissues of the body  
including lymphoid organs such as the lymph nodes, spleen, and gut associated lymphoid tissue 
(GALT), brain, and kidney. The formation of reservoirs and insertion of the proviral genome into 
the host chromosomes are some of the reasons why this virus is so difficult to eradicate. The high 
viremia during the primary phase of infection results in immune responses with anti-HIV-1 
antibodies and CD8+ T-cell responses. Concurrently with the development of immune response, 
the plasma viral loads decrease, and the circulating CD4+ T cell levels rebounds. The primary 
stage of infection varies from weeks to months. The asymptomatic phase is associated with 
clinical normality with little or no symptoms. The immune response against HIV-1 during this 
stage is vigorous and able to keep the viral load at a “relatively” steady level. However, the level 
of circulating CD4+ T cells steadily decline over time. When the CD4+ T-cell counts drop to less 
than 200/µL, it marks the initiation of the AIDS phase of the disease. An infected individual is 
also classified as being in the AIDS phase of disease if they are HIV-1 positive and have an 
AIDS-defining conditio. In a typical progressor who is untreated, the median time from infection 
to the onset of AIDS is approximately 10 years (Stevenson, 2003). At this point, the immune 
system has been exhausted and the patients become susceptible to various opportunistic 
infections (OIs). The common OIs of AIDS patients are listed in Table 1.  
                 HIV-1 infection leads to the depletion of CD4+ T cells through several mechanisms. 
Infected cells can be directly killed by replicating virus or be eliminated due to recognition by 
CD8+ cytotoxic lymphocytes. HIV-1 can also kill uninfected bystander cells, causing them to die 
through apoptosis (Cox & Siliciano, 2014; Finkel et al., 1995; Garg, Mohl, & Joshi, 2012; 
Roshal, Zhu, & Planelles, 2001). When the levels of CD4+ T cells decline below a critical level 
14 
Table 1    Opportunistic Infections of AIDS patients 
 
Candidiasis of bronchi, trachea, esophagus, or lungs 
Invasive cervical cancer 
Coccidioidomycosis 
Cryptococcosis 
Cryptosporidiosis, chronic intestinal (greater than 1 month's duration) 
Cytomegalovirus disease (particularly CMV retinitis) 
Encephalopathy, HIV-related 
Herpes simplex: chronic ulcer(s) (greater than 1 month's duration); or bronchitis, pneumonitis, 
or esophagitis 
Histoplasmosis 
Isosporiasis, chronic intestinal (greater than 1 month's duration) 
Kaposi's sarcoma 
Lymphoma, multiple forms 
Mycobacterium avium complex 
Tuberculosis 
Pneumocystis carinii pneumonia 
Pneumonia, recurrent 
Progressive multifocal leukoencephalopathy 
Salmonella septicemia, recurrent 
Toxoplasmosis of brain 
Wasting syndrome due to HIV 
Progressive multifocal leukoencephalopathy 
Salmonella septicemia, recurrent 
Toxoplasmosis of brain 
Wasting syndrome due to HIV 
Table 1    Opportunistic Infections of AIDS patients 
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(200/µL), cell-mediated immunity becomes incapable of keeping common opportunistic 
infections under control. Ultimately, the elimination of CD4+ T cells leads to the collapse of the 
immune system, resulting in a progressive susceptibility to various OIs, tumors, and ultimately 
death (Kumar, Abbas, Aster, & Robbins, 2013).  
 
    3. HIV-1 structure and genome 
                 HIV-1 is an enveloped virus with a diameter of approximately 110-120 nm. Two 
identical, positive, single-stranded RNAs code for the nine viral genes essential for viral 
replication including reverse transcriptase, proteases, ribonuclease and integrase, are enclosed by 
a conical shaped capsid composed of 2000 copies of viral capsid p24 protein. This capsid is 
further packaged by a matrix protein composed of p17, which supports the integrity of the virion. 
The lipid envelope, which is derived from host cell plasma membrane during viral egress, 
contains the viral glycoprotein gp120/gp41 heterodimers that dictate viral tropism and virus entry 
(Chan, Fass, Berger, & Kim, 1997; Klein & Bjorkman, 2010). The structure of HIV-1 genome 
and virion is represented in Figure 6. 
                 The HIV-1 RNA genome consists of two long terminal repeats (LTR) at both ends, 
and nine genes (gag, pol and env; six accessory regulatory genes: tat, rev, nef, vif, vpr, and vpu 
(or vpx in HIV-2). The gag, pol and env encode for precursor molecules that are further cleaved 
by viral or cellular proteases into structural proteins, which are required for production of 
infectious virions. The Tat and Rev proteins are considered regulatory proteins, whereas Vpu, 
Vif, Vpr and Nef counter host defense mechanism. The corresponding functions and localization 









Figure 6. Structure of HIV-1 Genome and Virion. HIV-1 is an enveloped virus with a diameter 
of approximately 110-120 nm. Two identical, positive, single-stranded RNAs code for the nine 
viral genes essential for viral replication including reverse transcriptase, proteases, ribonuclease 
and integrase, are enclosed by a conical shaped capsid composed of 2000 copies of viral capsid 
p24 protein. This capsid is further packaged by a matrix protein composed of p17, which 
supports the integrity of the virion. The lipid envelope, which is derived from host cell plasma 
membrane during viral egress, contains the viral glycoprotein gp120/gp41 heterodimers that 
dictate viral tropism and virus entry. 
  








































Figure 7    HIV proteins and their size, funtion, and localization 
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Gag (group specific antigen) 
                 The Gag polyprotein is the main structural protein of HIV-1. Gag is translated from 
the unspliced full-length viral mRNA transcript of 9kb. Approximately 95% of the translation 
products from the full length viral RNA is the Gag precursor. A ribosomal frameshift signal at 
the 3’ end of the gag results in 5% of translation products as Gag-Pro-Pol. After translation, the 
Gag polyprotein hijacks the endosomal-sorting complexes required for transport (ESCRT) 
system (Carlton & Martin-Serrano, 2009; Hurley, 2010; Hurley & Hanson, 2010) which interacts 
with other cellular trafficking proteins, and packages two copies of viral genome to form a 
spherical array, interspersed by Gag and Gag-Pro-Pol polyproteins at the budding site of the cell 
membrane (Bell & Lever, 2013; Lever, 2007). During maturation, the 55kDa Gag polyprotein is 
cleaved into four components matrix (MA or p17), capsid (CA or p24), nucleocapsid (NC or p7), 
and C terminus p6 (Briggs & Krausslich, 2011; Briggs et al., 2009; Engelman & Cherepanov, 
2012; Ganser-Pornillos, Yeager, & Sundquist, 2008; Xue, Mizianty, Kurgan, & Uversky, 2012). 
The HIV-1 Gag structure and related functions are shown in Figure 8. 
MA (matrix protein) 
                 The MA protein originates from the full-length p55 precursor and is cleaved into the 
mature p17. The folded MA protein consist of five α-helices, a short 310 helix (310 helix is a type 
of secondary structure found in proteins and polypeptides. It is the fourth most common type 
observed, following α-helices, β-sheets and reverse turns. The amino acids in a 310-helix are 
arranged in a right-handed helical structure, with three residues per turn, and ten atoms per ring), 
and a three-strand mixed β-sheet (Massiah et al., 1994). MA can form trimers and into higher 
ordered hexamers (Alfadhi, Barklis, & Barklis, 2009; Alfadhli, Huseby, Kapit, Colman, & 







Figure 8: HIV Gag structure and functions. High-resolution structures of the major domains of 
Gag: matrix (MA), capsid (CA), nucleocapsid (NC) and p6. The major functions of each domain 
are also listed: MA is involved in Gag targeting, membrane binding (requires N terminal 
myristylation of MA), and envelope (Env) glycoprotein incorporation; CA participates in Gag 
assembly, conical capsid core formation, and regulation of the nuclear import of viral DNA. The 
CANTD contains a β-hairpin and cyclophilin A (CYPA)-binding loop that is rich in proline; the 
CACTD contains the major homology region (MHR). CANTD and CACTD are connected by a short, 
flexible interdomain linker which is not shown. Spacer peptide 1 (SP1) serves in Gag assembly; 
NC contains two zinc-finger domains that allow it to participate in RNA encapsidation, Gag 
assembly, and acts as an RNA chaperone; p6 is involved in ESCRT recuirment and in Vpr 
incorporation (Freed, E. O. (2015) HIV-1 assembly, release and maturation. Nature Reviews 













cytoplasmic tail of the Env gp41 and facilitating the incorporation of Env into the virion. As part 
of the Gag polyprotein, MA attaches Gag to the plasma membrane for budding, and also helps 
recruit other viral and host factors. Co-translational myristoylation of the Gag protein at the 
penultimate glycine residue of MA plays an important role in targeting Gag protein to the 
particle assembly sites-plasma membrane (Morikawa, Hockley, Nermut, & Jones, 2000). The N-
terminal myristoylated MA domain myr (+)MA mediates membrane binding by triggering the 
interactions with phosphatidylinositol 4,5-bisphosphate in the memberane (Chukkapalli & Ono, 
2011; Freed, 2015; H. Li, Dou, Ding, & Spearman, 2007; Ono, 2009). In addition, it has been 
identified that myristoylation is essential for Gag-Gag multimerization in living cells (H. Li et 
al., 2007). When cleaved, it fills the space between the lipid envelope and the capsid of the virion 
(Datta et al., 2007; Ghanam, Samal, Fernandez, & Saad, 2012; Hurley, Boura, Carlson, & 
Rozycki, 2010).  
 
CA (capsid protein) 
                 The capsid protein (p24) originates from p55, p41, and p25. The CA is the most 
abundant protein in the virion with approximately 2000 copies of p24 per virion. It forms both 
hexameric and pentameric rings, which are essential for production of the conical shaped mature 
core (Campbell & Hope, 2015; Mateu, 2009, 2013; X. Meng et al., 2012; Pornillos et al., 2009; 
Pornillos, Ganser-Pornillos, & Yeager, 2011; von Schwedler, Stray, Garrus, & Sundquist, 2003). 
The capsid protein contains two domains that are connected by a flexible hinge: an N-terminal 
domain (CANTD) containing seven α-helices followed by a proline rich loop and a C-terminal 
domain (CACTD) containing a 310 helix followed by a strand of four α-helices (C. Tang, Ndassa, 
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& Summers, 2002; Worthylake, Wang, Yoo, Sundquist, & Hill, 1999). They form hexameric or 
pentameric rings with the CANTD facing the outer side towards the MA protein to stabilize the 
structure, while the CACTD faces towards the inside providing the base of the mature conical 
capsid core. The hinge interface forms a binding pocket for various host factors. The capsid 
packages the viral genome and associated enzymes that are required for the next round of viral 
replication. This not only provides an enclosed space that allows an efficient initiation and 
elongation of reverse transcription, but also protects the resulting linear dsDNA from being 
recognized by host factors. Recently, investigators showed that the CA is involved in the nuclear 
translocation of viral genome and is a key protein that allows HIV-1 to infect non-dividing cells 
(Yamashita & Emerman, 2004, 2006; Yamashita, Perez, Hope, & Emerman, 2007). 
                
NC (nucleocapsid protein) 
                 The nucleocapsid protein is a small protein of the Gag polyprotein, only 55 amino 
acids in length. It is made up of two zinc finger domains (Cys-X2-Cys-X4- His-X4-Cys), which 
are connected by a basic domain, RAPRKKG (Godet et al., 2012). Despite its small size, the NC 
plays several important roles in viral replication including the: 1) support of the structural 
interaction between Gag proteins for assembly (de Rocquigny et al., 2014; K. Lu, Heng, & 
Summers, 2011; Muriaux & Darlix, 2010); 2) recognition of nucleic acids for packaging; 3) 
contribution to the viral synapse formation and cell-cell transmission (Llewellyn, Hogue, Grover, 
& Ono, 2010); and 4) facilitation of viral budding by hijacking ESCRT (endosomal sorting 




                 The p6 domain is derived from the C terminus of Gag and consists of 52 amino acids. 
It produces two proteins: 1) the inframe Gag p6; and 2) the -1 frameshifted Gag-Pol p6 (p6*) 
(Bell & Lever, 2013). The p6 is structurally more stable and functionally important. Helix 18 of 
p6 (432SFRSG466) is responsible for TSG101 binding, and the helix 19 of p6 
(481KELYPLTSLRSL492) provides the binding sites for ALIX and Vpr proteins. TSG101 is “a 
ubiquitin (Ub)- conjugating E2 enzyme variant (UEV) protein involved in regulation of 
intracellular trafficking, transcriptional regulation, and cell cycle control” (VerPlank et al., 
2001a).  The direct association of p6 and TSG101 reveals that cellular trafficking machinery 
plays a role in virus budding and maturation. In contrast, the p6* appears to be a poorly 
structured protein and is unable to bind those factors (Xue et al., 2012). The p6 protein is 
involved in many important aspects of viral replication, including virus budding, viral maturation 
(F. H. Yu, Chou, Liao, Huang, & Wang, 2015), recruiting TSG101 for Gag ubiquitination, and 
determining the size of the virus particle. (Bell & Lever, 2013) 
 
Pol (DNA polymerase): 
                 The Pol polyprotein is synthesized as a part of a larger polyprotein, Pr160GagPol, 
which results from the ribosomal frameshifting during Pr55Gag translation (1/20 molecules).  It 
encodes a polyprotein which harbors the precursor of the protease (PR), reverse transcriptase 
(RT), RNase H, and the integrase (IN). The structure and function of each protein resulting from 
Pol polyprotein cleavage is discussed below: 
 
RT (Reverse Transcriptase):  
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                 The RT of HIV-1 is an asymmetric heterodimer made with two related subunits, p66 
and p51. The larger subunit, p66, is 560 amino acids in length and contains the active sites for 
enzymatic activities of both reverse transcriptase and RNase H. The smaller subunit, p51, is 440 
amino acids in length and supports the structure of the enzyme (Jacobomolina et al., 1993; 
Kohlstaedt, Wang, Friedman, Rice, & Steitz, 1992; Sarafianos et al., 2009). The crystal structure 
of HIV-1 (RT) was resolved and the ribbon representation of HIV-1 RT in a complex with 
nucleic acid is shown in Figure 9. The polymerase domain in p66 is made up of four 
subdomains: the “fingers” (residues 1–85 and 118–155), “palm” (residues 86–117 and 156–236: 
the palm contains three catalytic carboxylates-D110, D185, and D186 that bind two divalent ions 
Mg2+), “thumb” (residues 237–318), and the “connection” (residues 319–426)” (Jacobomolina et 
al., 1993; Kohlstaedt et al., 1992). The smaller subunit p55 also folds into these four subdomains 
at different amino acid positions. The four polymerase subdomains and RNase H subdomain of 
p66 form the nucleic-acid binding cleft while the connection and thumb subdomains of p51 form 
the floor of the binding cleft. Therefore, the viral genome is able to contact both the polymerase 
and the RNase H active sites in the binding cleft. 
                 Reverse transcriptase reversely transcribes viral RNA into double stranded DNA 
(dsDNA). Like other RT molecules, the HIV-1-RT does not have an exonucleolytic proofreading 
function, resulting in an average error rate of 1/1700 nucleotides synthesized. Some hotspots 
have an error rate as high as 1/70 nucleotides (Roberts, Bebenek, & Kunkel, 1988). It is 
considered to be the least accurate reverse transcriptase known. This error-prone viral replication 
offers a unique advantage for HIV-1, by providing an enormous genetic potential and allowing 










Figure 9. Ribbon representation of HIV-1 RT in a complex with nucleic acid. The p66 subunit is 
shown in the upper part: fingers as blue, palm as red, thumb as green, connection as yellow, and 
RNase H as orange subdomains of the p66 subunit are shown in blue, red, green, yellow, and 
orange, respectively. The p51 subunit is at the bottom and is shown in dark brown. The template 
DNA is shown in light gray and primer DNA strands is shown in dark gray (Sarafianos, S. G, et 
al. (2009) Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of 









Figure 9    Ribbon representation of HIV-1 RT in a complex with nucleic acid 
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resist various antiviral drugs (Domingo & Holland, 1997; Rambaut, Posada, Crandall, & 
Holmes, 2004). However, this benefit comes at a cost. HIV-1 is believed to replicate at the 
threshold of an error catastrophe (E. C. Holmes, 2003; R. A. Smith, Loeb, & Preston, 2005). 
Thus, manually increasing the mutation rate to beyond the error threshold can limit viral 
replication.  
 
RNase H  
                 RNase H is located at the C terminus of the p66 protein. It consists of a five-stranded 
β-sheet surrounded by a distribution of four α-helices (Beilhartz & Gotte, 2010; T. J. Schmitt, 
Clark, & Knotts, 2009). It is an endonuclease that cleaves the 3’-O-P bond of RNA in a 
DNA/RNA hybrid. This function is important for removal of the t-RNA primer, RNA template, 
and polypurine tract (PPT) to allow elongation, strand transfer, and the completion of reverse 
transcription. This will be discussed later in greater detail. The ribbon representation of RNase H 
is shown in Figure 10. 
  
IN (integrase):  
                 The IN is an essential viral enzyme that facilitates the insertion of the double stranded 
linear viral DNA into the host chromosome. It contains three canonical domains: the N-terminal 
domain (NTD), catalytic core domain (CCD), and C-terminal domain (CTD), which are 
connected by flexible linkers that are susceptible to proteolysis. The NTD has a His2Cys2 motif 
that binds to zinc; the CCD is the core component that has the catalytic DDE motif and shares 











Figure 10. Ribbon representation of HIV-1 RNase H structure. It contains a five-stranded β-sheet 
which is surrounded by a distribution of four α-helices (Beilhartz, G. L, et al. (2010) HIV-1 









Figure 10    Ribbon representation of HIV-1 RNase H structure 
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like fold that nonspecifically binds DNA (SH3 domain consists five or six β-strands arranged as 
two tightly packed anti-parallel β sheets). The domain organization and structure of HIV-1 
domain is represented in Figure 11. IN forms a tetramer in the presence of viral DNA. This 
stable complex enables the integration of viral genome into host chromosome. IN interacts with a 
variety of host factors, including barrier-to-autointegration factor (BAF), lamina-associated 
polypeptide (LAP)-2a, integrase interactor 1 (INI1), lens epithelium-derived growth factor 
(LEDGF/p75), and cleavage and polyadenylation specificity factor subunit 6 (CPSF6) (Craigie & 
Bushman, 2012; Marini et al., 2015; Sowd et al., 2016a). In addition to the key function of viral 
integration, mutation studies have revealed that IN also plays a role in nuclear transport of PIC, 
reverse transcription, particle assembly & release, and viral maturation (Asante-Appiah & 
Skalka, 1999; Ceccherini-Silberstein et al., 2009; T. K. Chiu & Davies, 2004; Craigie, 2001; 
d'Angelo, Mouscadet, Desmaele, Zouhiri, & Leh, 2001; Engelman & Cherepanov, 2014; Feng, 
Larue, Slaughter, Kessl, & Kvaratskhelia, 2015; Grandgenett, Pandey, Bera, & Aihara, 2015; 
Hill, Tachedjian, & Mak, 2005; Nair, 2002; Pommier, Pilon, Bajaj, Mazumder, & Neamati, 
1997; Van Maele, Busschots, Vandekerckhove, Christ, & Debyser, 2006; Zeinalipour-Loizidou, 
Nicolaou, Nicolaides, & Kostrikis, 2007). 
 
PR (Protease) 
                 The PR is a retroviral aspartyl protease (retropepsin) that cleaves polyproteins at 
designated sites in a highly ordered sequence to induce structural arrangement. This maturation 
step is indispensable in converting immature, non-infectious into infectious virions. HIV-1 PR 









Figure 11. HIV integrase domain organization and domain structures. IN contains three 
canonical domains: the N-terminal domain (NTD), catalytic core domain (CCD), and C-terminal 
domain (CTD), which are connected by flexible linkers that are susceptible to proteolysis. The 
NTD has a His2Cys2 motif that binds to zinc; the CCD is the core component that has the 
catalytic DDE motif and shares similar structure with other polynucleotidyl transferases; the 
CTD has a Src-homology-3 (SH3)-like fold that nonspecifically binds DNA (SH3 domain 
consists five or six β-strands arranged as two tightly packed anti-parallel β sheets) (Engelman, A, 
et al. (2014) Retroviral integrase structure and DNA recombination mechanism. Microbiology 















mediated by its N- and C-termini, as shown in Figure 12. PR allows HIV-1 to use a single set of 
transcriptional and translational control elements in a defined stoichiometry. This space-saving 
strategy offers a great advantage for HIV-1 whose genome has a limited size. It allows HIV-1 to 
produce a variety of proteins required for particle formation, replication and spreading using a 
single set of transcriptional and translational control elements. (Blundell et al., 1990; Davies, 
1990; Fitzgerald & Springer, 1991; Huang et al., 2014; Konvalinka, Krausslich, & Muller, 2015; 
Louis, Ishima, Torchia, & Weber, 2007; Scharpe et al., 1991; J. Tang, Lin, Co, Hartsuck, & Lin, 
1992; vonderHelm, 1996). 
 
Env (Envelope)  
                 The HIV-1 Env glycoprotein is translated from a singly spliced, bicistronic vpu/env 
mRNA on the rough endoplasmic reticulum (RER) into a precursor polyprotein, known as 
gp160. The Env precursor is glycosylated with N- and O-linked oligosaccharide side chains. 
Monomers of gp160 form trimers in ER and these trimers are subsequently transported to the 
Golgi complex. In the Golgi complex, the conserved K/R-X-K/R-R motif is recognized by 
cellular furin or furin-like proteases resulting in cleavage of gp160 into gp120 and gp41 
(Checkley, Luttge, & Freed, 2011; Freed, Myers, & Risser, 1989; Mccune et al., 1988). 
Following cleavage, gp120 and gp41 interact through noncovalent bonds and form a 
heterotrimeric HIV-1 glycoprotein spike. The domains and structure of HIV-1 env are depicted 
in Figure 13. 
                 During virus assembly, gp120/gp41 heterotrimeric spikes are incorporated into the 
lipid bilayer of the virion and are responsible for receptor recognition, binding, and fusion for the 









Figure 12. Ribbon diagram of the HIV protease dimer: one monomer in orange and the other in 
blue. Each monomer folds into a four-stranded antiparallel β-sheet and dimerizes through their 
N- and C-termini (Venkatakrishnan, B, et al. (2012). Mining the protein data bank to 
differentiate error from structural variation in clustered static structures: an examination of HIV 






















Figure 13. (A) The structure of HIV-1 envelope glycoprotein (Env). (B) Schematic diagram of 
trimeric HIV-1 Env with sites of epitopes for broadly neutralizing antibodies. Following 
cleavage, gp120 and gp41 interact through noncovalent bonds and form a heterotrimeric HIV-1 
glycoprotein spike (Haynes, B. F, et al. (2012) B-cell-lineage immunogen design in vaccine 







Figure 13    HIV-1 envelope glycoprotein (Env) 
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virological synapses (VS), which contributes to the virus spread through direct cell-to-cell 
transmission (Acharya, Lusvarghi, Bewley, & Kwong, 2015; Araujo & Almeida, 2013; Burton & 
Mascola, 2015; Checkley et al., 2011; Freed et al., 1989; Mccune et al., 1988; Merk & 
Subramaniam, 2013; O'connell, Kim, & Excler, 2014; Postler & Desrosiers, 2013; Schiffner, 
Sattentau, & Duncan, 2013; Ward & Wilson, 2015). The gp160 has also been reported to play a 
critical role in CD4 downmodulation through binding to newly synthesized CD4 in the ER and 
preventing their transport to the cell surface (Ruiz, Guatelli, & Stephens, 2010; Wildurn, 
Schindler, Munch, & Kirchhoff, 2006). 
 
gp120  
                 The gp120 consists of five variable domains (V1-V5) interspersed with five relatively 
constant domains (C1-C5) (Willey et al., 1986).  The conserved domains are key determinants 
that bind the CD4 receptor, while the variable domain such as V3 loop is involved in coreceptor 
specificity. Eighteen Cys residues form nine intramolecular disulfide bridges that are essential to 
the formation of the Env tertiary structure. The gp120 is highly glycosylated, especially by N-
linked glycans, which aides HIV-1 escaping from the host immune surveillance, folds into a 
functional tertiary structure, and facilitates viral binding to susceptible target host cells (H. L. Li 
et al., 2008; Montefiori, Robinson, & Mitchell, 1988; Raska & Novak, 2010).  Following binding 
to the host cell receptor CD4, gp120 undergoes a remarkable degree of refolding. When gp120 
bound to CD4, it consists of an “inner” domain and an “outer” domain linked by a four-stranded 
“bridging sheet”, allowing CD4 to directly contact 26 residues in gp120 (the most important 
residues for this interaction are Phe43 and Arg59 of CD4 and Asp368, Glu370, and Trp427 of 
gp120 (Ryzhova et al., 2002)) and to expose the co-receptor binding sites (Kwong et al., 1998).  
41 
gp41 
                 The other component of the Env heterodimer is gp41, which consists three major 
domains: an extracellular domain (or ectodomain), a transmembrane domain (TMD), and a C-
terminal cytoplasmic tail (CT). The extracellular domain contains the major fusion determinants 
that include the hydrophobic fusion peptide which forms the fusion pore, a polar region, heptad-
repeat regions HR1 and HR2 (their interaction with each other drives the fusion process by 
forming a stable six-helix bundle that brings the viral and cell membranes close enough for 
fusion), and a highly conserved membrane-proximal external region (MPER) (Chan et al., 1997; 
Checkley et al., 2011; M. Lu, Blacklow, & Kim, 1995; Merk & Subramaniam, 2013; Postler & 
Desrosiers, 2013). The gp41 TMD consists of a α-helix that spans the membrane once and 
anchors Env in the lipid bilayer. The gp41 has a very long CT that is approximately 150 amino 
acids and is involved in many functions, including “Env incorporation into virus particles, virus 
infectivity, cell-surface Env expression, and Env-induced fusion” (Checkley et al., 2011). 
 
Tat (Trans-Activator of Transcription) 
                 Tat is an early regulatory protein that stimulates viral transcript elongation several 
hundred-fold by binding to the stem-loop structure of the viral RNA known as the trans-
activating response element (TAR).  This is achieved through: 1) recruiting cellular chromatin 
modifying complexes and histone modifying enzymes to relieve the repression on viral long-
terminal repeat (LTR); 2) phosphorylating the RNA polymerase II, transcription factors Sp1 and 
CREB, the α subunit of eIF2α, and NF-κB; and 3) facilitating the elongation of viral transcripts, 
as summarized in Figure 14. In addition to activating viral transcription, Tat modulates the 
expression of host genes by up-regulation of several cytokines, CCR5 and CD25 (Mayol, 
42 
Munier, Beck, Verrier, & Guillon, 2007; Zheng, Yang, Lu, & Salvato, 2005). It down-regulates 
expression of major histocompatibility complex (MHC) class I by repressing the activity of an 
MHC class I gene promoter up to 12-fold (Howcroft, Strebel, Martin, & Singer, 1993; Matsui, 
Warburton, Cogswell, Baldwin, & Frelinger, 1996). This regulation of host gene expression can 
result in apoptosis induction/inhibition and immune suppression (Romani, Engelbrecht, & 
Glashoff, 2010). Additionally, Tat plays an important role in viral reverse transcription by 
promoting the placement of tRNALys3 onto viral RNA, and suppressing reverse transcription at 
late stages of the viral replication.  Moreover, Tat has been implicated in AIDS-associated cancer 
progression and neurotoxicity (Johri, Mishra, Chhatbar, Unni, & Singh, 2011; King, Eugenin, 
Buckner, & Berman, 2006; W. X. Li, Li, Steiner, & Nath, 2009).  
                 HIV-1 Tat can be secreted by productively infected cells and can be taken up by 
neighboring non-infected cells through a paracrine/autocrine mechanism (Dahiya, Nonnemacher, 
& Wigdahl, 2012). The extracellular form of Tat also directly interacts with the cell surface 
receptors, such as cellular heparan sulfate proteoglycans and CXC-chemokine receptor 4.  This 
interaction promotes the expression of HIV-1 chemokine co-receptors in uninfected cells, which 
favors susceptibility to HIV-1 infection (Brigati, Giacca, Noonan, & Albini, 2003; Chiozzini & 
Toschi, 2016; Gatignol, 2007; Gibellini, Vitone, Schiavone, & Re, 2005; Hetzer, Dormeyer, 










Figure 14. The role of HIV-1 Tat in the synthesis of full-length viral mRNAs. In the presence of 
stimulation factors such as TNF- α, the latency inducing complex, p50 and HDAC1, are relieved 
from the viral LTR. The cellular chromatin modifying complexes and histone modifying 
enzymes such as CBP/p300 complex then binds to the promoter and acetylates the surrounding 
histones. The complex also acetylates Tat and the acetylated Tat interacts with CDK9 and cyclin 
T1, to recruit the stem–loop structure, TAR. The P-TEFb complex and Tat also activates the 
phosphorylation of RNA polymerase II in CTD. After initiation, Tat contributes to elongation of 
viral transcripts by facilitating the activated polymerase to synthesize full-length transcripts from 
the relieved template (Romani, B, et al. (2010) Functions of Tat: the versatile protein of human 









Figure 14    The role of HIV-1 Tat in the synthesis of full-length viral mRNAs 
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Rev                  
                 The Rev is a 13-kDa protein of 116 amino acids. There are two critical domains that 
are important to its nuclear import and export functions. The first is an arginine-rich motif 
(ARM) located at the N-terminus. The second domain is a Rev-activation domain (nuclear export 
signal or NES) located at the C-terminus. The domains and structure of HIV-1 Rev are shown in 
Figure 15. The ARM is responsible for tetramerization of Rev proteins, which is essential for its 
proper binding to the Rev response element (RRE). The nuclear export signal of Rev allows the 
intron-containing viral RNA to exit the nucleus into the cytoplasm. Rev exports and increases 
levels of the mRNAs that encodes structural proteins and (Gag, Pol, and Env) in the cytoplasmic, 
and down-regulates the expression of doubly spliced mRNA species that encodes the regulatory 
proteins (Rev and Tat) through a negative feedback loop (Hammarskjold et al., 1989; Hope, 
1999; Kjems, Calnan, Frankel, & Sharp, 1992; Malim, Mccarn, Tiley, & Cullen, 1991; Pollard & 
Malim, 1998; Rausch & Le Grice, 2015; Vercruysse & Daelemans, 2013; Zapp, Hope, Parslow, 
& Green, 1991). 
 
Nef (Negative Regulatory Factor) 
                 Nef, 27–35 kDa, is N-myristoylated. It is predominantly localized in the cytoplasm of 
infected cells but is also recruited to plasma membrane. Nef is not essential for viral replication 
in vitro. However, Nef is a virulence factor in vivo and is a key contributor in the disease 
progression. Nef facilitates AIDS pathogenesis by: 1) down-regulating CD4 levels on cell 
surface by endocytosis and lysosomal degradation; 2) down-regulating major histocompatibility 










Figure 15. HIV-1 Rev domain and structure. (A) Linear domain organization of Rev: 
oligomerization motifs are shown in cyan, arginine-rich motif /nuclear localization sequence 
(ARM/NLS) shown in navy blue, and nuclear export signal (NES) shown in dark gray. (B) 
Ribbon representation of Rev monomer showing a helix-loop-helix motif with coplanar helices 
(DiMattia, M. A, et al. (2010) Implications of the HIV-1 Rev dimer structure at 3.2 Å resolution 
for multimeric binding to the Rev response element. Proceedings of the National Academy of 














recognition by manipulating host cell vesicular transport, cytoskeleton dynamics, cell mobility 
and T cell receptor signaling; and 4) enhancing viral particle infectivity independent of CD4 
modulation (Abraham & Fackler, 2012; Arien & Verhasselt, 2008; Basmaciogullari & Pizzato, 
2014; Baur, 2004; Das & Jameel, 2005; Foster, Denial, Temple, & Garcia, 2011; Foster & 
Garcia, 2007, 2008; Geyer, Fackler, & Peterlin, 2001; M. Harris, 1999; Jere, Fujita, Adachi, & 
Nomaguchi, 2010; Joseph, Kumar, & Mitra, 2005; Olivetta, Arenaccio, Manfredi, Anticoli, & 
Federico, 2016; Pawlak & Dikeakos, 2015; Percario, Ali, Mangino, & Affabris, 2015; Pereira & 
daSilva, 2016; Quaranta, Mattioli, Giordani, & Viora, 2009; Roeth & Collins, 2006; Wei, Arora, 
Foster, Sodora, & Garcia, 2003; Witkowski & Verhasselt, 2013).  
 
Vpr (Viral Protein R) 
                 Vpr is a 14 kDa protein that is 96 amino acids in length. It forms three α-helical 
secondary structures. Unlike other accessory proteins of HIV-1, Vpr is packaged into the core of 
the mature virions at approximately 275 molecules per virion through a direct interaction with 
the C-terminal p6 region of the Gag precursor p55. Vpr regulates the nuclear import of HIV-1 
pre-integration complex (PIC), thus facilitates virus replication in non-dividing cells, such as 
macrophages. It also modulates the fidelity of reverse transcription, and induces cell cycle arrest 
at G2/M and causes apoptosis in proliferating cells leading to immune dysfunction. Additionally, 
Vpr causes metabolism alternations similar to the Warburg effect in cancer cells such as changes 
in glycolysis, gluconeogenesis, the pentose phosphate pathway, TCA cycle, mitochondrial 
functions, and hypoxia-inducing factors level (James, Nonnemacher, Wigdahl, & Krebs, 2016). 
Finally, Vpr has been shown to contribute to the neuropathogenesis of HIV-1 infection. Vpr has 
been found to exist in an extracellular form in the cerebrospinal fluid (CSF) from HIV-1-infected 
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patients. Vpr has been shown to directly affect neurons and induce the release of neurotoxic 
factors, cytokines, and chemokines from astrocytes and microglial cells (the resident macrophage 
in the brain) (Andersen & Planelles, 2005; Guenzel, Herate, & Benichou, 2014; James et al., 
2016; Kogan & Rappaport, 2011; Le Rouzic & Benichou, 2005; G. Li, Bukrinsky, & Zhao, 
2009; Pandey et al., 2009; Romani & Engelbrecht, 2009; Sharifi, Furuya, & de Noronha, 2012; 
Strebel, 2013; Thieu et al., 2009; Tungaturthi, Sawaya, Ayyavoo, Murali, & Srinivasan, 2004; 
Tungaturthi et al., 2003; Zhao, Li, & Bukrinsky, 2011). 
 
Vpu (Viral Protein Unique) 
                 The Vpu protein is found exclusively in HIV-1 and select simian immunodeficiency 
virus (SIV) isolates. Vpu is an oligomeric, type I membrane protein with a size of 16 kDa 
consisting 81-86 amino acids. Vpu and Env are translated from the same bicistronic mRNA in a 
Rev-dependent manner, through leaky scanning of ribosomes. Vpu contains an N-terminal leader 
sequence that also serves as a hydrophobic transmembrane domain while the cytoplasmic tail (a 
54 residues, hydrophilic domain) contains a high level of charged resides. The transmembrane 
domain has a stable helical structure with a small tilt angle to the plane of the membrane (Park, 
De Angelis, Nevzorov, Wu, & Opella, 2006). The cytoplasmic domain forms two α-helices 
which are connected though a flexible segment that contains two conserved kinase II 
phosphorylation site S(S/T-X-X-E/D). These two conserved serine residues are critical for the 
interaction between Vpu and the human β-transducin-repeat containing protein (β-TrCP), which 
is directly involved in the degradation of CD4 (Bour & Strebel, 2003; Hout et al., 2004; Montal, 
2003).  
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                 Vpu facilitates the degradation of CD4 in the endoplasmic reticulum via inducing the 
degradation of CD4 molecules bound by Env (gp160) and targeting it for proteolysis in the 
cytosolic ubiquitin-proteasome pathway (Lenburg & Landau, 1993; Lindwasser, Chaudhuri, & 
Bonifacino, 2007). This targeted degradation not only prevents newly synthesized CD4, but also 
liberates gp160, allowing transport to the cell surface (A. Andrew & Strebel, 2010; Binette & 
Cohen, 2004; Dube, Bego, Paquay, & Cohen, 2010; Ruiz et al., 2010). In addition, Vpu promotes 
viral particle release from the plasma membrane of infected cells. The enhancement of virion 
release is independent of CD4 destabilization and requires the transmembrane domain of Vpu. 
Vpu contributes to viral egress by down-regulating the restriction factor BST-2 (Neil, Zang, & 
Bieniasz, 2008; Van Damme et al., 2008). The detailed interaction between Vpu and BST-2 will 
be expanded in later chapters. Additionally, Vpu down-regulates lipid-antigen presenting protein 
CD1d in antigen-presenting cells, and NTB-1 in natural killer cells. (A. Andrew & Strebel, 2010; 
Binette & Cohen, 2004; Bour & Strebel, 2003; Dube et al., 2010; Ewart, Sutherland, Gage, & 
Cox, 1996; Gonzalez, 2015; Guatelli, 2009; Hout et al., 2004; Hsu, Seharaseyon, Dong, Bour, & 
Marban, 2004; Moll, Andersson, Smed-Sorensen, & Sandberg, 2010; Montal, 2003; Neil et al., 
2008; Ruiz et al., 2010; Schubert et al., 1996; Shah et al., 2010; Strebel, 2014; Van Damme et 
al., 2008). 
 
Vif (Viral Infectivity Factor):  
                 Vif is a 23 KDa phosphorylated protein with 192 amino acids that is produced at a 
high level in the late stage of viral life cycle. Vif primarily resides in the cytoplasm and cellular 
membrane, co-localizing with Gag. Vif is indispensable for viral replication in non-permissive 
primary CD4+ T cells, macrophages, CD4+ T cell lines, and some leukemic T-cell lines that have 
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the host restriction factor APOBEC3G. Vif will be discussed later in great details along with the 
APOBEC family proteins (Goila-Gaur & Strebel, 2008; Kim, 2015; Kremer & Schnierle, 2005; 
Lake et al., 2003; Miller, Presnyak, & Smith, 2007; Rose, Marin, Kozak, & Kabat, 2004; Stanley 
et al., 2008; Strebel, 2003, 2007). 
    4. HIV-1 life cycle  
                 The HIV-1 replication cycle includes the following steps: 1) entry; 2) reverse 
transcription; 3) integration; 4) transcription and translation; 5) assembly; 6) budding; and 7) 
maturation. The HIV-1 replication cycle in CD4+ T cells is shown in Figure 16 
Virus Entry: 
                 HIV-1 entry into susceptible cells can occur through three mechanisms including the 
classical binding/attachment and fusion, endocytosis, and direct cell-cell transmission via viral 
synapse fusion. 
 Binding/attachment and fusion: In this mechanism, the initial attachment between Env and 
cell surface receptors can be nonspecific, such as to surface heparin sulfate proteoglycans, or 
more specific such as α4β7 integrin and DC-SIGN (Arthos et al., 2008; Pohlmann et al., 2001). 
This attachment is not essential but facilitates Env coming into close proximity to the viral 
receptor and co-receptors for further binding. Env is a heavily glycosylated trimer of gp120 and 
gp41 heterodimers. Initially, gp120 binds to CD4 receptor on T cell and undergoes a 
conformational change resulting in a repositioning of bridging sheet and V3 loop. This leads to 
the exposure of their chemokine binding domain and allows it to interact with target chemokine 
receptors-like CXCR4 on T cells and CCR5 on T cells and macrophages. This more stable 
attachment triggers the exposure of the hydrophobic gp41 fusion peptide, which penetrates the  





Figure 16. HIV-1 replication cycle in CD4+ T cells. This schematic picture shows the typical 
HIV-1 replication cycle in CD4+ cells. First, the Env protein gp120 will binds to CD4 receptor on 
T cells and undergo conformational change which will expose their chemokine binding domain 
and allows them to interact with target chemokine receptors like CXCR4 or CCR5. This more 
stable attachment will initiate gp41 (the transmembrane protein) to unfold and penetrate cell 
membrane and allows for fusion and subsequent entry of the viral capsid. After entry into cells, 
the viral RNA and reverse transcriptase in the capsid begin reverse transcription. This will result 
in a double strand viral DNA. The integrase escorts the PIC to nucleus and the viral DNA is 
integrated into host chromosome. Transcription process initially results in the early synthesis of 
regulatory HIV-1 proteins such as Tat and Rev. Tat will binds to the transactivation response 
element (TAR) and stimulates the transcription of longer RNA transcripts. Rev assists in this 
process, as well as ensures the export from nucleus to cytoplasm of the correctly processed 
messenger and genomic RNA. The viral RNA and proteins are and Env is concntrated at the 
plasma membrane leading to viral egress. The final maturation step is cleavage of the Gag and 












The stabilization of the membrane fusion allows the subsequent entry of the viral capsid. 
However, this cell free spread has several disadvantages: First, the Env heterotrimers require 
multiple receptors available on cell surface for an effective binding. Second, free virions 
encounter more immunological challenges such as neutralizing antibody (Overbaugh & Morris, 
2012). Finally, it is rate limiting compared to direct cell-to-cell transmission (Ambrose & Aiken, 
2014; Brandenberg, Magnus, Regoes, & Trkola, 2015; Klasse, 2012; Melikyan, 2014; Micewicz 
& Ruchala, 2013; Wilen, Tilton, & Doms, 2012a, 2012b). The schematic representation of HIV-
1 entry through binding and fusion is shown in Figure 17. 
 
Endocytosis: In the second mechanism, HIV-1 can also enter cells by endocytosis. The whole 
virus particles are internalized into cells through clathrin-dependent, dynamin-dependent 
endocytosis (Hela cells and lymphoid CEMss cells), or macropinocytosis (macrophage) (Daecke, 
Fackler, Dittmar, & Krausslich, 2005; de la Vega et al., 2011; Gobeil, Lodge, & Tremblay, 2013; 
Miyauchi, Kim, Latinovic, Morozov, & Melikyan, 2009; von Kleist et al., 2011). Following the 
engulfment of the intact virions, the viral nucleocapsid is released into the cytoplasm and begins 
reverse transcription. The HIV-1 entry through endocytosis is shown in Figure 18. This strategy 
offers several advantages. It minimizes the exposure of virus antigens to the immune system by 
hijacking cellular endocytic machinery; and, it allows quick transport of the virus to a 
perinuclear space where the virus appears to fuse with endosome (Miyauchi et al., 2009; 
Miyauchi, Marin, & Melikyan, 2011), facilitating reverse transcription and nuclear entry of PIC 
(Carter, Bernstone, Baskaran, & James, 2011; Chauhan & Khandkar, 2015; Chauhan, Tikoo, 
Patel, & Abdullah, 2014; Daecke et al., 2005; Hamamoto & Yamamoto, 2010; Permanyer, 










Figure 17. HIV-1 entry through binding and fusion. The Env protein gp 120 will bind to CD4 
receptor on cells and undergo conformational change which will expose their chemokine binding 
domain and allows Env to interact with target chemokine receptors like CXCR4 or CCR5. This 
stable attachement will initiate gp41 (the transmembrane protein) to unfold and penetrate cell 





















Figure 18: HIV-1 entry through endocytosis. After binding of HIV to the CD4 receptor, the virus 
can enter target cells through endocytosis. HIV particles are internalized into cells through 
clathrin-dependent, or dynamin-dependent endocytosis (cell surface internalization). Following 
the engulfment of the intact virions, coreceptor engagement could result in fusion of  the viral 
and endosomal membrane and release the viral nucleocapsid into the cytoplasm for reverse 
transcription; Alternatively, in the absence of the appropriate coreceptor or coreceptor 
independent transfer, viruses may be recycled back to the extracellular medium (Permanyer, M, 












Cell-to–cell transmission: In the final mechanism of viral entry, retroviruses can be transmitted 
directly from an infected cell to receptor-expressing uninfected cells via viral synapse (VS) 
formation and nanotubes. HIV-1 replication is significantly stimulated in the presence of VS.  
VS has been characterized between T cells (Jolly, Kashefi, Hollinshead, & Sattentau, 2004a), 
between dendritic cells (DC) and T cells (Cameron et al., 1992; McDonald et al., 2003), and 
between macrophages and T cells (Groot, Welsch, & Sattentau, 2008). The formation of the 
HIV-1 VS is a multistep process that requires donor and target coming to close contact with each 
other. Generally, it is initially triggered by the binding of the HIV-1 envelope (Env) glycoprotein 
on the donor cells to the CD4 receptors expressed on the target cells. Noteworthy, Env/CD4 
interactions are dispensable to form the DC-T cell VS, while the recognition and binding 
between cellular membrane adhesion proteins, such as ICAM-1-3 on the donor and the ligand 
LFA-1 on targets, are required (Rodriguez-Plata et al., 2013). In addition, lipid raft recruitment 
also plays an important role in VS formation (Jolly & Sattentau, 2005). Remodeling of adhesion 
molecules, actin cytoskeleton in both donor cells and target cells, and the repositioning of the 
microtubule- organizing center (MTOC) in donor cells contributes to the VS formation (Jolly, 
Welsch, Michor, & Sattentau, 2011b). Figure 19 depicts IV-1 entry through cell to cell 
transmission (from DC to CD4+ T cell). This direct cell-cell transmission: 1) is more rapidly and 
efficiently (1000-fold more efficient than free-virus transmission); and 2) minimizes immune 
exposure and promotes evasion from host system recognition. (Agosto, Uchil, & Mothes, 2015; 
Casartelli, 2016; Costiniuk & Jenabian, 2014; Jolly, Kashefi, Hollinshead, & Sattentau, 2004b; 












Figure 19. HIV-1 entry through cell to cell transmission (from dendritic cell (DC) to CD4+ T 
cell). (A) Virions are concentrated in compartment of DCs; (B) The membrane protrusions of 
CD4+ T cells reach to DCs. (C) The CD4+ T cell protrusions invade the virus-containing 
compartments and bind to viruses; (D) Viruses migrate along the protrusion to infect CD4+ T 
cells (Wilen, C. B, et al. (2012). HIV: cell binding and entry. Cold Spring Harbor Perspectives 













Reverse Transcription of Viral Genome:  
                 Once the nucleocapsid enters the cytoplasm, it is partially uncoated, and the process of 
reverse transcription begins, which results in the two copies of single-stranded RNA converted 
into double-stranded linear viral DNA. Reverse transcription of HIV-1 is a complicated process 
involving two strand transfers. First, tRNALys3 packaged in the virions is hybridized to a 
complementary region of the virus genome and is called the primer binding site or PB. 
Complementary DNA is synthesized to the U5 (non-coding region) and R region (a direct repeat 
found at both ends of the RNA molecule) of the viral RNA. This priming initiates the synthesis 
of the minus strong stop DNA (R-U5). The reverse transcriptase pauses, and another domain on 
the reverse transcriptase enzyme, RNAse H, degrades the 5’ end of the RNA, which removes the 
U5 and R region. The minus strand strong stop DNA then ‘jumps’ and hybridizes to the 
complementary R region on the 3’ end of the viral RNA, completing the first strand transfer. 
With exception of a region referred to as the polypurine tract (PPT), the first strand of 
complementary DNA (cDNA) is extended, and the majority of viral RNA is degraded by RNAse 
H. The PPT serves as a primer to initiate the synthesis of the second strand of DNA-plus strong 
stop DNA. Once the second strand of DNA finishes LTR and PB synthesis, the PPT and tRNA is 
degraded, and another ‘jump’ will occur, in which the PB from the second strand hybridizes with 
the complementary PB on the first strand. Both strands are further extended, resulting in a 








Figure 20. HIV-1 Reverse transcription. HIV reverse transcription is a complicated process that 
involves two strand transfers. In this Figure, I have used black to represent the viral original 
RNA and red as the newly synthesized DNA. The dashed lines means they are degraded by 
Rnase H. A specific cellular tRNA, shown in blue, acts as a primer and hybridizes to a 
complementary part of the virus genome called the primer binding site or PB, which initiates the 
synthesis of the first piece DNA. Complementary DNA synthesized to the U5 (non-coding 
region) and R region (a direct repeat found at both ends of the RNA molecule) of the viral RNA. 
Another domain on the reverse transcriptase enzyme, RNAse H, degrades the 5’ end of the RNA 
which removes the U5 and R region The primer then ‘jumps’ to the 3’ end of the viral genome, 
which is referred to as the first strand transfer. The newly synthesised DNA strands hybridizes to 
the complementary R region on the RNA. The first strand of complementary DNA (cDNA) is 
extended and the majority of viral RNA is degraded by RNAse H, except a region called 
PPT(polypurine tract). The PPT will serve as a primer and initiate the synthesis of second strand 
DNA. Once the second strand of DNA synthesized (LTR and PB), the PPT and tRNA will be 
degraded by Rnase H and another ‘jump’ occur where the PB from the second strand hybridizes 
with the complementary PB on the first strand. Both strands are further extended, resulting in a 














associates with integrase to form the preintegration complex (PIC). The PIC and other proteins 
are transported to the nuclear pore. It has been reported that HIV-1 Vpr facilitates nuclear entry 
of viral nucleic acids in nondividing cells, such as macrophages, and also causes a G2/M cell-
cycle arrest (Aida & Matsuda, 2009; Vodicka, Koepp, Silver, & Emerman, 1998). The double-
stranded viral DNA and intergrase enter the nucleus, and the double stranded linear DNA is 
ligated into the host chromosome. In the first step (3’ end processing), two nucleotides, in most 
cases are removed from each 3’ end of the blunt-ended linear viral DNA by integrase. The 
resulting 3’ end of the viral DNA in all cases terminate with the conserved CA-3’ sequence. In 
the second step (DNA-strand transfer), these 3’ ends, with the help of integrase, attack a pair of 
phosphodiester bonds on opposite strands of the target DNA, across the major groove. The 
resulting integration intermediate involves the 3’ end of the viral DNA hybridized to the target 
DNA. The single-strand gaps and the two-nucleotide overhang at the 5’ end of the viral DNA 
must be repaired by cellular enzymes to complete integration. The sites of joining the two target 
DNA strands are separated by five base pairs, resulting in a five base-pair duplication (Craigie & 
Bushman, 2012). The integration sites were originally thought to be random but more recent 
studies (Singh et al., 2015; Sowd et al., 2016b) have shown that cleavage and polyadenylation 
specificity factor 6 (CPSF6), and the host chromatin-binding factor LEDGF/p75, guide HIV-1 
integration to preferred sites of the genes that are transcriptionally active. The interaction 
between host factors and PIC does not only determine the integration sites, but also cloaks the 
provirus from cellular pathogen-associated molecular pattern (PAMP) recognition. HIV-1 










Figure 21. HIV-1 integration. First, the exonuclease activity of integrase trims two nucleotides 
from each 3' end of the linear viral DNA duplex. This is followed by a double-stranded 
endonuclease activity that cleaves the host DNA at the integration site, allowing hybridization of 
the viral DNA into the chromosome. Finally, a ligase activity generates a single covalent linkage 


















                 After provirus integrates into transcription-active cellular genes, cellular transcription 
factors, such as NF-κB, initiate the basal transcription of HIV-1 (Hiscott, Kwon, & Genin, 2001). 
However, the RNA polymerase II pauses shortly after promoter clearance (Toohey & Jones, 
1989). Thus, majority of the initial transcripts are short and abortive, and full-length transcripts 
are infrequent. The first viral protein, Tat, is expressed at low levels from the rarely produced 
full-length transcripts that are multiply spliced (Lassen, Bailey, & Siliciano, 2004). The 
p300/CBP-associated factor (PCAF) acetylates Tat at lysine 28, and the acetylated Tat recruits 
the positive transcription elongation factor β (P-TEFβ) from a large inactive complex containing 
7SK snRNA, the methylphosphate capping enzyme MePCE, the La-related protein LARP7, and 
hexamethylene bis-acetamide inducible 1 (HEXIM1 protein) (Barboric et al., 2007; Krueger et 
al., 2008; Sedore et al., 2007). This results in the production of doubly spliced mRNAs that 
encode Tat and another HIV-1 regulatory protein, Rev. The Tat-P-TEFβ complex binds to the 
Transactivation Response element (TAR), while autophosphorylated CDK9 phosphorylates 
additional host factors and stimulates the transcription of full-length mRNA transcripts (Garber 
et al., 2000; Ott, Geyer, & Zhou, 2011). Tat is subsequently acetylated at lysine 50 by p300/CBP 
and a histone acetyltransferase hGCN5, and recruits host factors, such as P300/CBP-associated 
factor PCAF and SWItch/Sucrose Non-Fermentable (SWI/SNF) to further enhance HIV-1 
transcription. The synthesis of full-length viral transcripts is elevated by more than 100-fold 
(Cullen, 1986; Mousseau, Mediouni, & Valente, 2015). Rev also facilitates this process to ensure 
the export of unspliced and incompletely spliced mRNAs that encode the structural proteins from 
the nucleus to the cytoplasm. Rev increases cytoplasmic levels of the mRNAs encoding both 
structural proteins (Gag, Pol, Env, Vif, Nef, Vpr) and non-structural protein Vpu, but decreases 
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                 The initiation of HIV-1 mRNA translation does not use the typical ribosomal scanning 
mechanism since the exon-1 of HIV-1 contains several highly structured regions, such as TAR 
sequence, the primer binding site, the poly(A) hairpin, and RNA packaging sequence. Rather, 
HIV-1 uses an internal ribosome binding site (IRES) to initiate the translation of Gag precursor. 
It has also been reported that HIV-1 uses post-transcriptional elements (PCEs), which bind to 
cellular RNA binding proteins to enhance translation initiation. Ribosomal frameshifting is 
essential for the HIV-1 replication cycle. A (-1) shift occurs approximately 5% of the time in the 
translational reading frame to shift from the production of the Gag precursor reading frame to 
translate a Gag-Pro-Pol precursor. This frameshifting requires two upstream cis-acting sequence: 
a hexanucleotide “slippery” sequence (UUUUUUA) and a stem-loop pseudoknot structure 
located just 30 nts to the 3’ heptanucleotide sequence (UUUUUUA) (Karn & Stoltzfus, 2012). 
 
Assembly 
                 Assembly begins with the synthesis of the Gag polyprotein in the cytoplasm and its 
translocation to the site of assembly. The Gag precursor requires myristoylation of Gag-Gag 
multimerization in cells (H. Li et al., 2007). Each domain of Gag precursor (MA, CA, NC, p6) 
plays an important role in the translocation. The MA domain, via its myristic acid moiety, targets 
Gag to the plasma membrane and fosters incorporation of the viral Env glycoproteins into the 
progeny virions. The basic residues clustering on top of MA allows the protein to interact 
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electrostatically with the negatively charged inositol headgroup of phosphoinositide 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), which is highly enriched in the inner 
leaflet of the plasma membrane (Ono, Ablan, Lockett, Nagashima, & Freed, 2004).  Myristate 
exposure is triggered by the binding of PtdIns (4,5)P2 to MA, and may promote the insertion of 
MA into the inner leaflet of the plasma membrane (Saad et al., 2006). Investigators have 
proposed that the interaction between MA and gp41 cytoplasmic tail of Env may play a central 
role in Env glycoprotein incorporation (Tedbury & Freed, 2014). The C-terminal domain of CA 
(CACTD) contains a dimer interface and drives Gag multimerization during assembly. In addition, 
interaction between NC and RNA also promotes Gag multimerization (Burniston, Cimarelli, 
Colgan, Curtis, & Luban, 1999; Lingappa, Dooher, Newman, Kiser, & Klein, 2006). The NC 
recruits the viral RNA genome encapsidation and facilitates the assembly process with the dimer 
initiation signal (DIS) located at 5ʹ UTR, inducing viral RNA dimerization.  The RNA dimer 
then serves as the recognition unit for packaging into progeny virions. Retroviral RNA usually 
uses a psi site (φ) in the 5ʹ UTR as the packaging signal. However, the 5ʹ UTR of the HIV-1 
genomic RNA contains several highly structured elements (K. Lu et al., 2011). It is more likely 
that the multiple folding conformations of 5’UTR, rather than a small, defined ψ‐element, serve 
as the packaging signal for dimerized viral RNA. The NC contains two Cys-Cys-His-Cys zinc-
finger-like (or ‘zinc‐knuckle’) domains flanked by basic residues. These two domains increase 
the affinity of NC for RNA binding and NC functions as a nucleic acid chaperone (Levin, Guo, 
Rouzina, & Musier-Forsyth, 2005). The p6 domain hijacks the cellular endosomal sorting 
complex required for transport (ESCRT) apparatus and catalyses the membrane fission step to 
complete the budding process. The ESCRT system was originally found to be responsible for the 
biogenesis of multivesicular bodies (MVBs) and the sorting of ubiquitinated cargo into designed 
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endocytic organelles (O. Schmidt & Teis, 2012). It consists of a network of class E vacuolar 
protein sorting (Vps) proteins that is made up with components of ESCRT-I, -II and -III 
complexes (Usami et al., 2009; Votteler & Sundquist, 2013). Initially, ESCRT-I recognizes 
ubiquitinated protein cargo via its Tsg101 (tumor susceptibility gene 101) subunit. The initial 
recognition activates ESCRT-II and then leads to the assembly of ESCRT-III on the cytosolic 
side of endosomal membranes. HIV-1 hijacks this system by binding directly to this cellular 
budding machinery. This direct association requires two late-assembly domains (L domains) on 
the C-terminal p6 domain of HIV-1 Gag. The most important domain is called PTAP (Pro-Thr-
Ala-Pro). PTAP motif is located near the N terminus of p6 and interacts directly with tumour 
susceptibility gene 101 (TSG101) - a component of ESCRT-I (Garrus et al., 2001; VerPlank et 
al., 2001b). Each of the four residues (Pro-Thr/Ser-Ala-Pro) directly interacts within an extended 
groove on the amino-terminal ubiquitin E2 variant (UEV) domain of TSG101. The second L 
domain on p6 is called LYPXn L (Leu-Tyr-Pro-Xaan-Leu), which serves as a docking site for 
ALG-2 (apoptosis-linked gene 2)-interacting protein X (Alix) (Demirov, Ono, Orenstein, & 
Freed, 2002; Freed, 2015; Garrus et al., 2001; Martin-Serrano, Zang, & Bieniasz, 2001; B. Meng 




                 Following assembly of the immature Gag precursor lattice at the plasma membrane, 
the nascent particle must undergo a membrane fission event to be released from the cell surface. 
PTAP motif of p6 recruits ESCRT, a host system that plays a vital role in virus release.  ESCRT 
has been observed to assemble into circular arrays or spirals. The assembled filaments may 
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create closed “domes” that constrict the opposing membranes and promote fission as they inward 
(Hanson, Roth, Lin, & Heuser, 2008; Shen et al., 2014). In addition, ESCRT has been proposed 
to provide energy for the membrane scission event by recruiting the AAA ATPase vacuolar 
protein soring 4 (VPS4) (B. Meng & Lever, 2013). The HIV-1 budding and the associated 
ESCRT pathway is shown in Figure 22. 
 
Maturation  
                 HIV-1 virus particles egress from cells as non-infectious, immature particles and 
require the proteolytic activity of the viral protease (PR) for maturation. The HIV-1 protease is 
an aspartyl protease. Since the active site is located in a cleft at the dimer interface, the protease 
needs to be dimerized for function (Wlodawer & Erickson, 1993). In the immature particle, Gag 
molecules are packed in a radial manner. Following cleavage, “MA remains associated with the 
inner leaflet of the viral membrane, forming a discontinuous matrix shell that lacks long-range 
order” while the CA protein reassembles to form a conical shaped capsid core as represented in 
Figure 23 (Sundquist & Krausslich, 2012)  (Frank et al., 2015; Keller et al., 2013). 
 
5. Current HIV-1 Antiretroviral strategies 
                 In the early 1990s, the process of antiretroviral drug development increased due to the 
advent of: “(1) high throughput compound screens with virus-specific replication or enzymatic 
assays; (2) optimization of inhibitors using lead compounds based on homologous enzymes or 
targets; and (3) rational drug design modeled on the 3-dimensional structures of viral proteins” 









Figure 22. Schematic depiction of ESCRT pathway recruitment and retrovirus budding. Cellular 
adaptors are underlined and ESCRT factors are shown in white background. Polyubiquitin chains 
are represented by connected yellow hexagons, solid arrows refer to known protein-protein 
interactions, dashed arrows denote inferred or indirect protein-protein interactions, and question 
marks indicate undetermined site(s) of ubiquitin attachment (Votteler, J, et al. (2013). Virus 



















Figure 23. HIV-1 virion maturation. The three different stages in the maturation of HIV-1 are 
illustrated schematically along with the electron micrographs at each step. In (A), the particle is 
budding from the cell, In (B), the immature particle that has left the cell is shown, and (C), the 
mature particle is formed viral protease cleavage of the Gag and Gag-Pro-Pol precursors 
(Gelderblom, H. R. (1997). Fine Structure of HIV and SIV. Los Alamos National Laboratory, 








Figure 23    HIV-1 virion maturation 
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(1) chemokine receptor antagonists; (2) fusion inhibitors; (3) nucleoside-analog reverse 
transcriptase inhibitors (NNRTIs); (4) non–nucleoside reverse transcriptase inhibitors (NNRTIs); 
(5) integrase inhibitors; and (6) protease inhibitors (PIs) (Arts & Hazuda, 2012). I will discuss 
the different classes of anti-retroviral drugs in the context of the viral replication cycle. 
                 Inhibitors of virus entry include the attachment inhibitors, chemokine receptor 
antagonists, and fusion inhibitors. In the history of entry inhibitor development, investigators 
have focused on ways to hinder the interaction between viral envelope protein gp120 and cell 
surface receptor CD4. One inhibitor that targets the entry process is a small-molecule called 
BMS-378806. It alters the conformation of the envelope protein by binding to a pocket on gp120 
that is important for CD4 binding (Lin et al., 2003). Besides these molecules, investigators have 
developed antibodies to prevent gp120 binding to CD4. TNX-355 is a humanized anti-CD4 
monoclonal antibody that binds to CD4 without compromising CD4 function in immunological 
contexts, thus inhibiting HIV-1 envelope binding (Reimann et al., 1997). However, neither 
BMS-378806 nor TNX-355 have been approved for clinical application. The step after gp120 
binding to CD4 is the gp120 binding to chemokine coreceptor. Two agents have been approved 
by FDA, which target the interaction between Env and the coreceptor CCR5: fuzeon (T20) and 
maraviroc. Fuzeon is a peptide-based fusion inhibitor. The rational design of fuzeon is based on 
the finding that two homologous leucine zipper domains in the viral gp41 protein must interact 
with each other for fusion.  Replacing one of the domains with a heterologous protein, such as 
alpha-helical peptides, can disrupt the intramolecular interaction of the gp41. Based on the 
ordered solution structure, investigators ultimately developed fuzeon with potent antiviral 
activity in 2003. Maraviroc is a small-molecule antagonist of CCR5 that targets a hydrophobic 
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transmembrane cavity of CCR5. The binding alters the conformation of the second extracellular 
loop of CCR5 and prevents its interaction with the V3 stem loop of gp120. 
                 Reverse transcription has been extensively used as a target for antiretroviral drug 
development. Two types of reverse transcriptase inhibitors currently exist: 1) the nucleotide 
reverse transcriptase inhibitors (NRTIs); and 2) the non-nucleotide reverse transcriptase 
inhibitors (NNRTIs). NRTIs are nucleoside analogues with altered nucleosides lacking 3’-
hydroxyl groups. Thus, the incorporation of NRTIs prevents the formation of 3’-5’-
phosphodiester bond for the incoming 5’-nucleoside triphosphates, resulting in chain 
termination. NRTIs are prodrugs that require host cell entry and require phosphorylation by 
cellular kinases into triphosphates. There are currently seven FDA-approved NRTIs. Zidovudine 
(AZT) was the first antiretroviral drug approved by the FDA in 1987 for the treatment of HIV-1. 
Other FDA approved NRTIs are Didanosine (ddI), Stavudine (d4T), Lamivudine (3TC), 
Abacavir (ABC), Emtricitabine (FTC), and Tenofovir (Viread). The other class of RT inhibitors 
is the NNRTIs, which inhibit reverse transcription by binding to the hydrophobic pocket 
proximal to the active site. This binding alters the spatial conformation of the substrate-binding 
site, thus reducing the polymerase activity.  There are currently four FDA-approved NNRTIs: 
Etravirine, Rilpivirine, Efavirenz, and Nevirapine. Unlike NRTIs, NNRTIs only target HIV-1 (M 
group) but not the reverse transcriptase of other lentiviruses such as HIV-2 and SIVs. 
Interestingly, many NNRTI-resistance mutations are found in the wild- type sequences in HIV-1 
group O and HIV-2 viruses (Arts & Hazuda, 2012). 
                 The integrase catalyzes 3’ end processing of viral DNA and strand transfer. All 
integrase inhibitors (InSTIs) target the strand transfer step by interacting with both the integrase 
enzyme and its substrate-viral DNA. InSTIs are comprised of two components: a metal-binding 
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pharmacophore, sequestering the two essential magnesium metal ion cofactors between the 
integrase active site and the viral DNA, and a hydrophobic group interacting with both the viral 
DNA and the enzyme in the complex (Grobler et al., 2002). There are currently three FDA 
approved InSTIs: Raltegravir (RAL), Dolutegravir (DTG), and Elvitegravir (EVG). InSTIs-
resistance mutations map to the integrase active site near the amino acids that coordinate the 
essential magnesium cofactors. Thus, mutant viruses usually have damaged enzymatic function 
and dampened viral replication (Hazuda et al., 2000; Marinello et al., 2008). 
                 The protease is the key enzyme involved in virus maturation to produce infectious 
virions. Protease inhibitors (PIs) prevent the cleavage of viral Gag and Gag-Pro-Pol precursors 
by binding to HIV-1 protease binding pocket. There are currently eight PIs approved by FDA: 
atazanavir (ATV, Reyataz), darunavir (DRV, Prezista), fosamprenavir (Lexiva), indinavir (IDV, 
Crixivan), nelfinavir (NFV, Viracept), ritonavir (FOS-APV, Norvir), saquinavir (SQV, 
Fortovase/ Invirase), and tipranavir (TPV,Aptivus). Although the number of FDA approved PIs 
is impressive, the significant drawback is that all PIs share similar structures and bind to the 
same pocket of protease. Thus, cross-resistance is a common occurrence (Arts & Hazuda, 2012). 
Similar to InSTIs, resistant mutants and primary PI-resistant mutations cluster near the active site 
of the enzyme.  Thus, these mutations result in damaged enzymatic function and impaired 
replication fitness. However, investigators have found that HIV-1 viruses can: 1) undergo 
secondary/compensatory mutations to repair the enzymatic functions while maintaining the 
escaping capacity from PIs; and 2) select mutants that have altered cleavage sites of the 
polyproteins to serve as substrates for the mutated protease. As a result, the dramatic plasticity of 
HIV-1 genome helps the viruses to escape from drug recognition, while maintaining replication 
fitness. The HIV-1 life cycle presents many potential opportunities for therapeutic intervention. 
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Theoretically, any steps of the viral life cycle that can be distinguished from host systems can be 
exploited for novel therapeutics. Here, I have only discussed the viral replication steps that have 
yield FDA approved antiretroviral drugs.  
                 Due to the high mutation rate of HIV-1 (approximately one mutation in each viral 
genome with every replication cycle), current therapy uses a combination or cocktail of different 
drugs called highly active antiretroviral therapy (HAART) and more recently combined ART 
(cART). The critical number of CD4+ cell count for HAART initiation was raised from 350 to 
500 cells/mL in the US and from 200 to 350 cells/mL in mid- and low-income countries. Most 
current HAART regimens consist of three drugs: 2 NRTIs ("backbone")+ a PI/NNRTI/INSTI 
("base"). Initial regimens prefer drugs with a high efficacy and low side effect. As of July 2016 
(DHHS, 2016), the United States Department of Health and Human Services (US DHHS) 
recommended the following initial regimens: 1) tenofovir/emtricitabine and raltegravir; 2) 
tenofovir/emtricitabine and dolutegravir; 3) abacavir/lamivudine (two NRTIs) and dolutegravir 
for patients who have been tested negative for the HLA-B*5701 gene allele; 4) 
tenofovir/emtricitabine, elvitegravir (an integrase inhibitor) and cobicistat (inhibiting metabolism 
of the former) in patients with good kidney function (gfr > 70); 5) tenofovir/emtricitabine, 
ritonavir, and darunavir. HAART has dramatically increased the patient outcome of HIV-1-
infected individuals. But this requires strict adherence of the drug cocktails, which are very 
expensive and have significant side effects. Unfortunately, there is currently no solution to 
eliminate the virus completely from infected patients. Even with proper adherence, reservoirs 
viruses can slowly cause problems such as HIV-1-associated neurocognitive disorder (HAND). 
 
B Host Restriction of HIV-1 replication  
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(See Figure 24 for currently known host restriction factors against HIV-1) 
 
    1. TRIM5α 
                 TRIM5α is short for tripartite motif-containing protein 5 alpha isoform, which is also 
known as RING finger protein 88. It plays an important role in the innate immune defense by 
mediating species-specific restriction of retroviruses at an early post-entry stage. HIV-1 has a 
very narrow host range that is limited to humans and chimpanzees. TRIM5α plays a critical role 
in restricting HIV-1 replication in Old World monkey cells, such as rhesus and pig-tailed 
macaques (Shibata, Sakai, Kawamura, Tokunaga, & Adachi, 1995). 
                 TRIM5α is 493 amino acids in length and has a RING domain, B-box 2 domain, 
coiled-coil domain, and PRYSPRY domain. The RING and B-box 2 domains are required for 
efficient restriction activity of TRIM5α. The RING domain is located at the N-terminus, and 
contains a cysteine-rich zinc binding sequence. TRIM5α is able to self-ubiquitinate in a RING 
domain-dependent manner, and can also be ubiquitinated by another E3 ubiquitin ligase, Ro52 
(Yamauchi, Wada, Tanji, Tanaka, & Kamitani, 2008). The ubiquitination of TRIM5α is essential 
for HIV-1 restriction. The B-box 2 domain facilitates the cooperative binding to the HIV-1 
capsid by mediating higher-order self-association (X. Li & Sodroski, 2008). The coiled-coil 
domain, composed of multiple α-helices, promotes protein-protein interactions and is responsible 
for TRIM5α oligomerization, which contributes to the binding avidity to the target capsid. The 
PRYSPRY domain of TRIM5α forms dimers and directly interacts with various viral capsids to 
determine species specificity of retroviral restriction (Langelier et al., 2008; Song, 2009).  
                 TRIM5α is present in the cytoplasm and recognizes motifs on the capsid protein 









Figure 24. Cellular restriction factors. Decades of antiviral research have revealed that several 
host restriction factors including SAMHD1, Trim5α, APOBEC3 and BST-2 that target different 
steps of viral replication. However, the virus has also evolved strategies to counteract these 
restriction facotrs. For example Vif protein, short for Viral Infectivity Factor, can target 















inhibits the initiation of reverse transcription and the transport of the preintegration complex 
(PIC) to the nucleus. Proteasome activity also contributes to the restriction activity of TRIM5α 
(Anderson et al., 2006). Unlike other restriction factors, there is no viral accessory protein to 
counteract TRIM5α. The amino acid sequences of the variable region 1 (V1) of TRIM5α 
PRYSPRY domain have been shown to determine the aforementioned species-specific restriction 
of retrovirus infection (Nakayama, Miyoshi, Nagai, & Shioda, 2005). Thus, it is possible to 
modify the human TRIM5α gene through mutations in the V1 region or insertion of a CypA gene 
as found in monkeys to render restriction towards HIV-1 replication (Nakayama & Shioda, 
2015). The structure and function of TRIM5α is shown in Figure 25. 
 
    2. BST-2 and Vpu 
                 BST-2 (bone marrow stromal antigen 2), also known as tetherin, CD317, or HM1.24, 
is a lipid raft associated protein (Ishikawa et al., 1995). In 2008, two independent groups 
reported that BST-2 or tetherin acts as a host restriction factor that is counteracted by HIV-1 
protein Vpu (Neil et al., 2008; Van Damme et al., 2008). In addition, BST-2 has been found to 
trap the budding of several enveloped viruses including Kaposi's sarcoma-associated herpesvirus 
(KSHV), Ebola virus, Sendai virus, Chikungunya virus (CHIKV), Herpes simplex virus 1 (HSV-
1) by tethering progeny virus like particles (VLPs) to the cell surface (Swiecki, Omattage, & 
Brett, 2013). Additionally, it can reduce cell-to-cell transmission by inhibiting virological 
synapse formation. (Giese & Marsh, 2014) Similar to HIV-1, those viruses also evolved viral 
proteins to counteract the inhibition of BST-2 (Cao et al., 2009). One study has found that the 
topology of tetherin with two membrane anchors and a flexible ectodomain rather than the 
specific amino acid sequence is the determinant of preventing virions leaving the cells  
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Figure 25. TRIM5α structure and function. (A) Schematic representation of the domain structure 
of human TRIM5a protein. It has a RING domain, B-box 2 domain, coiled-coil domain, and 
PRYSPRY domain; (B) Postentry restriction (premature uncoating) by TRIM5α (Song, B. 











Figure 25    TRIM5α structure and function 
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BST-2 is constitutively expressed in only a few cell types including mature B cells, plasma cells 
and plasmacytoid dendritic cells. In many other cells, the expression level of BST-2 can be 
dramatically induced by IFN-α and IFN-γ. (Van Damme et al., 2008) 
                 BST-2 is a type 2 integral membrane protein, which consists of “a short N-terminal 
cytoplasmic tail (CT), a single transmembrane region (TM) consisting of a single α-helix, an 
ectodomain (ED), a second membrane anchor, and a C-terminal glycosylphosphatidylinositol 
(GPI)”. (Picture 26 shows the structure of BST-2 and the models of BST-2 antiviral action) 
(Swiecki et al., 2013). The ectodomain by itself is unstable and denatures at apporximately 35◦C. 
Crystal structure studies of the BST-2 ectodomain reveal that it forms a more stable parallel 
homodimer and serves as an adaptor connecting the host plasma membrane and progeny viruses 
at a distance of 170Å. (Hinz et al., 2010; Swiecki et al., 2011) 
                 BST-2 seems to be an ideal broad-spectrum inhibitor since it is able to restrict many 
enveloped virus like-particles tested to date. In addition, it targets a host cell derived component 
(viral envelope from the host cell plasma membrane) instead of a virus element that is very 
susceptible to mutations. In many cases, inhibitors targeting a viral component result in 
corresponding viral mutations that are able to counteract the drug.  In contrast, it is way more 
difficult for viruses to mutate their lipid envelope as it originated from host cells. As such, the 
envelope is more resistant to mutations than viral components. (Swiecki et al., 2013) However, 
viruses have evolved mechanisms to counteract the inhibition mediated by BST-2 (Swiecki et al., 
2013).  
                 The HIV-1 Vpu protein counteracts the action of BST-2. Vpu down-regulates the 









Figure 26. Structure of BST-2 and models of BST-2 antiviral action. (A) BST-2 contains a short 
N-terminal cytoplasmic tail (CT), a single transmembrane region (TM) consisting of a single α-
helix, an ectodomain (ED), a second membrane anchor, and a C-terminal 
glycosylphosphatidylinositol (GPI); (B) A dimeric assembly based on the mouse BST-2 crystal 
structure; (C) Direct tethering mode of BST-2-mediated inhibition of viral budding. Parallel 
BST-2 dimers insert one set of membrane anchors each into the viral membrane and host 
membrane. (D) BST-2 oligomers stabilize the tubulation and prevent membrane scission 
(Swiecki, M,et al. (2013). BST-2/tetherin: structural biology, viral antagonism, and 















network (TGN) and Vpu inhibits the transport of BST-2 to the plasma membrane (A. J. Andrew, 
Miyagi, & Strebel, 2011; Dube et al., 2009; S. Schmidt, Fritz, Bitzegeio, Fackler, & Keppler, 
2011). Second, Vpu induces the ubiquitination and degradation of BST-2 at the cell plasma 
membrane. The conserved di-serine motif (DSGxxS) in the cytoplasmic part of Vpu recruits the 
Skp, Cullin, F-box containing complex (SCF) E3 ubiquitin ligase complex via the adaptor 
protein β-TrCP. The ubiquitinated BST-2 enters the ESCRT-dependent endolysosomal pathway 
for degradation (Goffinet et al., 2010; Mangeat et al., 2009; Sauter, 2014; Swiecki et al., 2013). 
HIV-2 uses its Env protein, especially the endocytic motif in gp41, to induce clathrin-dependent 
internalization and sequestration of BST-2 to TGN (Hauser et al., 2010; Le Tortorec & Neil, 
2009). Most SIV Nef proteins interact with the N-terminus of BST-2 and recruits the endocytic 
adaptor AP-2, resulting in clathrin-dependent intracellular sequestration (Gotz et al., 2012; Serra-
Moreno, Jia, Breed, Alvarez, & Evans, 2011; Serra-Moreno, Zimmermann, Stern, & Evans, 
2013). Kaposi’s sarcoma-associated herpesvirus (KSHV, HHV-8) has a protein K5, which is an 
E3 RING-CH ubiquitin ligase. K5 protein is recruited to BST-2 via the N-terminal cytoplasmic 
tail (NT) of BST-2 and induces its proteasomal or ESCRT-dependent endo-lysosomal 
degradation (Bartee, McCormack, & Fruh, 2006; Mansouri et al., 2009; Pardieu et al., 2010). 
Interestingly, Ebola virus does not inhibit the action of BST-2 by decreasing the surface levels of 
this restriction factor. (Lopez et al., 2010) The mechanism of how Ebola virus escapes BST-2 
restriction is unknown. However, investigators have identified that the glycoprotein (Gp) of 
Ebola, especially the GP2 subunit, is critical in enhancing virion release (Kuhl et al., 2011; 
Lopez et al., 2010). Finally, glycoprotein M (gM) of HSV-1 also serves as an antagonist of BST-
2 restriction through at least two independent mechanisms: gM-mediated relocalization and a 
antagonists of BST-2 is shown in Figure 27. 
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gM-independent suppression of tetherin mRNA (Y. Liu et al., 2015). A summary of viral 
                 In addition to its antiviral function, BST-2 plays important roles such as: 1) serving as 
a ligand for the leukocyte inhibitory receptor ILT7 and modulating the IFN responses of the 
human plasmacytoid dendritic cells (pDCs) in a negative feedback manner (Cao et al., 2009; 
Gilliet, Cao, & Liu, 2008); 2) promoting metastasis and tumor cell evasion from immune 
surveillance (Cai et al., 2009; Yi et al., 2013); 3) enhancing viral entry and mediates early 
detection (Cao et al., 2009; Viswanathan et al., 2011); 4) facilitating monocyte adhesion to 
endothelial cells (Yoo, Park, Ye, & Kim, 2011); and 5) promoting cellular interactions (Swiecki 
et al., 2013). 
            
    3. SAMHD1 and Vpr 
                 SAMHD1 is short for sterile alpha motif (SAM) and histidine-aspartic domain (HD) 
containing protein 1. As the most recently identified HIV-1 restriction factor (Hrecka et al., 
2011; Laguette et al., 2011). SAMHD1 is a host deoxynucleoside triphosphate phosphohydrolase 
that hydrolyzes deoxynucleoside triphosphates (dNTP) into corresponding deoxynucleosides 
(dN) and inorganic triphosphates (Goldstone et al., 2011; Powell, Holland, Hollis, & Perrino, 
2011). Therefore, it is responsible for depleting the cellular dNTP pool that is required for the 
reverse transcription, which reduces the replication of HIV-1 in non-dividing cells, such as 
dendritic cells and macrophages. 
                 SAMHD1 is a tetramer (Yan et al., 2013) and is comprised of three regions: the N-
terminus, the catalytic core domain, and the C-terminus.  The N-terminus contains a nuclear 
localization signal at residues 11-14 (Brandariz-Nunez et al., 2012), and a sterile alpha motif 









Figure 27. Schematic representation of viral antagonists to BST-2: (A) SIV Nef; (B) HIV-1 Vpu; 
(C) HIV-2 Env; (D) HHV-8 K5; and (E) Ebolavirus Gp. Tetherin is shown in blue, the viral 
antagonists are shown in red (Sauter, D. (2015). Counteraction of the multifunctional restriction 







Figure 27    Schematic representation of viral antagonists to BST-2 
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contains the deoxyribonucleoside triphosphate triphosphohydrolase (dNTPase). The stability of 
the tetramer is closely linked to its antiviral activity (Yan et al., 2013). The initial GTP-binding 
to the primary sites results in the dimerization of SAMHD1 followed by dNTP binding to the 
secondary allosteric site to induce the conversion to a catalytically active tetrameric form. In 
addition to the well-characterized dNTPase activity, the catalytic core domain has a controversial 
DNA/RNA exonuclease activity (Beloglazova et al., 2013). The C-terminus (residues 600–626) 
forms a short α-helical structure with an extended loop (Schwefel et al., 2014). It also contains a 
conserved di-hydrophobic amino acid motif (Leu620-Phe621) that is recognized by cell cycle 
regulatory protein, cyclin A2-cyclin dependent kinase (cyclin A2-CDK). Cyclin A2 binds to this 
motif and allows CDK to mediate a critical post-translational phosphorylation at Thr592, which 
determines cell type dependent-HIV-1 restriction (Yan et al., 2015).  The phosphorylation at 
Thr592 determines the stability of the SAMHD1 tetramer and hence its antiviral activity. Both 
phosphorylated and non-phosphorylated SAMHD1 tetramers possess similar levels of 
catalytically activity (Arnold et al., 2015; Hansen, Seamon, Cravens, & Stivers, 2014). However, 
after depletion of dNTP pools, the phosphorylated SAMHD1 tetramer rapidly dissociates to an 
inactive form, while the low levels of cyclin A2-CDK in non-permissive and non-dividing cells 
allow unmodified SAMHD1 to form a long-lived, stable and catalytically active tetramer. 
(Arnold et al., 2015; Hansen et al., 2014). SAMHD 1 domain structures are shown in Figure 28. 
  
C APOBEC and Vif  
    1. APOBEC3 family of proteins 









Figure 28. SAMHD 1 Domain Structures. (A) A linear diagram of SAMHD1 comprising three 
domains; the N-terminus: Sterile Alpha Motif (purple), catalytic core: Histidine-Aspartic (HD) 
domain-containing domain (blue); and the C-terminus (yellow.) The nuclear localization signal 
(NLS) KRPR resides at amino acids 11–14. (B) The crystal structure of tetrameric human 
SAMHD1 catalytic core (each monomer is identified with distinct colors) in complex with dGTP 
(sphere) (Ahn, J. (2016). Functional organization of human SAMHD1 and mechanisms of HIV-1 















polypeptide-like” proteins 3. APOBEC3 proteins belong to a family of proteins that includes 
APOBEC1, activation-induced CDA (AID), APOBEC2, and APOBEC4. These proteins mediate 
the enzymatic conversion of cytosine (C) to uracil (U) on DNA (AID, A3) and/or RNA (A1) 
molecules, which results in multiple alternations of the nucleotide strand called hypermutaion. 
The A3 family contains seven cytidine deaminases (A3A, A3B, A3C, A3D, A3F, A3G and 
A3H). Human A3 genes are highly related and are tandemly located in a single cluster on 
chromosome 22 at q13.2 (Jarmuz et al., 2002). Old World monkeys, such as the rhesus macaque 
(Macaca mulatta), also express seven A3 genes, which are tandemly located on chromosome 10. 
This family plays an important role as sentinels in innate restriction to a broad numbers of 
mobile genetic elements (endogenous retroelements and exogenous viruses), including HIV-1, 
and other viruses such as parvoviruses and papillomavirus (Ahasan et al., 2015; H. Chen et al., 
2006; H. C. Smith, Bennett, Kizilyer, McDougall, & Prohaska, 2012). The activity of APOBEC4 
on RNA or DNA is currently unknown. 
                 All A3 proteins are characterized by one or two zinc-coordinating domains (Z 
domains) with the sequence H-x-E-x23–28-PC-x2–4-C. The histidine and cysteine residues 
coordinate Zn2+, while glutamic acid functions as a proton shuttle during the deaminase reaction 
(Betts, Xiang, Short, Wolfenden, & Carter, 1994). The Z domains catalyze cytidine deamination 
by removing the amine group (NH2) from cytosines, resulting in uracils on a variety of RNA/ 
DNA targets (Romani, Engelbrecht, & Glashoff, 2009). Three A3 family members (hA3A, 
hA3C and hA3H) have only one Z domain, while four (A3B, A3D, A3F and A3G) possess two Z 
domains (shown in Figure 29). Phylogenetic analysis revealed a clustering among A3 zinc-finger 
motifs, further classified as A3Z1, A3Z2 or A3Z3 (Wang, Schmitt, Guo, Santiago, & Stephens, 










Figure 29. Zinc (Z) coordinating-type domains of human A3 enzymes. The A3 proteins contain 
either a single cytidine deaminase domain (A3A, A3C, A3H) or duplicated domains (A3B, A3D, 
A3F, and A3G). Adapted from Feng, Yuqing, et al., Manipulation of the Host Cell by Viral 













active. An exception is A3B, which may have two catalytically active domains (Bogerd, 
Wiegand, Doehle, & Cullen, 2007).                   
               
    2. APOBEC3G and its restriction of HIV-1 (canonical and non-canonical pathway) 
                 A3G was the first identified A3 member with anti-HIV-1 activity and has been the 
most intensively characterized member of APOBEC3 family. The initial observation was that 
HIV-1 lacking vif (HIV-1Δvif) was severely restricted in the ability to replicate in non-
permissive cells, such as primary CD4+ T cells, macrophages and some T cell lines (e.g. H9, 
CEM) (Sova & Volsky, 1993). In contrast, HIV-1Δvif replicated well in permissive cell lines 
including Hela, COS, SupT1, Jurkat, CEM-SS (J. H. Simon, Gaddis, Fouchier, & Malim, 1998; 
Sova & Volsky, 1993). In order to explain the different phenotypes of non-permissive and 
permissive cell lines, two hypotheses were proposed. In the first hypothesis, permissive cells 
expressed additional factors to compensate the absence of Vif. The second hypothesis was that 
the non-permissive cells possessed inhibitory factors that were counteracted by Vif. To 
distinguish between these two possibilities, investigators applied an experimental approach by 
fusing a non-permissive cell to a permissive cell, and found that the transient heterokaryon did 
not support HIV-1Δvif replication. They concluded that the non-permissive cells “have an 
activity whose expression results in the inhibition of HIV-1 infectivity, and that the function of 
Vif is to counteract this”. This classic experiment is shown in Figure 30 (J. H. Simon et al., 
1998). Later in 2002, these investigators identified that this host restriction factor as CEM15 and 
later named APOBEC3G, through a complementary DNA subtraction strategy (Sheehy, Gaddis, 
Choi, & Malim, 2002).  









Figure 30. Strategy to test the infectivity of HIV-1 from transient non-permissive and permissive 
heterokaryons. A non-permissive cell and a permissive cell were fused. The transient 
heterokaryon did not support HIV-1Δvif replication. This classical experiment allows 
investigators to conclude that the non-permissive cells “have an activity whose expression results 
in the inhibition of HIV-1 infectivity, and that the function of Vif is to counteract this” (Simon, J. 
H, et al. (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nature 









Figure 30    Strategy to test the infectivity of HIV-1 from transient non-permissive and permissive heterokaryons 
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CD1 domain (A3G-CD1) and active C-terminal CD2 domain (A3G-CD2). A3G-CD1 is 
responsible for substrate binding like DNA and RNA. The incorporation of A3G into virions is 
essential for the 5’->3’ deamination processivity. In addition, it interacted with Vif to result in 
the recruitment of E3-ubiquitin ligase complex. However, the structure of A3G-CD1 remains 
elusive due to its poor solubility (Xiao, Li, Yang, & Chen, 2016). In contrast, the NMR and 
crystal structure of A3G-CD2 (residues 197– 380) was successfully resolved in 2008 (K. M. 
Chen et al., 2008; Holden et al., 2008). The A3G-CD2 has a core β-sheet that is composed of 
five β-strands surrounded by six α-helices.  Two of the six α-helices form the zinc-coordinating 
active site. The structure deduced from X-ray diffraction studies revealed that the AC loops 1 
and 3 and the regions near the active site form a deep, spacious groove that runs horizontally 
across the active center pocket and is involved in substrate recognition & binding (K. M. Chen et 
al., 2008; Holden et al., 2008).   The X-ray structure of A3G-CD2 is shown in Figure 31. The 
CD2 is catalytically active and critical for deamination and motif specificity. In general, in the 
absence of Vif, A3G is efficiently incorporated into progeny virions released from producer 
cells. It restricts further virus replication in target cells through both canonical (deaminase-
dependent) and non-canonical (deaminase-independent) pathways.  
                 In the absence of Vif, the newly translated A3G is recruited and packaged into HIV-1 
virions by associating with viral RNA. The binding to viral RNA is essential for the packaging of 
A3G. However, this association also diminishes the enzymatic activity of A3G. Nevertheless, 
this inactivation is relieved by viral RNase H during the reverse transcription in target cells 
(Soros, Yonemoto, & Greene, 2007). Studies have shown that N-terminal CD domain constitutes 
a viral packaging signal in A3G (Ma et al., 2013). More specifically, the tryptophan at position 










Figure 31. Ribbon representation of enzymatically active APOBEC3G-CD2 based on the X-ray 
structure (two views rotated 90°). It contains five-stranded-sheet core surrounded by six 
helices.The zinc is represented as a red sphere (Holden, L. G et al., (2008) Crystal structure of 
















A3G encapsidation (M. A. Khan et al., 2009). In addition, investigators identified that GC-
associated nuclear protein (GANP) contributes to A3G encapsidation into HIV-1 virions by 
revealing a positive correlation between cellular GANP level and A3G encapsidation level 
(Maeda et al., 2013).  
 Canonical pathway:  
                 In this pathway, as depicted in Figure 32, HIVΔvif infects non-permissive producer 
cells (i.e., expressing A3G) and A3G is incorporated into the virus released from the producer 
cells. Upon release from the producer cell, virus infects the “target cell” where the restriction 
occurs. A3G targets the newly made minus-strand DNA during reverse transcription and 
mediates extensive deamination of dC residues to dU residues, preferentially at the 3’-dC with 
context 5’-CC dinucleotides (R. S. Harris et al., 2003; H. Zhang et al., 2003). This mutation of 
dC to dU resides in the nucleotide strand is called hypermutation. The abnormal presence of 
uracils in DNA strand can be recognized by uracil-DNA glycosolase and subject to excision, 
leading to abasic sites that could result in DNA degradation in the presence of apurinic–
apyimidinic endonuclease (Yang, Chen, Zhang, Huang, & Zhang, 2007). For the few minus 
DNA strands that survive this attack, the dU in the minus template strand leads to dA during plus 
strand synthesis, resulting in the G to A mutation in the viral genome. This alters the viral 
opening reading frames and ultimately results in the mutation of codons leading to translation 
termination (R. S. Harris et al., 2003; Lecossier, Bouchonnet, Clavel, & Hance, 2003; Yang et 
al., 2007; H. Zhang et al., 2003). In addition, A3G restricts the replication of other retroviruses, 
such as simian immunodeficiency virus (SIV), equine infectious anemia virus (EIA), murine 
leukemia virus (MLV), human foamy viruses (HFV), human T-lymphotropic virus (HTLV-1), 
and human hepatitis B virus (HBV) at various levels through its enzymatic deaminase activity  
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Figure 32. In the Absence of Vif- Canonic Pathway of A3G restricting HIV-1. In the absence of 
Vif, A3G is incorporated into viral particle and upon second round infection, A3G will target 
minus-strand DNA during reverse transcription and lead to C to U mutation. Then 2 things will 
happern. . One is with the abnormal presence of U in DNA strand, it will be recognized by 
uracil-DNA glysolase and subject to destruction or, second strand will still be synthesized. As A 
pairs with U, it will end up with a G to A hypermutation in the viral genome ultimately leading 
to G-to-A hypermutations in the viral genome. Also, A3G can function in deaminase 
independent manner (Chiu, Y. L et al., (2009). Philosophical Transactions of the Royal Society 














                 Human A3G also functions in deaminase-independent manner by inhibiting reverse 
transcription and integration. The incorporation of A3G into the HIV-1Δvif virions also reduces 
the ability of tRNALys3 to prime reverse transcription by over 50 percent (F. Guo, Cen, Niu, 
Saadatmand, & Kleiman, 2006). A3G also reduces the efficiency and specificity of primer tRNA 
processing and removal of tRNALys3 during plus-strand DNA transfer, leading to the formation 
of aberrant viral DNA ends that ultimately hinders the integration of PIC into host chromosome 
(Mbisa et al., 2007). Finally, the N-terminal linker region of A3G is a docking site for the C-
terminal domain of HIV-1 integrase. The association of A3G protein with integrase may prevent 
the entry of PIC into the nucleus and impair viral DNA integration. (Luo et al., 2007)  
    3. APOBEC3/Vif Interactions 
                 Human A3G expression in non-permissive cells significantly restricts the replication 
and spread of HIV-1Δvif. However, it is incapable of restricting wild type HIV-1 replication 
since the viral protein Vif counteracts the action of human A3G. Vif serves as an adaptor protein 
in organizing the Vif–CBFβ–CUL5–ELOB–ELOC-Rbx2 pentameric complex that ultimately 
results in the polyubiquitylation and degradation of both A3G and Vif (Jager et al., 2011). First, 
Vif contains a SOCS-box motif to serve as a receptor for a Cullin-RING E3 ubiquitin-ligase 
complex consisting of Cul5, EloB and EloC, and the RING protein, Rbx2. Vif then specifically 
binds and recruits the substrate APOBEC3 proteins (A3C, D, F, G, or H) to the E3 ubiquitin 
ligase for covalent modification with polyubiquitin chains, which act as a target for proteasomal 
degradation (Salter, Morales, & Smith, 2014). Additionally, two independent groups identified 
that a cellular chaperone protein, core binding factor β (CBF-β), is required for the stabilization  
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of the interactions among Vif, the E3 ubiquitin-ligase complex, and APOBEC3 (Jager et al., 
2011; W. Zhang, Du, Evans, Yu, & Yu, 2011).  
                 Specifically, the N-terminal region of Vif binds to an N-terminal region of A3G 
(amino acids 54–124); the SLQ(Y/F)LA motif (amino acids 144–150) of Vif mediates binding to 
the elongin C (EloC) component of the E3 ligase complex; the zinc-binding motif, (HCCH, 
amino acids 108–139) within Vif, containing two conserved cysteines, mediates a second 
interaction with the Cullin 5 (Cul5) component;  and CBF-β forms three critical interactions with 
the N-terminus and zinc-binding domain of Vif. The complex of Vif- CBF-β-EloB-EloC-
Cullin5-Rbx2 E3 ubiquitin-ligase complex is depicted in Figure 33 (Y. L. Chiu & Greene, 2009; 
Conticello, Harris, & Neuberger, 2003; Y. Guo et al., 2014; Marin, Rose, Kozak, & Kabat, 2003; 
Sheehy, Gaddis, & Malim, 2003). 
                 Additionally, Vif is capable of down-regulating A3G expression level by partially 
impairing the translation of A3G mRNA. Unlike the well-characterized Vif-induced degradation 
of A3G, the functional role of the inhibition of A3G translation by Vif remained unclear until 
Santiago and colleagues reported that Vif requires stem-loops 2 and 3 in the 5′UTR of A3G 
mRNA to inhibit translation (Guerrero et al., 2016). The specific molecular mechanism still 
remains unknown. However, this down-regulation is possible through direct interaction since Vif 
binds to a few high-affinity binding sites in this region (Guerrero et al., 2016; Mercenne et al., 
2010; Stopak, de Noronha, Yonemoto, & Greene, 2003). Investigators have also found that the 
proteasomal degradation and translation inhibition of A3G by HIV-1 Vif are two independent 
pathways since “K26R mutation in Vif abolishes degradation of A3G by the proteasome but has 
no effects at the translational level” (Guerrero et al., 2016). These two pathways also appear to 







Figure 33. Cartoon depiction of a Vif-CBF-β-EloB-EloC-Cullin5-Rbx2 E3 ubiquitin-ligase 
complex. (A) Schematic depiction of Vif-mediated E3 ubiquitin-ligase complex. A3 proteins 
(red) are recruited to the N-terminal half of Cul5 (blue) through specific interaction with Vif 
(purple). EloB/EloC substrate adaptor(grey and green) bound to the Vif facilitates the association 
between Vif and Cul5. CBF-β stabilizes interactions of Vif with Cul5 and A3 substrates. The C-
terminal half of Cul5 bound to Rbx2 recruits an E2 ubiquitin conjugation enzyme responsible for 
ubiquinating A3 proteins. (B) Functional motifs of Vif involved in protein–protein interactions 
of the E3 ubiquitin ligase complex. Regions of Vif that interact with CBFβ, Cul5, EloC, are 
colored cyan, blue, and green respectively. Regions implicated in binding A3 proteins are color 
highlighted in red.  (Salter, J. D, et al. (2014). Structural insights for HIV-1 therapeutic strategies 












Figure 33    Cartoon depiction of a Vif-CBF-β-EloB-EloC-Cullin5-Rbx2 E3 ubiquitin-ligase complex 
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degradation is sufficient to partially restore viral infectivity (Guerrero et al., 2016).    
 
    4. Restriction by other human A3 proteins  
A3F 
                 A3F is the most closely related member to A3G in the APOBEC3 family with a 
sequence identity of approximately 50 %, and most significantly, their N termini (first 60 amino 
acids) are nearly identical. Although less potent than A3G, A3F shows a similar antiviral activity 
against HIV-1, which is antagonized by HIV-1 Vif (Bishop, Holmes, Sheehy, Davidson, et al., 
2004; Liddament, Brown, Schumacher, & Harris, 2004; Takaori-Kondo, 2006). In addition, it is 
able to restrict simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), 
and foamy viruses (FV) replication to equivalent level as A3G (Delebecque et al., 2006; 
Zielonka et al., 2009). 
                 As mentioned earlier, A3F contains two CD domains. The structure of A3F-CTD was 
resolved in 2013. It has “a canonical DNA cytosine deaminase fold, composed of five β strands, 
six α helices, and the catalytic zinc-binding site” (Bohn et al., 2013). Investigators also identified 
that “the zinc-coordinating residue (C283) and the catalytic residue E251 are located on helices 
α2 and α3 and define the catalytic pocket” (Bohn et al., 2013). The structure of human A3F-CTD 
is shown in Figure 34. 
                 Similar to A3G, A3F is incorporated into progeny virions and induces G-to-A 
hypermutation, to a less extent compared to A3G (at least 10 times less than the antiviral activity 
of A3G) (Bishop, Holmes, Sheehy, Davidson, et al., 2004; Liddament et al., 2004; B. Liu, Sarkis, 
Luo, Yu, & Yu, 2005). As with A3G, the enzymatic C-terminal CD domain mediates 










Figure 34. A3F-CTD  structure. The A3F-CTD has a canonical cytosine deaminase fold with five 
β strands and six α helices and the catalytic zinc-binding site. Th β1-β2 loop region (inset) has 
conformational plasticity (Bohn, M. F, et al. (2013). Crystal structure of the DNA cytosine 














packaging into virions (R. K. Holmes, Koning, Bishop, & Malim, 2007; Jonsson et al., 2006). 
Despite the shared features and sequence homology between A3F and A3G, A3F targets a 
different consensus dinucleotide 5’-TC (substrate cytidine underlined) for deamination. 
Moreover, A3F also appears to be capable of inducing C-to-T mutations in plus-stranded HIV-1 
cDNA at low levels (Bishop, Holmes, Sheehy, Davidson, et al., 2004; Bishop, Holmes, Sheehy, 
& Malim, 2004). Interestingly, the cytidine deaminase activity of A3F is not absolutely required 
for its antiviral activity (R. K. Holmes et al., 2007). In addition to the canonical hypermutation 
antiviral strategy, both A3G and A3F have been found to interact with HIV-1 integrase, hence 
inhibiting proviral DNA formation (Luo et al., 2007). 
                 Although A3F is also targeted by HIV-1 Vif through the recruitment of the Cullin5-
elongin B/C-Rbx2 ubiquitin ligase complex for proteasomal degradation similar to A3G, A3F is 
less efficiently degraded by Vif-activated pathways than A3G (Marin, Golem, Rose, Kozak, & 
Kabat, 2008). In addition, these two enzymes require distinct determinants for interactions with 
Vif. Amino acids 40YRHHY44 of Vif are essential for A3G binding while 14DRMR17of Vif is 
critical for A3F binding (Russell & Pathak, 2007; V. Simon et al., 2005; Tian et al., 2006). 
Substituting the critical binding sites for A3F/A3G in Vif to alanine revealed that A3G exerts a 
greater restriction effect on HIV-1 than A3F and A3DE in primary CD4+ T cells and 
macrophages (Chaipan, Smith, Hu, & Pathak, 2013). Investigators also identified that the 
289EFLARH294 region, and E324 of hA3F as critical for interactions with HIV-1 Vif and 
proteasomal degradation (Albin et al., 2010; J. L. Smith & Pathak, 2010). In addition, 
substitution of lysine at position 128, a residue critical for A3G and HIV-1 Vif association, does 
not affect the interaction between A3F and Vif (B. Liu et al., 2005). In addition to their most 
potent anti-HIV-1 activities among the APOBEC family, A3G and A3F are both expressed in 
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human CD4+ T cells, which is the principal target for HIV-1 infection in vivo. This further 
supports the central role of both enzymes as innate host restriction factors that can naturally 
encounter HIV-1, and the virus evolves different determinants in Vif to evade the anti-viral 
activities of each (Franca, Spadari, & Maga, 2006; Russell & Pathak, 2007). 
 
A3B 
                 A3B only has a weak anti–HIV-1 activity in cell culture assays. A3B contains two 
CDA that are both enzymatically active. The inhibition of HIV-1 by A3B protein is at least 
partly independent of DNA editing since inactivation of both catalytic domains didn’t completely 
abolish its antiviral activity (Bogerd et al., 2007; Doehle, Schafer, & Cullen, 2005; Malim, 
2009). Interestingly, this restriction is not relieved by HIV-1 Vif protein. Therefore, A3B is able 
to restrict wild-type HIV-1 replication to a limited extent (Doehle et al., 2005). Unfortunately, 
endogenous A3B is barely expressed in primary human lymphoid cells including CD4+ T cells, 
thus is unlikely to significantly reduce HIV-1 replication during natural infection. However, this 
dilemma also raises the possibility of a novel strategy for inhibiting HIV-1 replication in vivo 
through activation of the endogenous A3B gene expression in primary human lymphoid cells 
(Doehle et al., 2005). 
                 In addition to its anti–HIV-1 activity, A3B has been revealed to restrict other 
exogenous viruses and endogenous retrotransposons. It is able to inhibit human T-lymphotropic 
virus type 1 (HTLV-1) in a deaminase-dependent manner (Ooms, Krikoni, Kress, Simon, & 
Munk, 2012). A3B is capable of suppressing HBV replication in hepatocytes, and has been 
reported to result in less persistence, and a lowered risk for hepatocellular carcinoma (HCC) 
development (T. Zhang et al., 2013). A3B restricts HBV by inhibiting a positive regulator of 
118 
HBV expression, heterogeneous nuclear ribonucleoprotein K (hnRNP K), thus reducing its 
transcription. A3B is also a potent inhibitor of core-associated HBV DNA replication (W. Zhang 
et al., 2008).  It has been shown that A3B expression is upregulated by HPV E6/E7 oncoproteins. 
A cellular zinc-finger protein, ZNF384, plays an important role in the proximal-region-mediated 
activation of A3B by E6 (Mori, Takeuchi, Ishii, & Kukimoto, 2015). Additionally, investigators 
found that endogenous A3B appears to restrict Long Interspersed Nuclear Element-1 (LINE-1 or 
L1) retrotransposition in a broad range of cell types, including pluripotent human embryonic 
stem cells (hESCs) (Wissing, Montano, Garcia-Perez, Moran, & Greene, 2011). 
                 Moreover, A3B has been revealed to play a role in cancer development (Ooms et al., 
2012). A3B is the only family member of APOBEC that has steady-state nuclear localization 
(Lackey et al., 2012). The presence of A3B in the nucleus provides A3B with the potential to edit 
cellular DNA. It has been reported that A3B can impair genomic stability by inducing base 
substitutions in genomic DNA in human cells (Shinohara et al., 2012). The investigators also 
found that “A3B is highly expressed in several lymphoma cells and somatic mutations occur in 
some oncogenes of the cells highly expressing A3B” (Shinohara et al., 2012). Additionally, A3B 
mRNA was found to be overexpressed in tumors and a clinical study showed that A3B high 
expression status is associated with aggressive phenotype such as lymph node metastasis and 
pathological nuclear grade in Japanese breast cancers (Tsuboi et al., 2016). 
 
A3A 
                 A3A is generally thought to have no anti–HIV-1 activity (Franca et al., 2006; R. S. 
Harris & Liddament, 2004; Malim, 2009). However, investigators later found that A3A is critical 
in monocyte resistance to HIV-1 (Peng et al., 2007). It contains a single CDA domain, is 
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naturally expressed in immature monocytes, and can be induce by IFN- αA more detailed 
discussion of human A3A and its antiviral activity will be discussed later. 
 
A3C 
                 A3C also contains a single CDA domain. It is expressed in CD4+ T cells, and can act 
in target cells to introduce limited G-to-A mutations at sub-lethal levels during infection by some 
HIV-1 strains. Since the A3C induced G-to-A mutation doesn’t abolish the viral replication, it 
may instead contribute to viral fitness and diversity, helping virus to escape from immune 
surveillance and antiviral drugs treatment (Bourara, Liegler, & Grant, 2007; Malim, 2009). A3C 
is sensitive to Vif-mediated degradation. Specifically, residues Leu72, Phe75, Cys76, Ile79, 
Leu80, Ser81, Tyr86, Glu106, Phe107 and His111 in A3C are critical for forming interaction 
with Vif, while Arg122 is important for A3C encapsidation into progeny virions (Kitamura et al., 
2012; Stauch et al., 2009). The A3C and Vif interface is marked by a hydrophobic bottom and 
hydrophilic edges (Kitamura et al., 2012). Investigators found that A3C dimerization is critical 
for its antiviral activity (Stauch et al., 2009). 
                 In addition to its weak antiviral activity to HIV, human A3C can effectively restrict 
SIVmacΔVif and SIVagm ΔVif (Q. Yu et al., 2004). Studies have shown that the counteraction of 
Vif and A3C is species specific that Vif proteins from diverse HIV/SIV lineages have distinct 
interaction interfaces with A3C (Z. Zhang et al., 2016). It can also inhibit the replication of 
human papillomavirus (HPV) infectivity (Ahasan et al., 2015). The restriction of HPV is not 
mediated by hypermutation, but possibly through a direct interaction between A3C and HPV16 
pseudovirion capsid protein L1 (Ahasan et al., 2015). 
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                 The crystal structure of full-length human A3C has been resolved in 2012. “The A3C 
structure has a core platform composed of six α-helices (α1–α6) and five β-strands (β1–β5), with 
a coordinated zinc ion that is well conserved in the cytidine deaminase superfamily” (Kitamura 
et al., 2012), as shown in Figure 35. The core structure of A3C and A3G C-terminus domain 
(A3G CTD) are similar, while their loop structures are distinct. The β2-strand of A3C exhibits a 
continuous well-ordered characteristics with high stability, which is remarkably different from 
that of the A3G CTD (Kitamura et al., 2012). 
 
A3D 
                 A3D is previously referred as A3D/E. A3D can also modestly inhibit HIV-1 infection 
when overexpressed in virus producing cells. In the absence of Vif, A3D can be packaged into 
progeny virions and is cable of inducing G-to-A mutations in viral minus strand during reverse 
transcription at a lower frequency (0.13%) compared to A3G (0.5%). A3D targets a novel 
dinucleotide site 5’CC3’ (substrate cytidine underlined) and is expressed at higher levels than 
A3F in non-permissive cells including MT4, H9, PM1, Hut78, JM1, and CEM cells and primary 
peripheral blood lymphocyte (PBL), and is broadly expressed in tissues in a more abundant 
manner (Dang, Wang, Esselman, & Zheng, 2006). In addition, it forms heteromultimers with 
A3F or A3G in the cell, which might contribute to the intracellular defense network (Dang et al., 
2006; Malim, 2009).  A3D is also sensitive to Vif-mediated degradation. Vif mediates A3D 
polyubiquitylation by Cul5-based E3 ligases, which is further degraded in the 26S proteasome 
(Dang et al., 2006). Ten residues in A3D (Leu268, Phe271, Cys272, Ile275, Leu276, Ser277, 









Figure 35. The X-ray crystal structure of full-length A3C. Two views of the A3C structure, 
rotated by 90°. A3C contains six α-helices (red) and five β-strands (yellow). The zinc is 
represented as a blue sphere (Kitamura, Shingo, et al. "The APOBEC3C crystal structure and the 
















Similar to A3F, 14DRMR17 motif in Vif is necessary for the degradation of APOBEC3D (Sato et 
al., 2014). In addition to its antiviral activity to HIV-1, it also restricts the replication of SIVagm, 
and SIVmac, but is not able to inhibit Murine leukemia virus (MLV) (Dang et al., 2006). 
                 A3D, similar as A3G, A3H, and A3F, fundamentally works as restriction factor 
against HIV-1 by inducing hypermutation in the viral genome. However, at the same time, the 
mutations may positively contribute to viral diversification and evolution in vivo. Investigators 
have shown that viruses are specifically and significantly diversified in a humanized mouse 
model (Sato et al., 2014). 
                 Interestingly, it has recently been reported that human A3D is able to antagonize A3F 
and A3G restriction of HBV replication through direct binding to itself, A3F, and A3G proteins. 
Thus, A3D suppresses the antiviral activity of A3F and A3G, resulting in an enhanced HBV 
replication (Bouzidi et al., 2016). 
  
A3H 
                 Human A3H is the only APOBEC3 protein that contains a single copy of a Z3-type 
APOBEC3 catalytic domain. Several studies revealed that several stable APOBEC3H haplotypes 
are present in vivo and act as barriers to HIV-1Δvif propagation, and Vif is capable of adapting to 
these restrictive pressures, reaching for an evolutionary equilibrium (Ooms et al., 2013; Refsland 
et al., 2014). 
                 There are several single-nucleotide polymorphisms (SNPs) been found in A3H gene, 
making it as the most polymorphic member of the APOBEC3 family. Seven haplotypes (hap I–
VII) and four mRNA splicing variants (SV) of A3H have been identified (Gu et al., 2016). 
Different haplotypes possess great variability in protein stability, subcellular distribution, and/or 
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RNA binding and virion packaging (Gu et al., 2016; Zhen, Du, Zhou, Xiong, & Yu, 2012). There 
are primarily four haplotypes circulating in human population: HapI, 18R/105G/121K/178E; 
HapII, 18R/105R/121D/E/178D; HapIII, d15N/18R/105R/121D/E/178D; and HapIV, 
d15N/18L/105R/121D/E/178D (Zhen, Wang, Zhao, Xiong, & Yu, 2010). It has been observed 
that functional APOBEC3H polymorphisms are associated with the susceptibility to HIV-1 
infection and progression to AIDS in vivo (Sakurai et al., 2015). 
                 A3H_HapII and A3H_HapI differ only three amino acids. However, they share 
distinct characteristics and antiviral profiles. A3H_HapII is the most stable and restricts HIV-
1ΔVif at the highest level (Harari, Ooms, Mulder, & Simon, 2009). Similar to A3G, A3H_HapII 
induces proteasome-mediated degradation in the presence of Vif. The E121 residue in hA3H 
hapII plays a critical role in determining its sensitivity to HIV-1 Vif derived from the NL4-3 
strain. Noteworthy, the interaction between A3H_HapII and Vif is mediated through unique 
substrate recognition domains of Vif that are distinct from those for the human A3G and A3F 
proteins. Although A3H_HapI is less stable to A3H_HapII, investigators have found that it is 
insensitive to Vif-mediated degradation. Further, a single amino acid change in HapI (G105R) 
greatly stabilized the protein and increased its antiviral activity against wild type HIV-1 (Zhen et 
al., 2010).  
                 A study comparing primate A3H sequences revealed that a premature termination 
codon was identified on the fifth exon of the human and chimpanzee A3H genes, leading to a 
significant decrease in their mRNA and protein expression. Specifically, the investigators found 
that the truncated protein was as stable as the full-length protein while the truncated mRNA is 
very unstable. Restoring full length A3H expression by correcting the premature termination 
codon allows human A3H to reduce HIV-1 infectivity up to 150-fold through a deamination-
125 
independent mechanism. Despite the fact that HIV-1 Vif is capable of to form a direct 
association with the optimized A3H (A3H helixes α3 and α4 interact with the Vif β-sheet (β2-β5) 
(Ooms, Letko, & Simon, 2016)), it is unable to counter the restriction carried by A3H (Dang et 
al., 2008; Malim, 2009; Sakurai et al., 2015). Thus, optimizing the expression of endogenous 
A3H in vivo could be a novel strategy of anti-HIV therapy (Dang et al., 2008). However, this 
study didn’t specify which haplotype of A3H was studied. 
                 A3H_HapII can be packaged in human T-lymphotropic virus (HTLV-1) particles and 
has been found to restrict HTLV-1 replication. Interestingly, this restriction is acted in a 
deaminase-independent manner, thus A3H hapII does not require an intact deaminase domain for 
function (Ooms et al., 2012). 
                 Noteworthy, A3H_HapI is thought to contribute to breast and lung cancer 
mutagenesis. Previously, A3B was shown to play a critical role in causing cytosine mutations 
within TCA/T motifs. However, it has been observed that A3B-null breast tumors still have this 
mutational bias. The investigators were surprised to find that a previously deemed unstable and 
inactive variant - A3H_HapI showed a statistically significant association with the mutations. 
They further testified that A3H_HapI is catalytically active through biochemical and cell-based 
assays. In addition, A3H_HapI has increased nuclear localization, providing a mechanism for 
accessing genomic DNA. (Starrett et al., 2016). 
 
D APOBEC3A and HIV-1  
    1. Human A3A 
                 Human A3A belongs to the APOBEC family and has only one zinc-coordinating 
domain (Holden et al., 2008; Kitamura et al., 2012). Human A3A has been shown to play an 
126 
important role in the innate restriction by displaying a broad range of activities against 
exogenous viral pathogens and endogenous retrotransposons (Y. L. Chiu & Greene, 2008). 
                 The nuclear magnetic resonance (NMR) structure of A3A (residues 10-194 of 199 aa) 
has been resolved. The structure consists of six helices surrounding a central β sheet of five 
strands (shown in Figure 36), which is common to all known APOBEC protein structures (Byeon 
et al., 2013). Specifically, A3A NMR structure is most similar to the X-ray structure of the A3G-
CTD (residues 191-384), with some differences in the loop region. An interesting feature of 
hA3A is the presence of four amino acids between the two cysteine residues of the canonical 
deaminase domain. The group also shows that A3A binds TTCA- or CCCA-containing single-
stranded oligonucleotides (≥9 nt). It has been noted that A3A binds to ssDNA much more 
weakly (~1000-fold) than A3G (Byeon et al., 2013). Interestingly, the NMR experiment shows 
that RNA binding is specific, but almost tenfold weaker than binding of the corresponding 9-nt 
DNA. However, gel shift assays with a 40nt of ssRNA and ssDNA results in a different 
conclusion: the binding efficiency is three folds higher for ssRNA than for the corresponding 40-
nt ssDNA. This observed difference in the binding affinity may attribute to the differences in the 
EMSA and NMR, as well as the specific and non-specific binding to a long RNA (Byeon et al., 
2013; Mitra et al., 2014). 
                 Human A3A was previously thought to exist as monomers. However, a recent salient 
finding showed that A3A actually forms homodimers and the dimerization creates a highly 
positive groove that connects the active site of both monomers, allowing the A3A homodimers to 
recognize substrate cooperatively with high affinity and specificity. The investigators also 
identified that H11/H56 and H16/K30 are critical for cooperative DNA binding (Bohn et al., 










Figure 36. Ribbon representation of human A3A based on NMR structure. It consists of six 
helices (hot pink) surrounding a central β sheet of five strands (royal blue) (Byeon, In-Ja L., et al. 
"NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme 
















Figure 36    Ribbon representation of human A3A based on NMR structure 
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                 Human A3A has been involved in regulating the activity of many viruses.  
                 Importantly, human A3A can act as a specific inhibitor of the early phases of HIV-1 
infection in myeloid cells such as dendritic cells and macrophages (Berger et al., 2011). Human 
A3A is expressed at high levels in cells of the myeloid lineage including monocytes and 
macrophages, and its expression is stimulated in response to interferon-alpha (IFN- α) (Koning et 
al., 2009; Peng et al., 2007; Refsland et al., 2010; Thielen et al., 2010). The high level of A3A 
expression explains why myeloid cells are generally resist to HIV-1 infection during the early 
phase of infection. In addition, silencing of A3A in monocytes was associated with increased 
susceptibility to HIV-1 infection. Finally, A3A-specific editing of HIV-1 minus-strand DNA 
during reverse transcription was found to occur in infected myeloid cells, suggesting a role for 
A3A deaminase activity in HIV-1 restriction (Berger et al., 2011; Peng et al., 2007). 
                 In another study, it was shown that A3A, together with A3C and A3H, are expressed 
in keratinocytes and skin, and is able to edit human papillomavirus (HPV) DNA. As a result, this 
editing contributes to the initial benign and precancerous lesions, eventually promoting skin 
cancer development (Vartanian, Guetard, Henry, & Wain-Hobson, 2008). In contrast, another 
study suggests that human A3A actually exerts a protective effect by significantly suppressing 
HPV propagation. They first noticed that HPV-positive cervical and head-and-neck cancers 
exhibited higher rates of APOBEC3 mutation signatures than most HPV-negative cancers. Then 
they found that hA3A expression levels are highly elevated in HPV-positive keratinocytes and 
cervical tissues in early stages of cancer progression. Importantly, the team reported that HPV 
virions assembled in the presence of human A3A have significantly lower infectivity compared 
to HPV virions assembled in the absence of A3A or with the presence of a catalytically inactive 
mutant, hA3A/E72Q. However, no evidence of mutations was found (Ahasan et al., 2015).  
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Additionally, knocking-down A3A in human keratinocytes results in a significant increase in 
HPV infectivity (Warren et al., 2015). Thus, human A3A may act as a double-edged sword: it 
serves as restriction factor against HPV infection, while contributing to cancer mutagenesis at a 
cost. 
                 Investigators also found that the alpha-retrovirus, Rous sarcoma virus (RSV), is 
susceptible to inhibition by all human APOBEC proteins tested including human A3A. The fact 
that alpha-retroviruses resides in avian hosts and usually do not have access to human APOBEC3 
proteins in their normal life cycle, but are susceptible to restriction of all human APOBEC3 
proteins, “suggests that the resistance of mammalian retroviruses to inhibition by the APOBEC3 
proteins expressed in their normal host species is likely to have evolved subsequent to the 
appearance of this family of mammalian antiretroviral proteins some 35 million years ago; i.e., 
the base state of a naive retrovirus is susceptibility to inhibition.” (Wiegand & Cullen, 2007) 
                 The single-stranded DNA viruses, parvovirus, is also a target of human A3A (H. Chen 
et al., 2006; Narvaiza et al., 2009). The first report reveals that human A3A potently inhibits 
parvovirus adeno-associated virus (AAV) replication. Although the conserved amino acids of the 
hA3A active site are needed, there are no mutations found in the retroelement sequences (H. 
Chen et al., 2006). In addition, a more recent study confirmed that deaminase activity is not 
required for the antiviral activity of A3A against parvoviruses. Through generation the chimeric 
proteins of A3A and A3G, they were able to define that the VS1 region of A3A (residues 60 to 
67) contributes to the antiviral activity against parvovirus (Narvaiza et al., 2009). 
                 Human A3A is also able to inhibit human T-lymphotropic virus type 1 (HTLV-1) in a 
deaminase dependent manner. The investigators showed that human A3A was efficiently 
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packaged in HTLV-1 virions, and a catalytic-site mutant abolished HTLV-1 restriction (Ooms et 
al., 2012).   
                 More recently, a study analyzed the restriction of the retrovirus murine leukemia virus 
in hA3A and hA3G transgenic mice in a mouse A3-knockout background (Stavrou et al., 2014). 
These investigators showed that hA3G and hA3A restricted murine retroviruses by different 
mechanisms. They observed that hA3G was packaged into virions and caused extensive 
deamination of the viral genome, while hA3A was not packaged into virions and restricted 
infection when expressed in target cells (Stavrou et al., 2014). This study also found that hA3A 
can restrict murine retroviruses by a deamination-independent mechanism (Wang, Schmitt, et al., 
2016). 
                 In addition, human A3A is capable of recognizing and degrading foreign DNA 
(Stenglein, Burns, Li, Lengyel, & Harris, 2010), inhibiting retrotransposition of LINE-1, Alu, and 
LTR retroelements. Interestingly, the signature mutation of A3A was not detected in LINE-1 and 
other retrotransposon DNA sequences (Bogerd et al., 2006; Kinomoto et al., 2007; Muckenfuss 
et al., 2006). Furthermore, it possesses a unique ability of deaminating 5-methylcytosine, a 
methylated form of the DNA base cytosine that is involved in the regulation of gene 
transcription, to thymine (T) (Carpenter et al., 2012; Wijesinghe & Bhagwat, 2012). It has been 
reported that overexpression of A3A in cells results in increased level of DNA breaks and 
activation of damage responses in a deaminase-dependent manner, leading to cell cycle arrest 
(Landry, Narvaiza, Linfesty, & Weitzman, 2011). However, those experiments are done using 
overexpression of exogenous A3A, while the endogenous A3A has been shown to reside 
primarily in cytoplasm, thus nongenotoxic. It should be noted that the antibody used to detect 
endogenous hA3A in the study was probably not specific to human A3A. More convincing proof 
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like identification of a cytoplasmic retention signal similar to that of human A3G is needed for 
further confirmation (Taggart et al., 2013). A study has shown that cellular genome becomes 
especially vulnerable to A3A editing during DNA replication when cytoplasmic A3A accesses 
nuclear DNA (Green et al., 2016). This genomic instability caused by A3A is relieved and 
balanced by the expression of Tribbles Homolog 3 (TRIB3), a human protein kinase induced by 
NF-κB. Either overexpression of A3A or knock-down of TRIB3 leads to elevated levels of 
nuclear DNA editing and cell cycle arrest (Aynaud et al., 2012). 
      
    2. Non-human primate A3A proteins 
                 This part is an excerpt from Wang, Y., Schmitt, K., Guo, K., Santiago, M. L., & 
Stephens, E. B. (2016). Role of the single deaminase domain APOBEC3A in virus restriction, 
retrotransposition, DNA damage and cancer. Journal of General Virology, 97(1), 1-17. 
                 In contrast to hA3A, a previous study in our laboratory about rhesus macaques 
showed that rhesus macaque A3A (rhA3A) was capable of restricting the replication of Vif-
deficient SHIVΔvif at similar levels as rhesus macaque A3G (rhA3G) (Schmitt et al., 2011). 
Although another group observed that rhA3A did not restrict replication (Hultquist et al., 2011), 
this discrepancy was probably due to the position of the hemagglutinin (HA) tag fused to the 
rhA3A (Schmitt et al., 2013). Furthermore, hA3A was capable of significantly restricting 
SHIVΔvif although not to the same extent as rhA3G (Schmitt et al., 2011). These results indicate 
that hA3A is capable of restricting lentiviruses other than HIV-1Δvif. Similar to the conclusions 
observed above for hA3A (Love, Xu, & Chelico, 2012), we observed that rhA3A was capable of 
cytidine deamination but not at the same frequency as rhA3G (Schmitt et al., 2011).  
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                 Our results with rhA3A raised the question of whether the A3A proteins from other 
non-human primates restrict HIV-1/SIV/SHIV and the importance of the 3 amino acids deletion 
in hominid A3A proteins. Recently, we examined the restriction properties of A3A proteins from 
an additional hominid (Lars gibbon; gibA3A), two additional Old World monkeys [African 
green monkey (agmA3A) and black and white colobus monkey (colA3A)] and two New World 
monkeys [squirrel monkey (sqmA3A) and northern owl monkey (nomA3A)] (Schmitt et al., 
2013) . Similar to hA3A, gibA3A did not restrict HIV-1Δvif or SHIVΔvif, indicating that the 
lack of HIV-1Δvif restriction is probably conserved among hominids. Similar to rhA3A, we 
found that agmA3A and colA3A restricted the replication of SHIVΔvif and that all three Old 
World monkey A3A proteins (agmA3A, colA3A, and rhA3A) restricted HIV-1Δvif to some 
extent, with mndA3A being the most effective. Among the New World monkeys, sqmA3A 
restricted SHIVΔvif but not HIV-1Δvif, whereas nomA3A restricted neither SHIVΔvif nor HIV-
1Δvif (Schmitt et al., 2013). As the A3A proteins from select Old World monkeys could restrict 
HIV-1Δvif, we investigated the molecular determinants that define restriction. Using the distinct 
phenotypes of rhA3A (virus restriction) and hA3A (no virus restriction) in epithelial cells, a 
series of hA3A/rhA3A chimeric proteins were constructed and their restriction properties on 
HIV-1Δvif were analyzed (Schmitt et al., 2013). Our results showed that a chimeric A3A protein, 
designated rh25-33hA3A, which had the AC loop 1 region of hA3A replaced by the AC loop 1 
region of rhA3A, restored the restriction properties of hA3A to a similar level as rhA3A 
restriction of SHIVΔvif (Schmitt et al., 2013). Interestingly, rhA3A amino acids 25–33 map to 
the AC-loop1, and molecular modeling suggests that the AC-loop1 of rhA3A has a greater 
molecular surface compared with hA3A. Due to its predicted solvent accessibility, this additional 
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molecular surface may be an important region for protein–protein interactions that do not occur 
with hA3A. 
                 The finding that sqmA3A restricted SHIVΔvif is interesting, as the New and Old 
World monkeys branched approximately 30–35 million years ago with the separation of South 
America from Africa. To date, no lentiviruses have been isolated from New World monkeys. 
This brings up the question of whether some New World monkey A3A proteins may have 
evolved to restrict other viruses. One potential candidate is the foamy viruses (FVs), which are 
exogenous, persistent and non-pathogenic retroviruses in the subfamily Spumaretrovirinae 
(Switzer et al., 2005). FVs have been isolated from a broad range of mammals including non-
human primates (both New and Old World monkeys), horses, cows and cats (Hussain et al., 
2003; Meiering & Linial, 2001; Rethwilm, 2010). Previous studies have shown that the FVs have 
co-specieated with their mammalian hosts. For example, FVs express the Bet protein, which 
antagonizes A3 restriction and may play a role in both particle release and virus persistence 
(Alke et al., 2001; Chareza et al., 2012; Lochelt et al., 2005; Russell et al., 2005; Saib, Koken, 
van der Spek, Peries, & de The, 1995). A remarkable feature of the FVs is that they have the 
capacity to cross species barriers and pose a significant risk of interspecies transmission to 
humans (Heneine, Schweizer, Sandstrom, & Folks, 2003; Switzer et al., 2005). While no disease 
has been associated with the transmission of FVs to humans, the ease of primate-to-primate 
transmission implies the co-evolution of host restriction factors, as viral disease mechanisms are 
not sufficient to prevent cross-species transmission (A. S. Khan, 2009; Leendertz et al., 2008). 
As the FVs are promising candidates for the development of viral vectors for gene delivery and 
vaccination, it will be of interest to determine whether New and Old World monkey A3A 
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proteins are capable of restricting the replication of spumaviruses (Rethwilm, 2010; Schwantes, 




Chapter II : Identification of three Old World Monkey A3A proteins that 
were able to inhibit WT HIV-1 
 Abstract    
                 Previous studies have shown that human A3A (hA3A) normally does not restrict the 
replication of HIV-1Δvif in CD4+ T cells. The exception is that, when expressed at high levels in 
macrophages and monocytes in response to IFN-α, hA3A restricts HIV-1Δvif without 
incorporation. The mechanism of restriction is still unknown (Berger et al., 2011; Bishop, 
Holmes, Sheehy, & Malim, 2004; Koning, Goujon, Bauby, & Malim, 2011; Thielen et al., 2010). 
Previous research in our lab revealed that A3A proteins from various hominid and non-human 
primates possess distinct restriction patterns towards HIV-1/SIV/SHIV. Similar to rhA3A, we 
found that agmA3A and colA3A restricted the replication of SHIVΔvif and that all three Old 
World monkey A3A proteins (agmA3A, colA3A, and rhA3A) restricted HIV-1Δvif to some 
extent, with mndA3A being the most effective. More importantly, three OWM A3A-colA3A, 
mndA3A and debA3A were not only able to inhibit the replication of HIV-1Δvif, but also WT 
HIV-1 and HIV-1Δvif. 
 
Introduction 
                 The inability of hA3A to restrict HIV-1Δvif has been linked to its poor incorporation 
into the nucleoprotein complex (NPC) during maturation. Targeting hA3A to the nucleoprotein 
complex by either fusion to the N-terminal domain of A3G or fusion to Vpr results in enhanced 
incorporation and restriction activity (Aguiar, Lovsin, Tanuri, & Peterlin, 2008; Goila-Gaur, 
Khan, Miyagi, Kao, & Strebel, 2007). In contrast to hA3A, a study in rhesus macaques showed 
that rhesus macaque APOBEC3A (rhA3A) is capable of restricting both simian–human 
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immunodeficiency virus (SHIVΔvif) and human immunodeficiency virus (HIV-1Δvif) to a 
greater extent than hA3A. More impressively, previous work in our lab showed that the A3A 
protein from the black and white colobus monkey (mantled guereza; Colobus guereza; colA3A) 
potently inhibited not only HIV-1Δvif replication but also wild-type HIV- 1 in producer cells 
(Schmitt et al., 2013) Sequence alignment of various A3As revealed an important region - AC 
loop 1 in determining the restriction pattern against lentiviruses. Thus, we analyzed the ability of 
A3A proteins from Mandrillus sphinx (mndA3A) and Cercopithecus neglectus (debA3A), which 
have similar AC-loop1 region as colA3A, to restrict HIV-1. 
 
Results 
Cells expressing HA–colA3A inhibit HIV-1 production 
                 293 cells were co-transfected with the vector expressing colA3A and either HIV-1 or 
HIVΔvif. In the presence of colA3A, HIV-1 and HIVΔvif released 0.1% p24 (HIV-1: mean of 
0.58 ng/ml, range of 0.21 to 0.91 ng/ml; HIV-1Δvif: mean of 0.48 ng/ml, range of 0.18– 0.60 
ng/ml) compared to the other A3A proteins (HIV-1: mean of 1110 ng/ml, range of 700–1272 
ng/ml; HIV-1Δvif: mean of 2781 ng/ml; range of 1112–4985 ng/ml (Schmitt et al., 2013) (Figure 
37). 
                 Similar to the co-transfection experiment in 293 cells, we expressed colA3A 
expression into a more relevant cell line, TZM-bl cells. TZM-bl cells were transfected with a 
vector expressing HA–colA3A and selected for G-418 resistance for 2 weeks. The resulting G-
418 resistant cells were analyzed for the expression of HA–colA3A by immunoprecipitation 
using an antibody against the HA-tag. The immunoprecipitation analysis revealed that the TZM-
bl cells transfected with the vector expressing HA–colA3A expressed HA–colA3A while the 
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parental TZM-bl cell line was negative for HA–colA3A expression (Figure 38A.). We used these 
HA–colA3A expressing cells to determine if they would restrict the replication of HIV-1. TZM-
bl cells expressing HA-colA3A were inoculated with HIV-1 at an MOI of 1.0 and at 48 h post-
inoculation, the culture supernatants and cell lysates were assessed for Gag p24 release and 
infectivity test on TZM-b1 cells (Figure 38B). Diagram of the restriction assay is shown in 
Figure 39. The results indicate that HIV-1 production was significantly inhibited in TZM-bl cells 
expressing HA–colA3A (Katuwal et al., 2014). 
 
Comparision of the N-terminal sequences of the several OWM A3As 
                 N-terminal sequences of the several OWM A3As were aligned together to determine 
if the A3A sequences from other OWM were similar to colA3A (Figure 40). Our analysis 
indicates that the A3A proteins from Mandrillus sphinx (mndA3A) and Cercopithecus neglectus 
(debA3A) had an AC-loop1 region that was similar to colA3A. We generated constructs in  
pcDNA3.1(+) vector as we previously described for HA–rhA3A, and HA–colA3A. 
 
Other Old World monkey A3A proteins restrict HIV-1 replication similar to colA3A  
                 Both mndA3A and debA3A were expressed well in 293 cells (Figure 41). 293 cells 
were transfected with vectors expressing either hA3A, rhA3A, colA3A, debA3A, or mndA3A 
and plasmids with the genomes of HIV-1. The culture supernatants were harvested and cell 
lysates prepared at 48 h and assayed for p24 content and infectivity using TZM-bl cells. The 
experiment was repeated at least four times. As shown in Figure 41B, colA3A, debA3A and 








Figure 37. The colA3A inhibits HIV-1Δvif and HIV replication by a novel mechanism. Panels A-
D. The colA3A restricts the synthesis and release of viral p24. 293 cells were transfected with 
vectors expressing either rhA3G, hA3A, rhA3A, gibA3A, agmA3A, colA3A, nomA3A or 
sqmA3A and either HIV-1, or HIV-1Δvif genomes. At 48 h, the culture medium was collected 
and lysates prepared from cells. The levels of p24 in the medium (Panels AB) and cell lysates 
(Panels CD) were determined using commercial p24 kits. In all panels, error bars correspond to 
standard deviations from triplicate determinations and statistical differences with the wild-type 



















Figure 38. TZM-bl cells expressing HA–colA3A restrict HIV-1 replication. Panel A. TZM-bl 
cells were transfected with pcDNA3.1(+) expressing HA–colA3A and selected with G-418 for 
two weeks. These cultures were starved for methionine/cysteine and then radiolabeled with 
200 µCi of 35S-methionine/cysteine for 6 h. Cell lysates were prepared and HA-containing 
proteins immunoprecipitated using an anti-HA antibody. The proteins were separated by SDS-
PAGE (12% gel) and visualized by standard autoradiography techniques. Lane 1. HA-containing 
proteins immunoprecipitated from TZM-bl–colA3A cells using a control rabbit antibody. Lane 2. 
HA-containing proteins immunoprecipitated from TZM-bl–colA3A cells using a rabbit anti-HA 
antibody. Panel B. TZM-bl cells expressing HA–colA3A cells restrict HIV-1 replication. TZM-
bl and TZM-bl cells expressing HA–colA3A in 6-well plates were inoculated with 103 TCID50 of 
HIV-1 or HIV-1Δvif for 4 h. The inoculum was removed, washed three times and fresh medium 
added to cultures. At 48 h, the culture medium was harvested and virion infectivity measured 
using TZM-bl cells. The experiments were performed at least three times. Shown is the mean 
percentage virion infectivity of virus inoculated onto TZM-bl cells normalized to 100%. 
Statistical differences with the wild-type control were evaluated using a two-tailed Student׳s t-

















Figuew 39. The procedure of the restriction assay. 293 cells were co-transfected with various 
A3A genome or pcDNA3.1(+) as control, and viral genome. At 48 h post-transfection, culture 
supernatants were collected and titered on TZM-bl cells. The TZM-bl cell line is an engineered 
HeLa cell clone that expresses human CD4, CCR5 and CXCR4, which allows virus entry and 
contains HIV-1 Tat-regulated reporter gene ß-galactosidase. At 48 h post-infection, cells are 
fixed and stained with X-gal and blue reaction indicates the cells were infected, expressed 



















Figure 40. The N-terminal amino acid sequence of the A3A proteins from hominid and several 
Old World monkey species. The predicted AC-loop 1 region is within the box from each A3A 
showing that the AC loop 1 region of Homo sapiens (human), Hylobates lar (lar gibbon), 
Macaca mulatta (rhesus macaque), Chlorocebus aethiops (Grivet), Colobus guereza (black and 
white colobus monkey), Cercopihtecus neglectus (De Brazza's monkey) and Mandrillus sphinx 
(mandrill).  The AC loop 1 sequence of A3A proteins from De Brazza's monkey and mandrill are 


















colA3A, the levels of p24 in the culture supernatants and cell lysates prepared from producer 
cells were significantly reduced compared to empty vector controls or cells transfected with 
vectors expressing hA3A (Figure 41C and D). 
 
Discussion 
                 Deciphering the mechanism of colA3A restriction could be instrumental in designing 
novel antiviral strategies against HIV-1. We show here that TZM-bl cells expressing colA3A 
(TZM-bl–colA3A) inoculated with either HIV-1 or HIV-1Δvif viruses. Analysis of the AC-
Loop-1 regions from hA3A and colA3A revealed significant variability in N-terminal domain 
sequences. We analyzed the AC loop 1 sequence of the A3A proteins from other OWM and 
compare them to colA3A. We found that the A3A proteins from both C. neglectus (debA3A; 
25KPWVSGQRE33) and M. sphinx (mndA3A; 25KLWVSGQHE33) were either identical or nearly 
identical to colA3A in this region. Similar to colA3A, we observed that debA3A and mndA3A 
restricted HIV-1 with mndA3A being slightly more restrictive than colA3A and debA3A. The  
Old World monkeys (Family Cercopithecidae) are composed of two subfamilies 
(Cercopithecinae and Colobinae). The Cercopithecinae are further classified into two tribes, the 
Cercopithecini, and the Papionini. The Colobiniae are generally classified into the African and 
Asian colobines. Our findings indicate that restriction of wild type HIV-1 by A3A is represented 
by species in two tribes of the Cercopithecinae (Cercopithecini, debA3A; and Papionini, 
mndA3A) and by the African group of the Colobinae. These results also reinforce our hypothesis 
that the sequence of the AC Loop1 region is critical for restriction of wild type HIV-1 by OWM 





Figure 41. The A3A proteins from other Old World monkeys also restrict HIV-1 by a similar 
mechanism. Panel A. Expression of the wild type and chimeric A3 proteins. 293 cultures were 
transfected with the empty pcDNA3.1(+) vector or those expressing hA3A, rhA3A colA3A, 
mndA3A, or debA3A. At 48 h, cells were starved and radiolabeled with 35S-methionine/cysteine 
for 6 h. The medium was removed, cell lysates prepared in 1X RIPA buffer and HA-tagged 
proteins immunoprecipitated with a rabbit antibody against the HA-tag and protein A Sepharose. 
The proteins were resolved using SDS-PAGE and visualized by standard radiographic 
techniques. The lanes correspond to the vector used to transfect the 293 cells. Panels B–D. 293 
cells were transfected with pcDNA3.1(+)empty vector or vectors expressing either hA3A, 
colA3A, rhA3A, mndA3A, or debA3A and the vector with the HIV-1 genome. At 48 h, the 
culture supernatants were collected and assayed for infectious virus using TZM-bl as the 
indicator cell line or p24 levels in the culture supernatant and in cell lysates. Panel B. The level 
of infectious virus in the culture supernatants from transfected cells using TZM-bl assays. Panel 
C. Levels of p24 antigen in the culture supernatants from transfected cells using commercially 
available p24 antigen capture kits. Panel D. Levels of p24 antigen in the cell lysates from 













inhibit HIV-1 with a few amino acid substitutions mimicking the three OWM A3A proteins in 
the AC-loop 1 region. 
                 It should be noted that the A3A sequence we used in these studies for the colobus 
monkey, Debrazza’s monkey and mandrill were from a study that used primers in an exon-by-
exon amplification approach (Henry, Terzian, Peeters, Wain-Hobson, & Vartanian, 2012). 
However, in a recent study, it was shown that the oligonucleotides primers also matched the 
intronic sequence on either side of exon 5 of A3G. Thus, it is likely that the studies with the 
colA3A were most likely a colA3A/G chimeric protein (McLaughlin, Gable, Wittkopp, 
Emerman, & Malik, 2016). Further, these investigators that the actual colA3A of the colobus 
monkey doesn’t contain the WVS motif in the AC loop 1 gene and no restriction of HIV-1 is 
observed with the correct colA3A sequence. Although the correct A3A sequence for Mandrill 
and Debra is not examined, it is very possible that the mndA3A and debA3A we used are also 
mndA3A/G and debA3A/G chimeras. It was frustrating to find that the old world monkey A3A 
sequences we used wre an artifacts of the oligonucleotides used in the PCR process, we later 
appreciate this unexpected “accident” resulted in chimeric APOBEC proteins (colA3A/G, 
mndA3A/G, and debA3A/G) that are were able to restrict wild type HIV-1 and leads to our later 
finding that the AC loop 1, especially the WVS motif, is critical in restoring hA3A’s antiviral 
activity.  
 
Materials and Methods 
Cells and viruses 
                 293 cell line is a specific cell line originally derived from human embryonic kidney 
cells grown in tissue culture. TZM-bl cell line is an engineered HeLa cell clone that expresses 
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human CD4, CCR5 and CXCR4 and contains HIV-1 Tat-regulated reporter genes for firefly 
luciferase and β-galactosidase as shown in Figure 42. 293 cells were used for transfection of 
vectors expressing various A3 proteins, full-length HIV-1 (NL4-3) or HIV-1Δvif. The TZM-bl 
indicator cell line was used to measure the infectivity of viruses. Both cell lines were maintained 
in Dulbecco׳s minimal essential medium (DMEM) with 10% fetal bovine serum (R10FBS), 10 
mM Hepes buffer, pH 7.3, and 100 U/ml penicillin and 100 µg/ml streptomycin and 5 µg 
gentamicin. A plasmid with the genome of HIV-1 strain NL4-3 (referred to in the text as HIV-1; 
NIH AIDS Research and Reference Reagent Program) and a Δvif version (referred to in text as 
HIV-1Δvif; Schmitt et al., 2011). To make the HIV-1Δvif plasmid, NL4-3 plasmid was digested 
with PflM1, phenol:chloroform extracted, and ethanol precipitated. The 5’-protruding ends were 
filled using DNA Polymerase I Large Fragment (Klenow; Promega). The resulting Klenow 
fragment reaction produced blunt ended fragments that were purified and re-ligated. The 
resulting plasmid was sequenced and found to contain a deletion in pNL4-3 vif between base 
pairs 5301 to 5308. Therefore, only the first 79 amino acids of pNL4-3 Vif could be expressed 
(Schmitt et al., 2011) 
 
Expression of colA3A in TZM-bl cells 
                 TZM-bl cells in 6-well plates (approximately 50% confluent) were transfected with 
pcHA-colA3A (the colA3A gene with a HA-tag at the N- terminus subcloned into the KpnI and 
EcoRV sites of pcDNA3.1(+) using ExGen500 reagent according to the manufacturers' instruc- 
tions. At 48 h, the medium was removed and replaced with growth medium containing 1 mg/ml 
of G-418. The cells were incubated with the medium replaced every 3 days until non-transfected 








Figure 42. The principle behind titration of infectious virus on TZM-bl cells. The parent TZM-bl 
cell line was engineered HeLa cell clone that expresses human CD4, CCR5 and CXCR4 and 
contains HIV-1 Tat-regulated reporter gene for ß-galactosidase. On the right, when restriction 
factors are not present, functional Tat protein is produced and induces the transcription of LaZ 
gene under the promoter of TAR. β-galactosidase is produced and results in blue color reaction 
in the presence of X-gal. On the left, when a restriction factor such as A3G is present, a non-
functional Tat protein is produced (due to deamination) and the lacZ gene not transcribed and 













seeded into each well of 96 well plate. Cells were allowed to grow until they were confluent, 
trypsinized and seeded into 6 well plates and then into T-25 flasks. Cultures were examined for 
the expression of HA–colA3A using immuno- precipitation analysis using an antibody against 
the HA-tag (Santa Cruz Biotechnology). The TZM-bl cells were used for virus infectivity assays. 
 
Production of HIV-1∆vif and HIV virions in the presence of A3 proteins 
                 293 cells or TZM-bl cells were co-transfected with HIV-1 or HIV-1Δvif and of HA-
tagged A3A proteins. After 48 h, supernatants were collected and the cellular debris was 
removed by low speed centrifugation. The cells were lysed in 500 µl of 1X RIPA (50 mM Tris–
HCl, pH 7.5, 50 mM NaCl, 0.5% deoxycholate, 0.2% SDS, 10 mM EDTA) and the nuclei 
removed by high speed centrifugation. The amount of Gag p24 present in the supernatants and 
cell lysates was measured using a commercially available p24 ELISA kit (Zeptometrix). The 
experiment was run in triplicate and the differences between the mean percentages were 
calculated using a two-tailed Student's t-test with p<0.05 considered significant. 
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Chapter III : Chimeric and deletion studies show that the AC loop1 region, 
especially the 27WVS29 motif is sufficient to restore anti HIV-1 activity while 
reducing anti AAV-2 restriction.  
 
Abstract 
                 Old World monkey (OWM) and hominid A3A proteins exhibit differential restriction 
activities against lentiviruses and DNA viruses. We identified that the N-terminal region of the 
colA3A, mndA3A, and debA3A contains the critical determinants for restricting HIV-1 
production through chimeric and truncation experiments. We further confirmed that the AC 
Loop 1 region is crucial through constructing a chimeric hA3A/mndA3A in which the AC Loop 
1 region of hA3A (27GI-GRHK32) was exchanged for AC Loop 1 region of mndA3A 
(27KLWVSGQRE35). More specifically, we constructed a chimeric hA3A with only three amino 
acids insertion (hA3A[27WVS29]) that conferred potent HIV-1 restriction activity. Interestingly, 
insertion of “WVS” into hA3A modestly reduces restriction of adeno-associated virus 2 (AAV-
2) while the insertion of the AC Loop-1 region of the mndA3A/G into hA3A abolished AAV-2 




                 Previous research in our lab showed that rhA3A has stronger restriction towards 
lentivirus replication than hA3A. In contrast to the weak antiviral activity of hA3A, rhA3A 
inhibits SHIVΔvif infectivity by approximately 20-fold and modestly inhibited HIVΔvif 
infectivity by about 3-fold. Comparison of the amino acid sequences of human and rhesus 
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macaque A3A reveals a monkey-specific insertion at positions 27–29 (SVR) that is critical for 
SHIVΔvif and HIV-1Δvif inhibition by rhA3A that was lost in the hominid lineage. Deletion of 
SVR from rhA3A result in the lost of antiviral activity, while the addition of the SVR motif to 
hA3A partially restored the inhibition against HIV-1Δvif. This suggests the importance of the 
SVR motif, which located in the AC loop 1 region in determining the antiviral activity. 
                 Additionally, a similar study in TRIM5α revealed that a single amino acid determines 
the antiviral potency of human TRIM5α (Stremlau, Perron, Welikala, & Sodroski, 2005). If a 
positively charged arginine residue in the C-terminal domain of human TRIM5α is either deleted 
or replaced with an uncharged amino acid, human cells gain the ability to inhibit HIV-1 infection 
(Y. Li, Li, Stremlau, Lee, & Sodroski, 2006; Stremlau, 2007). 
                 Previously, we showed that the A3A proteins from three Old World monkey species, 
the colobus monkey, DeBrazza's monkey and the mandrill were capable of restricting not only 
HIVΔvif but also HIV-1 (Katuwal et al., 2014). Thus, we want to determine the critical 
restriction motif of colA3A, mndA3A or debA3A, which can be used in designing gene-therapy 
approaches to restore hA3A antiviral activity. A unique feature of the reported A3A proteins 
from these Old World monkeys was the presence of an AC-loop 1 region characterized by the 
sequence (25KP/LWVSGQR/HE33), which differed from the sequence (25DLSV/IRGRH/RQ33) 
found in other Old World Monkeys (Henry et al., 2012). Therefore, it is of great interest to 
determine the molecular elements that are responsible for the restriction. 
 
Results 
Chimera studies showing the N-terminal region of the colA3A contains the critical 
determinants for restricting HIV-1 production. 
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                 We previously showed that hA3A did not restrict HIV-1Δvif while colA3A restricted 
both HIV-1 and HIV-1Δvif (Schmitt et al., 2011; Schmitt et al., 2013). Chimeric colobus/human 
A3A proteins were constructed to define the determinants of colA3A restriction. All 
human/colobus chimeric proteins were expressed well in 293 cells (Figure 43A). The first two 
chimeric colobus/human A3A chimeras tested was col1–100hA3A, in which the first 100 amino 
acids of colA3A were fused to the C-terminal region of hA3A and h1–100colA3A, in which with 
the first 100 amino acids of hA3A fused to the C-terminal region of colA3A. The results of the 
restriction assays indicated that col1–100hA3A but not h1–100colA3A restricted HIV-1 infectious 
virus production as measured using the TZM.bl assay (Figure 43B). We also examined chimeric 
proteins with the N-terminal 75, 50, 33 amino acids of colA3A fused to hA3A (col1–75hA3A, 
col1–50hA3A, col1–33hA3A). Restriction assays showed that col1–75hA3A, col1–50hA3A, col1–
33hA3A restricted HIV-1 at approximately 5%, 10%, and 15% of the empty vector control, 
respectively. We also examined the levels of p24 release and obtained similar results (Figure 
43C and D). However, if we normalized infectious titer to p24 levels we observed no effect on 
HIV-1 virion infectivity (Fig). These results indicate that the colA3A N-terminal domain harbor 
the critical determinants for HIV-1 restriction. 
 
Truncated colA3A, mndA3A and debA3A proteins can restrict HIV-1 
                 As the above results indicated that the first 100 amino acids of colA3A contained the 
determinants of HIV-1 restriction, we determined if truncated colA3A, mndA3A and debA3A 
proteins could also restrict HIV-1 replication. Truncated versions of colA3A were constructed   
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Figure 43. Chimeric colobus/human A3A proteins revealed that the N-terminal region of colA3A 
has the determinants to restrict HIV-1. Panel A. Expression of the wild type and chimeric A3 
proteins. 293 cultures were transfected with vectors expressing each wild type and chimeric 
protein. At 48 h, cells were starved and radiolabeled with 35S-methionine/cysteine for 6 h. The 
medium was removed, cell lysates prepared in 1X RIPA buffer and HA-tagged proteins 
immunoprecipitated with an antibody against the HA-tag and protein A Sepharose. The proteins 
were resolved using SDS-PAGE and visualized by standard radiographic techniques. The lanes 
correspond to the vector used to transfect the 293 cells. Panels B-D. 293 cells were transfected 
with plasmids expressing hA3A, colA3A, col1–100hA3A, h1–100colA3A, col1–75hA3A, col1–
50hA3A, or col1–33hA3A the plasmid with the HIV-1 genome. At 48 h, the culture supernatants 
were collected and assayed for infectious virus using the TZM-bl indicator cell line and p24 
levels in the culture supernatants and cell lysates. Panel B. The level of infectious virus in the 
culture supernatants from transfected cells using TZM-bl assays. Panel C. Levels of p24 antigen 
in the culture supernatants from transfected cells using commercially available p24 antigen 
capture kits. Panel D. Levels of p24 antigen in the cell lysates from transfected cells using 
commercially available p24 antigen capture kits. The experiments in Panels B–D were 
performed at least three times and statistical differences with the pcDNA3.1(+) empty 









Figure 43    Chimeric colobus/human A3A proteins revealed that the N-terminal region of colA3A has the 




that expressed the N-terminal 100 amino acids (colA3A1–100, mndA3A1–100, debA3A1–100). We 
next examined the intracellular localization of HA–colA3A and HA–colA3A1–100 in transfected 
293 cells using immunofluorescence and confocal microscopy to determine if the truncated A3A 
was localized in different compartments than the unmodified A3A protein. 293 cells were 
transfected with the empty vector or vectors expressing either mndA3A or mndA3A1–100. At 48 h 
cells were examined for the intracellular localization of the A3A proteins using an anti-HA 
antibody. The results indicate that similar to HA–colA3A, HA–colA3A1–100 was also localized in 
both the cytoplasmic and nuclear compartments of the cell. We next examined the restriction 
activity of these A3A proteins. 293 cells were transfected with plasmids with the HIV-1 genome 
and 48 h later the culture medium was harvested. The levels of p24 Gag were measured and 
levels of infectious virus determined using TZM-bl assays. Our results show that the truncated 
A3A proteins were just as effective as the full-length colA3A at restricting infectious HIV- 
1production (Figure 44B). The truncated colA3A, debA3A, and mndA3A also inhibited HIV-1 
p24 synthesis in producer cells and release into the culture supernatants, similar to the full length 
counterparts (Figure 44C and D). As negative controls, rhA3A did not restrict HIV-1 in these 
experiments. 
 
A chimeric hA3A containing the AC Loop1 region of mndA3A restricts HIV-1 
                 Previously we reported that substitution of the hA3A AC loop 1 region with rhA3A 
restricted the replication of HIV-1Δvif. We were very interested in the mndA3A as it restricted 
HIV-1 to a higher level than either colA3A and debA3A. We constructed and expressed a 
chimeric hA3A/mndA3A in which the AC Loop1 region of hA3A (27GI-GRHK32) was 




Figure 44. Truncated colA3A, mndA3A, and debA3A proteins restrict wild type HIV-1. Panel A. 
Expression of the wild type and chimeric A3 proteins. 293 cultures were transfected with the 
empty pcDNA3.1(+) vector or vectors expressing colA3A, mndA3A, debA3A, colA3A1–100, 
mndA3A1–100, or debA3A1–100. At 48 h, cells were starved and radiolabeled with 35S-
methionine/cysteine for 6 h. The medium was removed, cell lysates prepared in 1×RIPA buffer 
and HA-tagged proteins immunoprecipitated with an antibody against the HA-tag and protein A 
Sepharose. The proteins were resolved using SDS-PAGE and visualized by standard 
radiographic techniques. The lanes correspond to the vector used to transfect 293 cells. Panels 
B–D. 293 cells were transfected with either the empty vector or plasmids expressing hA3A, 
colA3A, colA3A1–100, mndA3A1–100, or debA3A1–100. At 24 h post-transfection, cells were 
transfected with plasmids with the HIV-1 genome. At 72 h, the culture supernatants were 
collected and assayed for infectious virus using TZM-bl assays and p24 levels in culture 
supernatants and in cell lysates. Panel B. The level of infectious virus in the culture supernatants 
from transfected cells using TZM-bl assays. Panel C. Levels of p24 antigen in the culture 
supernatants from transfected cells using commercially available p24 antigen capture kits. Panel 
D. Levels of p24 antigen in the cell lysates from transfected cells using commercially available 
p24 antigen capture kits. The experiments in Panels B–D were performed at least four times and 
statistical differences with the pcDNA3.1(+)/HIV-1 control evaluated using a two-tailed 
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mnd25–34hA3A, was used in restriction assays along with hA3A, mndA3A, colA3A and an empty 
vector control. The results of the restriction assays revealed that the mnd25–34hA3A was nearly 
as effective at mndA3A at restricting HIV-1 while hA3A did not restrict HIV-1 (Figure 45). 
These results indicate that the AC Loop1 region of mndA3A was critical to its restriction 
properties. 
 
The introduction of the 27WVS29 motif into hA3A is sufficient to restrict HIV-1 
                 We next analyzed the ability of HA-hA3A[27WVS29] to restrict HIV-1 and HIV-1Δvif 
virions. As shown in Figure 46A and we previously reported, neither hA3A nor hA3G restricted 
HIV-1 infectious titers as measured by the TZM.bl assay. As expected, HA- hA3G but not HA-
hA3A restricted HIV-1Δvif. In contrast to HA- hA3A, HA-hA3A[27WVS29] restricted both HIV-
1 and HIV-1Δvif (Figure 46A and B). These results indicated that the insertion of [27WVS29] into 
hA3A was sufficient to confer hA3A with the ability to restrict HIV-1 infectious titers. To 
determine if this effect is due to reduction in virus particle production, we next determined the 
levels of p24 in the supernatant. Interestingly, p24 released from cells transfected with HA-
hA3G, HA-hA3A or HA-hA3A[27WVS29] were similar to cells transfected with the empty 
pcDNA3.1(+) vector (Figure 46C). Analysis of the cell viability at the end of the experiment 
indicated that there was significant difference in cell viability at the end of the assay (48 h) 
(Figure 46F). Overall, our data indicates that HA-hA3A[27WVS29] inhibits HIV-1 virion 
infectivity. 
 







Figure 45. A chimeric hA3A containing the AC Loop1 region of mndA3A restricts HIV-1. 293 
cells were grown to 50% confluency and transfected with an empty vector or vectors expressing 
hA3A, mndA3A, mnd25–34hA3A, or hA3G and and a vector containing the HIV-1 genome. At 
48 h, the culture supernatants were collected and assayed for infectious virus using the TZM-bl 
indicator cell line or p24 levels in the culture supernatant and in cell lysates. Panel A. The level 
of infectious virus in the culture supernatants from transfected cells using TZM-bl assays. Panel 
B. Levels of p24 antigen in the culture supernatants from transfected cells using commercially 
available p24 antigen capture kits. Panel C. Levels of p24 antigen in the cell lysates from 
transfected cells using commercially available p24 antigen capture kits. The experiments in 
Panels A–C were performed three times and statistical differences with the pcDNA3.1(+)/HIV-1 
















Figure 46. The introduction of the motif WVS into hA3A results the ability of HA-
hA3A[27WVS29] to restrict HIV-1. 293 cells were co-transfected with either the empty vector or 
plasmids expressing HA-hA3A, HA-hA3A[27WVS29], or HA-hA3G and a plasmid with the HIV-
1 genome (pNL4–3) or HIV-1Δvif (pNL4–3Δvif). At 48 h, the culture supernatants were 
collected and cell lysates prepared. The levels of p24 determined in the culture supernatants was 
quantified using p24 antigen capture assays and equivalent levels of p24 were used to determine 
virus infectivity using TZM-bl cell assays. The expression of A3A proteins in cell lysates was 
determined by Western blot. Panels A and B. The level of infectious virus in the culture 
supernatants from cells co-transfected with pNL4–3 genome or pNL4–3Δvif and plasmids 
expressing the A3 proteins, respectively. Panel C. The quantity of p24 released from cells from 
four experiments following transfection with pNL4–3. Panels D and E. Western blots from 
representative transfections showing expression of HA-tagged A3A proteins from restriction 
assays. Restriction experiments were performed at least four times and statistical differences 
with the pcDNA3.1(+)/HIV-1 control evaluated using a two-tailed Student's t-test, with p<0.05 ( 
) considered significant. Panel F. The viability of transfected cells from a representative 
experiment from Panel A was assessed using the Cyto-Tox-Glo Cytotoxicity assay according to 












                 Previous studies have shown that hA3A could restrict the replication of adenovirus 
associated virus 2 (AAV-2) and we showed that rhA3A did not restrict AAV-2 (H. Chen et al., 
2006; K. Schmitt et al., 2011). We hypothesized that the AC-Loop1 region may be important in 
the restriction of AAV-2. We determined if HA-hA3A [25KLWVSGQHE33] and HA-
hA3A[27WVS29] could restrict AAV-2. 293 cells were transfected with the empty pcDNA3.1(+) 
vector or pcDNA3.1(+) expressing HA-hA3A (positive control), HA- mndA3A/G, HA-
hA3A[25KLWVSGQHE33], or HA-hA3A[27WVS29] and plasmids SSV9 (an infectious molecular 
clone of AAV-2) and pHelper. At 48h, the cells were harvested, the extrachromosomal DNA 
isolated by Hirt extraction and analyzed using Southern blots for the presence of replicating 
AAV-2 DNA (mRF and dRF). The results, shown in Figure 47, indicate that HA-hA3A inhibited 
AAV-2 replication as previously reported while HA-rhA3A did not restrict AAV-2 replication 
(Narvaiza et al., 2009; Chen et al., 2006; Schmitt et al., 2011). Cells transfected with HA-
mndA3A/G and HA- hA3A[25KLWVSGQHE33] did not significantly restrict AAV-2 while cells 
transfected with HA-hA3A[27WVS29] restricted AAV-2 replication at approximately 18% of the 
pcDNA3.1(+) control (Figure 47A). Similarly, we found that when HA-hA3A and HA-
hA3A[27WVS29] were expressed together, AAV-2 replication was similar in cells expressing 
hA3A or hA3A and pcDNA3.1(+) (Figure 47 B). A Western blot from an aliquot of the 293 
lysates showed that the A3 proteins were similarly expressed. These results indicate that the 
insertion of the WVS into HA-hA3A modestly reduced hA3A's restriction activity of AAV2 but 
that substitution of the entire AC loop1 region from mndA3A/G completely abrogated restriction 
of the parvovirus AAV-2. We also assessed the viability of transfected cells at the end of the 
experiment. Our results indicate that there was no significant loss of viability when compared to 







Figure 47. Human A3A[27WVS29] does not significantly restrict parvovirus AAV-2 DNA 
replication. Panel A . Low molecular weight DNA extracted from 293 cells co-transfected with 
recombinant AAV-2 plasmids and either empty vector pcDNA3.1(+) or vectors expressing HA-
hA3A, HA-mndA3A/G, HA-hA3A[25KLWVSGQHE33], or HA-hA3A[27WVS29]. A 1% 
Southern blot was run and hybridized with a 32P-labeled probe from SSV9 as previously 
described (Qiu et al., 2002). The following AAV replication products are shown as dRF (double 
replicative form), mRF (monomeric replicative form), and ssDNA. These experiments were 
performed two times with the same result. Panel B. Low molecular weight DNA extracted from 
293 cells transfected with recombinant AAV-2 plasmids and either empty vector pcDNA3.1(+), 
or vectors expressing HA-hA3A, HA-hA3A[27WVS29], HA-rhA3A, pcDNA3.1(+) and HA-
















                 Determining the sequence requirements that permit hA3A to gain function (i.e., 
restriction activity), may not only provide clues to the evolutionary and structural biology of 
these proteins but also inform translational strategies that utilize A3A with enhanced restriction 
properties.  
                 We previously used a chimeric protein approach to show that substitution of AC loop1 
of hA3A with that of rhA3A restored the ability to hA3A to restrict HIV-1Δvif ((K. Schmitt et 
al., 2013)). We hypothesized that the three amino acid insertion in AC loop 1 of rhA3A could 
result in a AC-Loop1 with a greater molecular surface compared to hA3A. Due to its predicted 
sol- vent-accessibility, this additional molecular surface may be an important region for protein–
protein interactions (K. Schmitt et al., 2013).  
                 Using a similar approach we found that determinants within the N-terminal domain 
(i.e. the first 100 amino acids) which includes the AC Loop-1 region of colA3A are likely 
involved in the restriction of HIV-1 as chimeric proteins col1–100hA3A restricted at levels similar 
to full length A3A while col1–75hA3A, col1–50hA3A, and col1–33hA3A showed a gradual 
reduction in the level of restriction although they were still at statistically significant levels. As 
our chimeric data showed that the N-terminal region of colA3A had the determinants for HIV-1 
restriction and that mndA3A and debA3A also restricted HIV-1, we determined if truncation of 
these A3A proteins retained the ability to restrict HIV-1. Our data clearly indicated that all three 
truncated A3A proteins (colA3A1–100, mndA3A1–100, and debA3A1–100) restricted HIV-1. Similar 
to the full-length A3A proteins, the restriction involved reduced Gag expression in the producer 
cells. 
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                 As our chimeric and truncation experiment indicated that the determinants of 
restriction were associated with the N-terminal domain, we determined if the AC loop1 region 
was once again critical to this restriction. As the mndA3A consistently restricted HIV-1 to a 
higher level of the three Old World monkey A3A proteins tested, we constructed a hA3A 
contained the mndA3A AC loop 1 region. Our results indicated that the level of virus restriction 
by HA- hA3A[25KLWVSGQHE33]  was similar to mndA3A indicating that this region was 
critical for restriction of HIV-1. Recently, it was shown that this region in hA3A was important 
in controlling substrate specificity(Logue et al., 2014). More support for the importance of this 
region in restriction has come from a recent study using oligonucleotide substrates with a single 
deamination site ((Logue et al., 2014). These investigators found that A3A preferentially 
deaminated at TC followed by an A or G residue. Further, using chimeric hA3A/hA3G proteins 
these investigators found that amino acids GI25–26 of AC-Loop 1 region of hA3A (referred to as 
the recognition loop 1; RL1) specified the 5’ nucleotide of the recognition motif and that a 
chimeric A3A/A3G with the RL1 of A3G was more flexible with respect to the 5’ nucleotide 
(AC, CC, GC all used with equal frequency). 
                 Finally, we showed that the introduction of a 27WVS29 motif into hA3A 
(hA3A[27WVS29]) was sufficient to restrict both HIV-1Δvif and HIV-1. While HA-
hA3A[27WVS29] restricted HIV-1, restriction appeared to occur through a different mechanism 
than with HA- hA3A[25KLWVSGQHE33] as the latter significantly reduced the levels of viral 
p24 released from cells compared to cultures transfected with HA-hA3A,HA-hA3G, and HA-
hA3A[27WVS29]. 
 
Materials and methods 
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Construction of chimeric colobus/human A3A and truncated colA3A proteins 
                 As the hA3A protein and colA3A were phenotypically different regarding restriction 
of HIV-1 in producer cells, we adopted to a chimeric approach to determine if specific regions of 
the colA3A protein were responsible for the inhibition of replication. We generated a series of 
chimeric colobus/human A3A proteins, which included col1–100hA3A (N-terminal 100 amino 
acids of colA3A substituted for same region of hA3A), h1–100colA3A, col1–75hA3A, col1–50hA3A 
and col1–33hA3A. All genes were synthesized with an HA-tag at the N-terminus (Genscript) and 
subcloned into the pcDNA3.1(+) vector and sequenced to confirm the integrity of the gene. All 
lots of A3A plasmids were prepared in Escherichia coli grown at 30oC and each lot sequenced to 
insure no mutations were introduced. The expression of each chimeric protein from each plasmid 
was confirmed by Western blot analysis before viral replication assays were performed. 
                 For construction of truncated colA3A, mndA3A and debA3A proteins, sited-directed 
mutagenesis was use to introduce stop codons after the N-terminal 100 amino acids (colA3A 
mndA3A1–100, debA3A1–100). All genes were sequenced to insure that only the desired mutations 
were introduced into the gene. 
Analysis of virus replication in the presence of A3A proteins 
                 To analyze the virus restriction properties of the different A3A proteins, chimeric 
colobus/human proteins and truncated A3A proteins described above, 293 cells were first 
transfected with a vector expressing one of the A3A proteins and with a plasmid containing the 
complete NL4-3 viral genome. At 48 h post-transfection, the culture medium was collected, 
clarified by low speed centrifugation and analyzed for virus infectivity using TZM.bl cells. The 
diagram of the restriction assay is shown in Figure 39. The parent TZM-bl cell line is an 
engineered HeLa cell clone that expresses human CD4, CCR5 and CXCR4 and contains HIV-1 
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Tat-regulated reporter genes for firefly luciferase and ß-galactosidase. The principle of TZM-bl 
assay is depicted in Figure 42. All assays were performed with hA3A (non-restrictive); and 
colA3A (restrictive). All assays were performed at least four times and analyzed for statistical 
significance using two-tiered Student's t-test.  
Immunofluorescence studies of A3A localization 
                 To examine the intracellular localization of HA–colA3A and the truncated HA–
colA3A1–100  proteins, 293 cells on cover slips were transfected with empty vector, or vectors 
expressing HA–colA3A or HA–colA3A1–100. At 48 h post-transfection, cells were washed twice 
in cold PBS, and fixed in 2% paraformaldehyde for 5 min at room temperature. The cells were 
washed three times in cold PBS, and incubated in a 0.5% Triton X-100 solution in PBS for 5 
min. Cells were once again washed with cold PBS and incubated with a rabbit antibody against 
the HA-tag conjugated with Alexa488 prepared in PBS with 1% BSA for 1 h. The cells were 
then washed three times with PBS, mounted and examined using a Leica TCS SPE confocal 
microscope using a 63X objective using filters for Alexa488 and DAPI. 
 
Analysis of AAV-2 replication in the presence of HA-hA3A, HA- mndA3A/G, HA-rhA3A, HA-
hA3A[25KLWVSGQHE33], and HA-hA3A [27WVS29] 
                 The ability of hA3A and hA3A[27WVS29] to inhibit the replication of AAV-2 was 
assessed. 293 cells were transfected using LipoD 293 transfection reagent (SignaGen Labs, 
Rockville, MD) into 60 mm dishes in duplicate with 1 µg SSV9 (an AAV2 infectious clone, 
psub201) (Oiu and Pintel, 2002), 2µg pHelper (Stratagene, La Jolla, CA) (Xiao et al., 1998), and 
1 µg of the empty expression vector (pcDNA3.1(+) ) or expressing HA-hA3A, HA-mndA3A/G, 
HA-hA3A[25KLWVSGQHE33], HA-hA3A[27WVS29]. At 48h post-transfection, the cells were 
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harvested and resuspended in PBS. The supernatant was discarded and Hirt DNA was extracted 
using Hirt solution (10 mM Tris-HCl, pH 7.5; 10 mM EDTA, 0.6% SDS) at room temperature 
for 10 min followed by 5 M NaCl at 4 °C overnight. The mixture was centrifuged at 14,000 rpm 
at 4 °C for 20 min. Following centrifugation, the pellet was discarded and the supernatant was 
treated with proteinase K (50 µg/ml) at 37 °C for 1 h. The low molecular weight (LMW) DNA 
was extracted twice with saturated phenol and once with chloroform/isoamyl alcohol. The 
resulting DNA was ethanol precipitated and column purified using the Qiagen gel extraction kit 
(Qiagen). The LMW DNA was run on a 1% agarose gel, transferred to nitrocellulose and 
analyzed by Southern hybridization using a 32P-labeled probe consisting of a fragment 
representing nucleotides 184–4490 (Xba I digestion) from SSV9 as previously described (Qiu & 
Pintel, 2002). Densitometry was performed on the MF and RF forms to determine the level of 
viral DNA replication with pcDNA3.1(+) serving as the control. To ensure that all samples were 
expressing the desired A3 proteins, aliquots of harvested cells utilized in the Southern blot were 
lysed in RIPA buffer. The nuclei were removed and the protein was precipitated using methanol, 
resuspended in 2X sample reducing buffer, and boiled for 5 min. Proteins were separated on a 
12% SDS- PAGE gel and probed using a rabbit polyclonal anti-HA antibody (HA-probe, Santa 
Cruz). The viability of cells transfected with the plasmids as described above was assessed using 
the Cyto-Tox-Glo Cytotoxicity assay (Promega) according to the manufacturer's instructions. 
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Chapter IV : Amino Acid determinants of restriction 
Abstract 
                 Previously, we showed that the insertion of three amino acids “WVS” to hA3A 
(hA3A[27WVS29]) is alone and sufficient to restore the antiviral activity against HIV-1. We 
further interrogated the amino acid requirements at these three positions in HIV-1 restriction 
through single amino acid substitution and single/double deletion mutants. We found that all 
single amino acid substitutions retained the ability to restrict HIV-1 at some level. While deletion 
of one amino acid still resulted in restriction of HIV-1, deletion of two amino acids resulted in 
restriction that was not statistically significant when compared to hA3A. Taken together, these 
results indicate that length of this sequence is more important than the charge or hydrophobicity 
of the amino acids at these positions amino acids accounted for restriction activity. 
 
Introduction 
                 It is known that the hA3A protein lacks restriction activity against wild type HIV-1. 
However, our lab identified that the A3A proteins from certain Old World monkeys including 
colobus monkey A3A (colA3A), mandrill A3A (mndA3A) and De Brazza’s monkey A3A 
(debA3A) possess significant antiviral activity against wild type HIV-1. Sequence analysis 
indicates that all hominid species have a three amino acids indel in the AC loop 1 region of this 
protein, while colA3A, mndA3A and debA3A all have a consistent WVS motif insertion at that 
spot. This WVS motif appears to play a very important role in restricting HIV-1.  We confirmed 
the importance of this WVS motif by constructing a chimeric hA3A containing the 27WVS29 
sequence from the Old World Monkey A3As known as hA3A[27WVS29] and the chimeric 
hA3A[27WVS29] retained potent HIV-1 restriction activity as WT mndA3A. It is of great interest 
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to further define the importance of each amino acids in the 27WVS29 motif. Thus, we 
substituted/deleted each amino acids in the 27WVS29 motif to determine the minimal molecular 
requirement for HIV-1 restriction. 
 
Results 
Amino acid substitutions within the 27WVS29 with differing charge and hydrophobicity do 
not affect HIV-1 restriction activity of the chimeric A3A  
                 We next determined if substitution each amino acid in the 27WVS29 motif of HA-
hA3A[27WVS29] with amino acids with either similar or different properties (hydrophobicity, 
charge) would affect the restriction of HIV-1. For amino acids with similar properties, we 
constructed HA-hA3A[27WVS29] mutants with the tryptophan at position 27 substituted with 
phenylalanine HA-hA3A [27YVS29], the valine at position 28 with leucine HA-hA3A [27WLS29] 
and the serine at position 29 with threonine HA-hA3A [27WVT29]. These A3A proteins were 
assayed for the ability to restrict HIV-1. The sequence alignment of the single amino acid 
mutants and expression in 293 cells are shown in Figure 48 and the structural illustration is 
depicted in Figure 49.  Our results show that HA-hA3A[27YVS29], HA-hA3A[27WLS29], and 
HA-hA3A[27WVT29] restricted HIV-1 to similar levels as the HA-hA3A[27WVS29] while 
negative controls hA3A and hA3G did not restrict HIV-1 (Figure 50). These results show that 










Figure 48. Panel A sequence alignment of hA3A[27WVS29] single amino acid mutant proteins, 
for each mutant, the amino acid substitution/insertion is bolded. Panel B The mutant proteins are 
stably expressed in cells. 293 cells were transfected with vectors expressing HA-hA3A, HA-
hA3A[27WVS29] or the mutant proteins. At 48 h, cell lysates were prepared, and processed for 
Western blots. HA-containing proteins detected using an anti-HA antibody. Western blot 
showing expressing of the single amino acid substitution mutants of HA-hA3A[27WVS29] (upper 









































Figure 50. Substitution of 27WVS29 with conservative or non-conservative amino acid changes 
also resulted in restriction of HIV-1. 293 cells were co-transfected with either the empty vector 
or plasmids expressing HA-tagged hA3A, hA3A[27WVS29], hA3A [27YVS29], hA3A[27FVS29], 
hA3A[27HVS29], hA3A[27WLS29], hA3A[27WTS29], hA3A [27WDS29], hA3A[27WVT29], 
hA3A[27WVA29], or hA3A[27WVD29] and a plasmid with the HIV-1 genome. At 48 h, the 
culture supernatants were collected. The levels of p24 in the culture supernatants were quantified 
using p24 antigen capture assays and equivalent levels of p24 were used to determine the levels 
of virus infectivity using TZM-bl cell assays. The level of infectious virus in the culture 
supernatants from transfected cells using TZM-bl assays. The experiments were performed at 
least four times and statistical differences with the pcDNA3.1(+)/HIV-1 control evaluated using 








Figure 50    Substitution of 27WVS29 with conservative or non-conservative amino acid changes also resulted in 
restriction of HIV-1 
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                 We also determined if substitution of 27WVS29 motif of HA- hA3A[27WVS29] with 
amino acids differing in polarity or charge would restrict HIV-1. These included the substitution 
of the tryptophan at position 27 with tyrosine HA-hA3A[27YVS29] or histidine HA-
hA3A[27HVS29], the valine at position 28 with threonine HA- hA3A[27WTS29] or aspartic acid 
HA-hA3A[27WDS29], and the serine at position 29 with alanine HA-hA3A[27WVA29] or aspartic 
acid HA-hA3A[27WVD29]. The sequence alignment of the single amino acid mutants and 
expression in 293 cells are shown in Figure 48 and the structural illustration is depicted in Figure 
49. Restriction assays with these mutants revealed that all six significantly restricted HIV-1 with 
most restricting at levels similar to HA-hA3A[27WVS29] (Figure 50). Combined, our results 
indicate that the nature of the amino acid was not critical for restriction of HIV-1 by HA-
hA3A[27WVS29]. 
 
The role of one or two amino acid deletions in the WVS motif of HA-hA3A[27WVS29] 
                 We next determined if removal of one or two amino acids from the WVS tripeptide 
would reduce the ability of the chimeric protein to restrict HIV-1. Five different constructs, HA-
hA3A[27VS28], HA-hA3A[27WS28], HA-hA3A[27WV28], HA-hA3A[27S], HA-hA3A [27V], and 
HA-hA3A[27W] were constructed and analyzed for expression and the ability to restrict HIV-1. 
The sequence alignment of deletion mutants are shown in Figure 51. All five mutants were 
expressed well in cells compared with HA-hA3A and HA- hA3A[27WVS29] as shown in Figure 
51. The single amino acid deletion mutants (HA-hA3A[27VS28], HA-hA3A[27WS28], and HA-
hA3A [27WV28]) modestly restricted HIV-1, varying from 16 to 26% (p<0.01) compared with 
8% for HA-hA3A[27WVS29] (Fig. 5A). However, deletion of two amino acids from the WVS 












Figure 51 Panel A. Sequence alignment of hA3A[27WVS29] deletion mutant proteins Panel B. 











Figure 51    hA3A[27WVS29] deletion mutant proteins 
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resulted in less restriction, with HA-hA3A[27S] and HA-hA3A[27V] restriction not being 
statistically significant (p<0.05) compared to HA-hA3A[27WVS29] (Figure 52). These results 
indicate that the presence of two amino acids in this region was critical for restriction of HIV-1. 
 
Chimeric HA-hA3A[27AAA29] and HA-hA3A[27GGG29] also restrict HIV-1 
                 As the above results indicated that length and not the nature of the amino acids were 
critical to the restriction activity, we next tested two additional constructs, one with the “WVS” 
motif substituted with “AAA” and a second with “GGG.” These constructs, HA-hA3A[27AAA29] 
and HA-hA3A[27GGG29], were analyzed for restriction of HIV-1 along with HA-hA3A and HA-
hA3A[27WVS29]. Both HA-hA3A[27AAA29] and HA-hA3A[27GGG29] along with HA- 
hA3A[27WVS29] restricted HIV-1 while HA-hA3A did not restrict HIV-1 (Figure 53). Thus, 
these results confirm that the amino acid length of this region was most important for activity. 
 
Discussion 
                 Previously, we analyzed the A3A proteins from several Old World monkey species 
and showed that they could restrict SHIVΔvif. Significantly, we showed that the A3A protein 
from the black and white colobus monkey, the mandrill and DeBrazza's monkey not only 
restricted HIV-1Δvif but also HIV-1. We further showed that the introduction of a 27WVS29 motif 
into hA3A (hA3A[27WVS29]) was sufficient to restrict both HIV-1Δvif and HIV-1 (Katuwal et 
al., 2014; K. Schmitt et al., 2013). Our results indicate that substitution of one amino acid of the 







Figure 52. Deletion of one or two amino acids from the WVS motif of HA-hA3A[27WVS29] 
chimeric protein reduces the ability of hA3A[27WVS29] to restrict HIV-1. 293 cells were co-
transfected with either the empty vector or plasmids expressing HA-tagged hA3A, 
hA3A[27WVS29], hA3A[27VS28], hA3A[27WS28], hA3A[27WV28], or hA3A[27S] and a plasmid 
with the HIV-1 genome. At 48 h, the culture supernatants were collected and cell lysates 
prepared. The levels of p24 were quantified in the culture supernatants using p24 antigen capture 
assays and equivalent levels of p24 were used to determine the levels of virus infectivity using 
TZM-bl cell assays. The level of infectious virus in the culture supernatants from transfected 
cells using TZM-bl assays. The experiments were performed at least four times and statistical 
differences with the pcDNA3.1(+)/HIV-1 control evaluated using a two-tailed Student's t-test, 





Figure 52    Deletion of one or two amino acids from the WVS motif of HA-hA3A[27WVS29] chimeric protein 







Figure 53. Chimeric HA-hA3A[27AAA29] and HA-hA3A[27GGG29] also restrict HIV-1. 293 cells 
were transfected with either the empty vector or plasmids expressing HA-tagged hA3A, 
hA3A[27WVS29], hA3A[27AAA29], or hA3A[27GGG28] and a plasmid with the HIV-1 genome. 
At 48 h, the culture supernatants were collected and cell lysates prepared. The levels of p24 were 
quantified in the culture supernatants using p24 antigen capture assays and equivalent levels of 
p24 were used to determine the levels of virus infectivity using TZM-bl cell assays. The 
expression of A3A proteins in cell lysates determined by Western blot. Panel A. The level of 
infectious virus in the culture supernatants from transfected cells using TZM-bl assays. Panel B. 
Western blot from a representative transfection showing expression of HA-tagged A3A proteins. 
The experiments were performed at least three times and statistical differences with the 















inconsequential in the restriction of HIV-1. In fact, replacement of this tripeptide region with 
alanines or glycines had no effect on HIV-1 restriction. These results indicate that the amino  
acids at these positions can have different properties (polar, non-polar, or charged) and retain 
restriction activity. While the nature of the amino acids in this region did not seem to be critical 
for HIV-1 restriction, our results indicate that deletion of one amino acid resulted in less 
restriction than HA-hA3A[27WVS29] and deletion of two amino acids resulted in even less 
restriction. These results suggest that the presence of the three amino insertion results in optimal 
restriction of HIV-1. 
 
Materials and Methods 
 
Site-directed mutagenesis of A3A genes 
                 The hA3A in these studies was constructed with an HA-tag at the N-terminus (HA-
hA3A) and expressed using the pcDNA3.1(+) vector (pHA-hA3A). The introduction of 
mutations resulting in amino acid substitutions or deletions was accomplished using a 
QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's protocol. 
All plasmid inserts were sequenced to ensure the validity of the mutations and that no other 
muta- tions were introduced during the mutagenesis or cloning processes. 
 
Detection of A3A proteins 
                 For analysis of A3A protein expression in cells, 293 cells in 6-well plates were 
transfected with either pcDNA3.1(+) or pcDNA3.1(+) expressing each of the A3A proteins and 
incubated at 370C. At 48 h, the medium was removed, cells lysed in 1X 
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radioimmunoprecipitation assay buffer (RIPA: 50 mM Tris–HCl, pH 7.5; 50 mM NaCl; 0.5% 
deoxycholate; 0.2% SDS; 10 mM EDTA). The nuclei and other cell debris removed by 
centrifugation in a mi- crocentrifuge for 10 min and the supernatant collected in a fresh tube. 
Equal aliquots of cell lysates were boiled in sample reducing buffer, separated by SDS-PAGE, 
and proteins transferred to membranes HA-containing proteins were detected by Western blot 
using a rabbit anti-HA antibody (Santa Cruz Biotechnology Y-11 (sc805), a secondary goat anti-
rabbit IgG-alkaline phosphatase antibody (Sigma, #A3687) and Novex AP chemiluminescent 
substrate (CDP-Star; InVitrogen, #WP20002). Proteins were detected using a Fuji 
Phosphoimager (LAS-4000). 
 
Analysis of virus replication in the presence of A3A proteins 
                 To analyze the virus restriction properties of the mutant A3A proteins, 293 cells were 
first transfected with either the empty pcDNA3.1(+) or a vector expressing one of the A3A 
proteins and with a plasmid containing either the HIV or HIV-1Δvif viral genome. At 48h post-
transfection, the culture medium was collected, clarified by low speed centrifugation and the 
supernatant analyzed for p24 using antigen capture assays. Equivalent levels of p24 were used to 
titrate virus infectivity using TZM.bl cell assays. All assays were performed with the empty 
pcDNA3.1(+) vector (non-restrictive for HIV or HIV-1Δvif), hA3AG (restrictive for HIV-1Δvif; 
nonrestrictive for HIV-1). All assays were performed at least four times and analyzed for 




Chapter V : Mechanism of HA-hA3A[27WVS29] inhibiting HIV-1 
Abstract 
                 Initially, we found that hA3A[27WVS29] expressing producer cells release similar 
amount of virions through p24 ELISA and pulse-chase experiments, while results in lower levels 
of HIV-1 protein synthesis in target cells, indicating that the restriction happens in the next round 
of replication in the target cells. Next we analyzed that viral RNA is packaged at similar level in 
the presence or absence of HA-hA3A[27WVS29]. Then it is revealed that the differences in the 
retroviral restriction properties by HA-hA3A and HA-hA3A[27WVS29] don’t come from the 
differences in the subcellular localization since both proteins were observed in both the 
cytoplasm and nucleus in the producer cell. Further we excluded the canonical mechanism that 
the hA3A[27WVS29] restrict HIV-1 through cytidine deamination of the viral genome. 
Furthermore, we showed that hA3A[27WVS29]  is package into progeny virions and it resulted in 
lower levels of HIV-1 transcripts in target cells. In addition, The presence of hA3A[27WVS29] 
results in decreased proviral integration in target cells. Finally, we confirmed that 
hA3A[27WVS29] restricts HIV-1 at the level of reverse transcription in target cells. However, 
colorimetric Reverse Transcriptase Assay revealed that hA3A[27WVS29] didn’t impair 
exogenous reverse transcriptase enzyme activity in vitro.  
 
Introduction 
                 Previously, we showed that the insertion of WVS motif is alone and sufficient to 
restore the antiviral activity towards HIV-1. Single amino acid substitution and single/double 
deletion mutants revealed that the length and not necessarily the nature of the amino acid is most 
important for defining HIV-1 restriction. However, the mechanism of HA-hA3A[27WVS29] 
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restricting HIV-1 remains unknown. Initial experiments showed that in the presence of 
hA3A[27WVS29], the virions can successfully been released but have impaired replication for the 
next round of infection. Thus we will follow the replication map (figure 54) to explore the 
possible inhibition mechanism step by step. 
 
Results 
Viral proteins are synthesized and processed similarly in the presence of hA3A or HA-
hA3A[27WVS29] 
                 Previously, we shown that the infectivity of virions produced from hA3A[27WVS29] 
expressing cells are down by TZM-bl tittering. To determine if there are less virions released or 
further infection/replication is impaired, we determined the level of p24 (HIV-1 capsid protein) 
released from producer cells using HIV-1 p24 Antigen ELISA 2.0 kit from Zeptometrix. In 
detail, 293 cells were co-transfected with APOBEC plasmids and pNL4-3 (widely used lab-
adpted HIV-1 strain). The supernatant, containing released virions was collected 48h post-
transfection and subjected to p24 ELISA. It was shown that the p24 level is not significantly 
lower than control. That means in the presence of hA3A[27WVS29], the virions can successfully 
been released but have impaired replication for the next round of infection.  
                 Then we confirmed that by showing that the biosynthesis and processing of viral 
proteins are same in the presence of the empty vector (pcDNA3.1(+), or in vectors expressing 
HA-hA3A or HA-hA3A[27WVS29] using pulse-chase. We performed pulse-chase analysis using  
293 cells transfected with either the empty vector pcDNA3.1(+), or vectors expressing HA-





























cells were starved and radiolabeled with 35S-methionine/cysteine followed by removal and 
chase in cold excess methionine/cysteine for 0, 3, and 6 h. Viral proteins were 
immunoprecipitated from the cell lysates and culture supernatants. Our results indicate that the 
synthesis and processing of the Env (gp160) and Gag (p55) precursors in cells and the release of 
gp120 and p24 into the culture supernatants were similar for cultures co-transfected with 
pcDNA3.1(+), HA-A3A, and HA-hA3A[27WVS29] (Figure 55). These results confirm that HA-
hA3A and HA-hA3A[27WVS29] expressed similar levels of viral proteins in producer cells. 
 
Viral RNA package in progeny virions in the presence of HA- hA3A[27WVS29] 
                 From previous experiments we knew that similar level of virions were released from 
producer cells, but we didn’t know if they were intact virons or “empty viruses” missing viral 
RNA. To examine that, we first collected viruses as previous described. Next, we subjected same 
amount of viruses (calculation is based on p24 ELISA data) to ultracentrifugation through at 
20% sucrose cushion to concentrate viruses. The viral RNA was extracted, reverse transcribed 
and quantified using qPCR. qPCR with HIV-1 Gag indicates that viral RNA is packaged at 
similar level either with or without the presence of hA3A[27WVS29] as shown in Figure 56. 
 
hA3A[27WVS29] results in lower levels of HIV-1 protein synthesis in target cells 
                 After transcription, both spliced and unspliced (full-length) RNA act as template for 
translation to produce various viral proteins. They will be assembled, packaged together with the 
full-length virus genome into progeny virions. The progeny virions will be released and undergo  
maturation after budding. To examine the viral protein synthesis in target cells, we infect TZM 





Figure 55. Pulse-chase analysis of viral proteins synthesized in the presence of empty 
pcDNA3.1(+) vector, HA-hA3A, or HA-hA3A[27WVS29]. 293 cells were transfected with a 
plasmid with HIV-1 NL4–3 genome (pNL4–3) and either pcDNA3.1(+) or pcDNA3.1(+) 
expressing HA-A3A, or HA-hA3A[27WVS29]. At 48 h post-transfection, cells were washed and 
starved for methionine/cysteine for 2 h. Cells were radiolabeled with 500 µCi of 35S-
methionine/cysteine was added for 30 min, the medium with radiolabel removed and cells 
incubated in medium containing cold excess methionine/cysteine for 0, 3, or 6 h. HIV proteins 
were immunoprecipitated from cell lysates using plasma pooled from several pig-tailed monkeys 
infected previously with SHIV and a monoclonal antibody directed against HIV-1 p24 as 
described in the Material and Methods. Uninfected 293 cells, radiolabeled and chased for 6 h 
served as a negative control. All immunoprecipitates were collected on protein A Sepharose, the 
beads washed with RIPA buffer, and the samples resuspended in sample reducing buffer. 
Samples were boiled and the SHIV specific proteins analyzed by SDS-PAGE (10% gel). Proteins 
were then visualized by standard autoradiographic techniques. Panel A. Proteins 
immunoprecipitated from culture supernatants and cell lysates from cells co-transfected with 
pcDNA3.1(+) and pNL4–3. Panel B. Proteins immunoprecipitated from culture supernatants and 







Figure 55    Pulse-chase analysis of viral proteins synthesized in the presence of empty pcDNA3.1(+) vector, HA-










Figure 56. Viral RNA is packaged in progeny virions at similar level in the absence and presence 
of hA3A[27WVS29]. The viruses were produced by co-transfecting 293 as previously described. 
Next, the same amount of viruses were subjected (calculation is based on p24 ELISA data) to 
ultracentrifugation through at 20% sucrose cushion to concentrate viruses. The viral RNA was 
extracted, reverse transcribed and quantified using qPCR. qPCR with HIV-1 Gag indicates that 













biosynthesis of viral protein by pulse-chase label. The viral protein are immunoprecipitated and 
run on gel for radioautograph. The results indicate that that the presence of hA3A[27WVS29] led 
to a decrease in viral protein biosynthesis and subsequent release of viral proteins from target 
cells (Figure 57). 
 
hA3A[27WVS29] and hA3A are localized to the intracellular compartments 
                 Previous studies have shown that the hA3G is localized in the cytoplasm of the cell 
while hA3A and rhA3A are distributed in both the cytoplasm and nucleus (K. Schmitt et al., 
2011; Wichroski, Ichiyama, & Rana, 2005). We determined if HIV-1 restriction by HA-hA3A 
[27WVS29] could be due to its intracellular localization. 293 cells were transfected with either the 
empty vector or one expressing HA-hA3A, HA-hA3A[27WVS29] or HA-hA3AG. At 48h, cells 
were fixed and immunostained using an antibody to the HA-tag. Using confocal microscopy, we 
found that both HA-hA3A and hA3A [27WVS29] were observed in both the cytoplasm and 
nucleus (Figure 58) while HA-hA3G was detected in the cytoplasm of cells. Thus, the 
differences in the retroviral restriction properties by HA-hA3A and HA-hA3A[27WVS29] could 
not be explained by differences in the subcellular localization. 
 
hA3A[27WVS29] is incorporated into virus particles similar to hA3A 
                 Previous studies have shown that hA3A is incorporated in both HIV-1 and HIV-1Δvif 
virus particles (Goila-Gaur et al., 2007). We determined if HA-hA3A[27WVS29] was 
incorporated into virus particles at higher levels than the unmodified hA3A. 293 cells were co-
transfected with the empty pcDNA3.1(+) vector or vectors expressing HA-hA3A, HA-HA-




Figure 57. Lower Level of Virions were Produced with hA3A[27WVS29] in target Cells. To 
assess/visualize the production and maturation of virus in the presence of hA3A[27WVS29], we 
used 35S-methionine/cysteine to radiolabel all proteins and immunoprecipitate viral proteins 
using antibody cocktail including anti-SHIV serum (which has antibodies against the Env 
protein), an anti-p24 monoclonal antibody, and an anti-Env monoclonal antibody. 293 cells were 
co-transfected with APOBEC3 plasmids and pNL4-3. At 48 h post-transfection, the culture 
medium containing virus was collected and incubated with 20% polyethylene glycol (PEG) 
overnight at 4oC. The next day, the mixture was spun at 18,000 x g for 20 min and virus was re-
suspended in FBS free medium. The concentrated virus was used to infect target cells for 48 h. 
Then the medium was removed and target cells were starved in methionine/cysteine-free medium 
for 2 h. The cells were then radiolabeled with 500 µCi of 35S-methionine/cysteine for 16 h. The 
viral proteins in both supernatant and cell lysate were immunoprecipitated using anti-SHIV, anti-
p24 and anti-Env antibodies for 18 h. The beads were washed three times and resuspended in 
same amount of sample reducing buffer. The samples were run on SDS-PAGE and visualized 
using standard autoradiographic techniques. The gel indicated that that the presence of 
hA3A[27WVS29] led to a decrease in viral protein biosynthesis and subsequent release of viral 
















Figure 58. Both hA3A and hA3A[27WVS29] are localized to the same intracellular compartments 
of the cell. Panel A-I. 293 cells were transfected with 1.5 µg HA-tagged vectors expressing HA-
hA3A[27WVS29] (Upper three panels), HA-hA3A (Middle three panels), or HA-hA3G (Lower 
three panels). At 48 h, cells were fixed and stained with an anti-HA-FITC antibody for 1h, 
washed and stained with DAPI or 5 min. The cover slips were mounted and examined using a 
Leica TCS SPE Confocal Microscope confocal microscope using a 63× objective with a 2× 
digital zoom using the Leica Application Suite X (LAS X, LASX) software package as described 
in Section 4. A 488 nm filter was used to visualize the FITC and a 405 filter used to visualize the 
DAPI staining. Shown are images for A3A (Left three panels), DAPI staining of nuclei (Middle 














supernatant was harvested and subjected to ultracentrifugation through a 20% sucrose cushion. 
The virus was then analyzed on Western blots for the presence of HA containing proteins. As 
shown in Figure 59, the cells 293 cells transfected with vectors expressing HA-hA3A and HA-
hA3A[27WVS29] were incorporated into HIV-1 and HIV-1Δvif particles at similar levels based 
on equivalent levels of p24 Gag). As expected, the levels of HA-hA3G was significantly 
decreased in HIV-1 virus particles. 
 
hA3A[27WVS29] does not restrict through cytidine deamination 
                 We examined whether cytidine deamination was the mechanism through which 
hA3A[27WVS29] restricted the HIV-1. We first examined whether HA-hA3A, HA-
hA3A[27WVS29], or HA- hA3G caused cytidine deamination of the HIV-1Δvif genome. 293 cells 
were transfected with pcDNA3.1(+) empty vector or one expressing HA-hA3A, HA-hA3G or 
HA-hA3A[27WVS29] and a plasmid containing the HIV-1Δvif genome. At 48h, the culture 
supernatant was harvested, DNase-I treated and the virus con- taining supernatant were used to 
infect TZM-bl cells for 16h. Total DNA was extracted and the nef gene was amplified, cloned 
and sequenced. The results of the analysis is presented in Figure 60 and Table 2 . As expected, 
cells transfected with vectors expressing HA- hA3G and HIV-1Δvif showed many G-to-A 
mutations (155 mutations/4850 base sequenced or 3.2%) in the nef gene, most of which were in 
the 5’-GG-3’(81.2%) and 5’-GA-3’(17.4%) contexts. Cells transfected with the empty vector or 
one expressing HA-hA3A or HA-hA3A[27WVS29] did not exhibit cytidine deamination of the 
nef gene product. Cells transfected with vectors expressing HA-hA3G, HA-hA3A, or HA- 
hA3A[27WVS29] and HIV-1 resulted in G-to-A mutation levels comparable to the empty 










Figure 59. Analysis of the incorporation of hA3A, hA3G and hA3A[27WVS29] into virus 
particles. 293 cells were transfected with empty vector pcDNA3.1(+) or with pcDNA3.1(+) 
expressing HA-hA3A, HA-A3G, or HA-hA3A[27WVS29] and a plasmid with the HIV-1 genome. 
At 36 h, the cells were starved for methionine/cysteine and radiolabeled with 35S-
methionine/cysteine for 18 h. The culture supernatants were collected and virus semi-purified as 
described in the text. Viral p24 was immunoprecipitated from the viral pellets using an anti-p24 
antibody and immunoprecipitates collected on protein A Sepharose as described in the text. The 
levels of p24 were normalized and the levels of HA-A3 proteins immunoprecipitated using an 
anti-HA antibody, boiled in sample reducing buffer and separated by SDS-PAGE and visualized 
by standard autoradiography. Shown are the A3 proteins in virus (panel A), and viral p24 (Panel 













Figure 60. hA3A[27WVS29] does not restrict HIV-1 through cytidine deamination. 293 cells were 
transfected with pcDNA3.1(+), or one expressing HA-hA3A, HA-hA3A[27WVS29], or HA-
hA3G and a plasmid with the HIV-1Δvif genome (strain NL4–3). At 48 h post-transfection the 
culture medium was harvested, DNase I treated, and used to infect TZM-bl cells. At 16 h 
following inoculation of TZM-bl cells, the cells harvested and total DNA extracted. A region of 
nef spanning the polypurine tract was amplified by PCR, cloned into pGEM-TEasy vector and 10 
clones sequenced. The number of G-to-A changes are presented as ticks on the region sequenced. 
Panel A. G-to-A mutations from cells transfected with HA-hA3G/HIV-1Δvif. Panel B. G-to-A 
mutations from cells transfected with HA-hA3A/HIV-1Δvif. Panel C. G-to-A mutations from 
cells transfected with HA-hA3A[27WVS29]/HIV-1Δvif. Panel D. G-to-A mutations from cells 



















bases	 A	mutations		 	in	5'-GG-3'	context		 	in	5'-GA-3'	context		
Vector	 	sequenced	(%	mutations)	(%	of	G-to-A	mutations)	 (%	of	G-to-A	mutations)	
hA3G	 4,850	 155	(3.2)	 126	(81.2)	 27	(17.4)	
hA3A	 4,850	 0	(0)	 0	(0)	 0	(0)	
hA3A[27WVS29]	 4,850	 0	(0)	 0	(0)	 0	(0)	
pcDNA3.1(+)	 4,850	 1	(0.02)	 1	(0.02)	 0	(0)	





hA3A[27WVS29] did not restrict HIV-1 through cytidine deamination of the viral genome. 
hA3A[27WVS29] leads to less viral transcripts in target cells 
                 Transcription process initially results in the early synthesis of regulatory HIV-1 
proteins such as Tat and Rev. Tat will bind to the Transactivation Response element and 
stimulates the transcription of longer RNA transcripts. Rev also helps with this process, and 
ensures the export of the correctly processed messenger (such as Gag) and genomic RNA from 
the nucleus to the cytoplasm. Thus, we will quantify the amount of early transcript (Rev) and 
later transcript (Gag) in target cells. 293 cells were co-transfected with either the empty 
pcDNA3.1 (+) vector or hA3A, hA3A[27WVS29] and pNL4-3(a plasmid containing the intact 
HIV-1 genome). After 48 h, the culture supernatant was harvested and the virus containing 
supernatant was used to infect TZM-bl cells for 48 h. Total RNA was extracted and subjected to 
qRT-PCR with either Rev or Gag primers and the probe. My results indicate that the RNA level 
of Rev and Gag transcirpts were significantly decreased in the presence of hA3A[27WVS29] as 
shown in figure 61. 
The presence of hA3A[27WVS29] results in decreased provial integration in target cells. 
                  After reverse transcription, the newly formed HIV c-DNA will be accompanied by 
integrase to form preintegration complex (PIC). The PIC enters nucleus and the double stranded  
linear template inserted into host chromosome at various sites with a preference on genes 
possessing high numbers of introns. To determine whether it function at integration step, We first 
examined the amount of 2-LTR in target cell post infection. Since TZM-b1 cells were engineered 
to contain HIV-1 Long terminal repeats (LTRs) consisting U3, R, and U5 region, we used HIV 
pseudotyped with VSV-G to infect 293 cells (pseudoviruses are produced as shown in figure 62). 









Figure 61. hA3A[27WVS29] results in less early transcription product (Rev) and less late 
transcription product (Gag). 293  cells were co-transfected with various A3A protein and HIV-1 
genome. 48h post transfection, supernatant were collected and used to infect TZM-bl cells for 
48h. Total RNA was extracted and subjected in vitro reverse transcription and the level of early 









































hA3A[27WVS29]. That means either hA3A[27WVS29] doesn’t inhibit integration step or the effect 
inefficient integration and low level of double strand viral DNA counteract each other. 
                 To distinguish these two possibilities, we checked the level of Alu-gag, which is the 
direct indicator of viral integration level. Alu is a family of repetitive transposable elements in 
the human genome. Each provirus has a unique distance to the nearest Alu sequence. Thus, with 
a primer specific to the Alu sequence and a prime specific for the inside of provirus sequence, we 
could amplify the conjunction part of the integration. However, since the distance between each 
provirus and the closet Alu sequence varies, it is difficult to produce a standard curve for 
quantification. Alternatively, we applied a two-step amplification by first performing a regular 
amplification using Alu-Gag primers followed by amplification of 1 ul of the sample from first 
round PCR to quantitative real-time PCR with R/U5 primers and a probe. The two-step 
amplification confirmed that in the presence of hA3A[27WVS29], the integration level was 
significantly diminished as shown in figure 63. 
  
hA3A[27WVS29] does not interfere with virion reverse transcriptase but does decrease 
reverse transcription in target cell 
                 We next examined the reverse transcriptase activity of virus grown in the presence of 
empty vector pcDNA3.1(+), or vectors expressing HA-hA3A, HA-hA3A[27WVS29], or HA-
hA3G. 293 cells were transfected with each pcDNA3.1(+) vector and a plasmid with the NL4–3 
genome. At 48 h, the culture medium was collected, centrifuged at low speed to remove cellular 
debris, and the virus pelleted through a 20% sucrose cushion. The p24 levels were determined 
and equivalent levels of virus (based on p24 content) were used in reverse transcriptase assays 









Figure 63. hA3A[27WVS29] Results in less Integration (Alu-Gag). 293  cells were co-transfected 
with various A3A protein or pcDNA3.1(+) as control, and HIV-1Δenv and VSV-G. 48h post 
transfection, supernatant are collected and used to infect 293 cells for 48h. Total DNA is 











Figure 63    hA3A[27WVS29] Results in less Integration (Alu-Gag) 
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that reverse transcriptase activity of the viruses grown in the presence of the three A3A proteins 
was similar, indicating that the presence of the A3A proteins did not block reverse transcriptase 
activity (Figure 64). Controls in which AZT (100 nM) was added to the reactions abolish reverse 
transcriptase activity. 
                 We also analyzed reverse transcription in target cells. For these experiments, 293 cells 
were transfected with plasmid with the pNL4–3 genome and either the empty pcDNA3.1(+) 
vector or vectors expressing HA-hA3A, HA-hA3G, or HA-A3A[27WVS29]. At 48 h the virus 
stocks were harvested and the p24 levels in stocks determined. Using equivalent levels of p24, 
viruses were used to inoculate C8166 cells for 24 h. Total cellular DNA was isolated and the 
early R/U5 and late U5/Gag reverse transcription products quantified using real DNA PCR as 
previously described (Suzuki et al., 2003). Our results indicate that the empty vector, pcDNA3.1 
(+), and vectors expressing HA-hA3A and HA-hA3G had similar levels of R-U5 and U5-gag 
products while HA-hA3A[27WVS29] had a reduction in the levels of R-U5 and U5-gag products 
compared to the pcDNA3.1(+) control as shown in figure 65. These results indicate that  HA-
hA3A [27WVS29] reduced the levels of reverse transcription products in target cells. 
 
Discussion 
                 Our results presented here indicate that viral protein synthesis and processing was 
similar in cells transfected with vectors expressing HA-hA3A or HA-hA3A[27WVS29]. We first 
exclude the possibility that HA-hA3A[27WVS29] inhibits HIV-1 replicating by causing cytidine 
hypermutation of the HIV-1 genome. We further showed that HA- hA3A and HA- 
hA3A[27WVS29] both had a nucleocytoplasmic localization in producer cells. We also analyzed 







Figure 64. The presence of HA-hA3A[27WVS29] does not decrease virion reverse transcriptase 
activity. Reverse transcriptase (RT) activity of virus grown in the presence of HA-hA3A, HA-
hA3A[27WVS29], and HA-hA3G. 293 cells were co-transfected with a plasmid with HIV-1 NL4–
3 genome and either pcDNA3.1(+) or expressing HA-A3A, or HA-hA3A[27WVS29], or HA-
hA3G. At 48 h, the culture supernatants were collected and partially purified as described in the 
text. The levels of p24 were quantified and equivalent levels of p24 were used to determine RT 
activity using a colorimetric Roche RT kit. Activity is plotted as percent RT activity with 
















Figure 65. The presence of HA-hA3A[27WVS29] decreases reverse transcription in target cells. 
293 cells were co-transfected with a plasmid pNL4–3 (containing the NL4–3 genome) and either 
empty vector pcDNA3.1(+) or one expressing HA-hA3A, HA-hA3A[27WVS29], or HA-hA3G. 
Virus was harvested, p24 levels determined, and equivalent levels of p24 were used to inoculate 
C8166 cells. At 24 h post-inoculation, the cells were washed three times, total DNA extracted, 
and the levels of early RT product R-U5 (Panel A) and late RT product U5-gag (Panel B) 
transcripts quantified using real time DNA PCR as described in the text. The values obtained are 
presented as percent product compared to the pcDNA3.1(+)/pNL4–3 control. AZT was used to 
inhibit reverse transcriptase activity.The experiments were performed three times and statistical 
differences with the pcDNA3.1(+)/pNL4–3 control were evaluated using a two-tailed Student's t-
























exogenous template. Our results indicate that RT activity was similar for HA-hA3A, HA-
hA3A[27WVS29], and HA-hA3G. These results suggest that incorporated HA-hA3A[27WVS29] 
did not directly interact with reverse transcriptase to block its activity. Alternatively, it is also 
possible that HA-hA3A[27WVS29] may interact weakly with the reverse transcriptase but that the 
conditions of the reverse transcriptase disrupted this interaction. However, when virus grown in 
the presence of HA-hA3A[27WVS29] was used to inoculate target cells, we observed a significant 
decrease in the levels of early (R-U5) and late (U5-gag) reverse transcriptase products. Since the 
RT activity of virus grown in the presence of HA-hA3A[27WVS29] was not significantly 
decreased, it suggests that HA-hA3A[27WVS29] may interact with the viral RNA to decrease 
levels of early and late RT products. This would explain the deaminase-independent restriction 
by HA-hA3A[27WVS29]. Previous studies have shown that hA3A binds to longer RNA templates 
(40 nucleotides) at a slightly higher binding affinity than single stranded DNA (Byeon et al., 
2013; Mitra et al., 2014) and it is possible that the insertion into HA-hA3A[27WVS29] may slight 
alter its structure to permit better binding to regions of the viral RNA. 
 
Materials and Methods 
Pulse-chase analysis of viral proteins in the presence of hA3 proteins 
                 293 cells were transfected with a plasmid conatining the HIV-1 NL4–3 genome 
(pNL4–3) and empty pcDNA3.1(＋) vector or expressing either HA-hA3A or HA-
hA3A[27WVS29]. At 48h post- transfection, the medium was removed and cells were incubated 
in methionine/cysteine-free medium for 2h. The cells were then radiolabeled with 500 mCi of 
35S-Translabel (methionine and cysteine, MP Biomedical) for 30 min. The radiolabel was 
chased in DMEM containing 100X unlabeled methionine/cysteine medium for 0, 3 and 6 h. HIV-
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1 proteins were immunoprecipitated using a monkey anti-SHIV antibody and a monoclonal 
antibody against p24 (#24-4 from the NIH AIDS Reagent Program; Fouchier et al., 1997; Simon 
et al., 1997) and immunoprecipitates collected on protein A-Sepharose beads. The beads were 
washed three times with 1X radioimmunoprecipitation buffer (RIPA: (50 mM TrisHCl, pH 7.5; 
50 mM NaCl; 0.5% deoxycholate; 0.2% SDS; 10 mM EDTA), and the samples resuspended in 
sample reducing buffer. The samples were boiled, proteins separated by SDS-PAGE (12% gel), 
and proteins visualized using standard autoradiographic techniques. 
 
Subcellular localization of hA3 proteins 
                 For intracellular localization of A3A proteins, 293 cells were plated onto 13 mm cover 
slips in a 6 well plate and transiently co-transfected with vectors expressing HA-A3A, 
hA3A[27WVS29] or hA3G using a polyethylenimine (PEI) transfection reagent (ExGenTM 500, 
MBI Fermentas) according to the manufacturer's instructions. Cultures were maintained for 48h, 
the medium re- moved, washed in PBS (pH 7.4) and fixed in 4% paraformaldehyde (prepared in 
PBS) for 15 min. Cover slips were washed in PBS, permeabilized in 2% Triton-X-100, and 
incubated in PBS containing 5% BSA. The coverslips were washed and incubated with a mouse 
monoclonal antibody against the HA-tag conjugated to FITC. (Abcam AB1208) for 1 h. The 
cover slips were counterstained with DAPI (1µg/ml) for 5 min, washed and mounted in glycerol 
containing mounting media (Slowfade antifade solution A, Invitrogen). The cover slips were 
examined using a Leica TCS SPE Confocal Microscope confocal microscope using a 63 
objective with a 2 digital zoom using the Leica Application Suite X (LAS X, LASX) software 
package. A 488 nm filter was used to visualize the FITC and a 405 filter used to visualize the 
DAPI staining. 
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Detection of hA3A[27WVS29] in virus particles 
                 To determine if hA3A[27WVS29] was incorporated into virus particles at higher levels 
than hA3A, 293 cells were transfected with a plasmid with the HIV-1 NL4–3 genome or one 
lacking a functional Vif (HIV-1Δvif) and either the pcDNA3.1(+) as the empty vector control or 
pcDNA3.1(+) expressing HA-hA3A, HA- hA3A[27WVS29], or HA-hA3G. At 36h, the cells were 
starved for methionine/cystine for 2h and radiolabeled with 35S-methionine/ cystine for 16h. At 
48h post-transfection, the culture medium was harvested, cell debris removed by low speed 
centrifugation at 1,200 rpm for 10 min. The virus containing supernatant was layered onto a 20% 
sucrose cushion and subjected to ultracentrifugation at 30,000 rpm (SW55Ti rotor, 109,000 g) 
for 2 h. The virus pellet was resuspended in PBS, pH 7.4 and viral p24 was immunoprecipitated 
from the viral pellets using an anti-p24 antibody and immunoprecipitates collected on protein A 
Sepharose. The levels of p24 were normalized and the levels of HA-A3 proteins 
immunoprecipitated using an anti-HA antibody, boiled in sample reducing buffer and separated 
by SDS-PAGE and visualized by standard autoradiography. 
 
Analysis of cytidine deamination by A3 proteins 
                 Previous studies have shown that hA3A did not significantly introduce G-to-A 
mutations into HIV-1Δvif. We determined if hA3A[27WVS29] could introduce G-to-A mutations 
into the HIV- 1Δvif genome. For hypermutation analysis, 293 cells were transfected with empty 
pcDNA3.1(+) vector or pcDNA3.1(+) expressing HA-hA3A, HA-hA3G or HA-
hA3A[27WVS29], and a vector with the HIV-1 or HIV-1Δvif genome. After 48h, the supernatant 
containing virus was subjected to low speed centrifugation. The resulting supernatant was DNase 
I-treated (Fermentas) at 370C for 30 min to eliminate any trace of plasmid carry-over from the in- 
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itial transfection. The DNase-I-treated supernatant was titrated on TZM-bl cells to assess both 
infectivity and hypermutation. Twenty-four hours post-infection, total DNA cellular DNA was 
harvested and extracted using the DNeasy kit and the manufacturer's instructions (Qiagen). The 
DNA was used in a DNA polymerase chain reaction to amplify a 480 base pair fragment of nef. 
The PCR reaction was carried out using rTaq, the manufacturer's instructions (Takara). The PCR 
reactions were performed using an Applied Systems 7500 Thermal Cycler with the following 
thermal profile: 95 0C for 2 min, 1 cycle; 95 0C for 30 s, 48 0C for 30 s, 65 0C for 2 min, 35 
cycles; 65 0C for 7 min. The PCR products were separated on a 1% agarose gel, isolated from the 
gel and the products from five reactions were pooled. The purified products were cloned into 
pGEM-T Easy vector and the inserts sequenced. The frequency of mutations were determined in 
the negative controls (pcDNA3.1(+) vector plus pNL4–3 and pcDNA3.1(+) vector plus pNL4–
3Δvif) and positive controls (HA-hA3G plus pNL4–3Δvif) and compared with hA3A and 
hA3A[27WVS29]. The flow path of hypermutation assay is shown in figure 66. 
 
Assessment of HIV-1 protein synthesis in target cells 
                 To assess/visualize the production and maturation of the progeny virions in the 
presence of hA3A[27WVS29], we used 35S-methionine/cysteine to radioactively label all proteins 
and immunoprecipitate viral proteins using an antiviral protein antibody cocktail that includes 
anti-SHIV serum, an anti-p24 monoclonal antibody, and an anti-env monoclonal antibody. 293 
cells were co-transfected with various APOBEC3 plasmids and pNL4-3. At 48h post-
transfection, the culture medium containing viruses was collected and incubated with 20% 
polyethylene glycol (PEG) overnight at 4oC. The next day, the mixture was spun at 18,000Xg for 
20 min, the viruses were re-suspended in FBS-free media. The concentrated virus preparation 
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was used to infect target cells for 48 h. Then, the media were removed, and target cells were 
starved in methionine/cysteine-free media for 2 h. The cells were then radiolabeled with 500 µCi 
of 35S-methionine/cysteine for 16 h. Viral proteins in both the supernatant and cell lysate were 
immunoprecipitated using the antiviral protein antibody cocktail for 18 h. The beads were 
washed three times and resuspended in same amount of the reducing sample buffer. The samples 
were run on SDS-PAGE and visualized autoradiographically. 
 
Assessment of viral transcripts in the presence of HA-hA3A[27WVS29] 
                 As shown in figure 67, to detect the viral transcripts level in the presence of HA-
hA3A[27WVS29], we will quantify the amount of early transcript (Rev) and later transcript (Gag) 
in target cells. 293 cells were co-transfected with either the empty pcDNA3.1 (+) vector or 
hA3A, hA3A[27WVS29] and pNL4-3 (a plasmid containing the intact HIV-1 genome). At 48 h, 
the culture supernatant was harvested and the virus containing supernatant was used to infect 
TZM-bl cells for 48 h. Total RNA was extracted and subjected to qRT-PCR with either Rev or 
Gag primers and probe. 
 
Assessment of integration in the presence of HA-hA3A[27WVS29] 
                 To determine if HA-hA3A[27WVS29]  interfered with viral genome integration, we 
employed two different assays. The first assay detected the presence of 2-LTR circles, which 
occurs at a higher frequency when integration is unsuccessful (Butler et al., 2001). To quantify 
the levels of 2-LTR circles, 293 cells were transfected with either the empty vector 
(pcDNA3.1(+)) or the vector expressing HA-hA3A[27WVS29]. At 24 h, equal infectious units of 







Figure 66. APOBEC3 hypermutation assay. 293 were co-transfected with the pNL4-3Δ vif 
genome and with the empty pcDNA3.1(+) vector or one expressing the APOBEC protein. Virus 
in the culture medium was collected and used to inoculate susceptible target cells. At 48 h, the 
DNA was extracted and PCR performed using nef primers. A3G, which is known to cause 





















Figure 67. The flowchat for detection of RNA transcripts in target cells. 293 cells were co-
transfected with the empty pcDNA3.1(+) vector or expressing various A3A protein, and HIV-1. 
At 48 h post-transfection, supernatants were collected and used to infect TZM-bl cells for 48 h. 
Total RNA was extracted and level of early transcript (Rev) and late transcript (Gag) are 













purified using DNeasy Blood & Tissue Kit from Qiagen. The 2- LTR circle levels were detected 
as previously described (Butler, Hansen, & Bushman, 2001). Real-time PCR was performed 
using the following oligonucleotide primers: 2-LTR circle forward, MH535: 5’-AAC- 
TAGGGAACCCACTGCTTAAG-3’; 2-LTR circle reverse, ES2448 (based on MH536): 5’ -
TCCACAGATCAAGGATCTCTTGTC-3’; and 2-LTR probe, MH603: 5’-(FAM)-
ACACTACTTGAAGCACTCAAGGCAAGCTTT-(TAM)-3’. A standard curve of the 
amplification being measured was run ranging from 10 to 1X1011 copies. Reactions containing 
1X premix (Takara), 0.5 µM forward primer, 0.5 µM reverse primer, 0.25 µM probe and 1X 
RoxDyeII in a 20ul volume. The thermal cycle is 95 0C for 30 s, followed by 40 cycles of 
amplification at 5s at 95 0C and 34s at 60 0C. 
                 In addition, we assessed the level of integration was by amplification Alu repeat/gag 
sequences. The oligonucleotides used for detecting Alu-gag products were: (a) Alu-gag forward 
oligonucleotide primer, MH535 (above); (b) Alu-gag reverse oligonucleotide primer: SB704: 5’-
TGCTGGGATTACAGGCGTGAG-3’. One microlitre of sample from first round regular PCR 
and subject to real-time PCR with R/U5 primers (forward primer: M667-5’-
GGCTAACTAGGGAACCCACTGC-3’; reverse primer: AA55-5’-CTGCTAGAGATT 
TTCCACACTGAC-3’) and probe (HIV FAM-5’-TAGTGTGTGCCCGTCTGTTGTGTGAC-3’-
TAM) (Suzuki et al., 2003). With each experiment, a standard curve of the amplicon being 
measured was run in duplicate ranging from 10 to 1 1011 copies plus a no-template control. 
Reactions contained 1 premix (Takara), 0.5 µM forward primer, 0.5 µM reverse primer, 0.25 µM 
probe primer and 100– 500 ng of template DNA and 1 RoxDyeII in a 20 µl volume. After initial 
incubations of 95 0C for 30 s, 40 cycles of amplification were carried out at 5 s at 95 0C, 34 s at 
60 0C. Reactions were analyzed using the ABI Prism 7500 sequence detection system (PE-
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Applied Biosystems, Foster City, California). The procedure of integration assay is shown in 
figure 68 and the two step PCR for quantification of Alu-gag is shown in figure 69 . 
 
Reverse transcriptase (RT) activity in viruses was measured by a reverse transcriptase 
colorimetric kit 
                 A reverse transcriptase colorimetric kit (Roche, USA) was used to measure the RT 
enzyme activity of progeny viruses from producer cells. Briefly, 293 cells were cotransfected 
with a plasmid with the NL4–3 genome (pNL4–3) and either the empty pcDNA3.1(+) vector or 
vectors expressing either HA-hA3A, HA-hA3G, or HA-hA3A[27WVS29]. At 48 h, the viral  
culture medium was collected, centrifuged at low speed to removed cellular debris and the virus 
containing supernatants layered onto a 20% sucrose cushion. The virus was pelleted for 2h at  
35,000 rpm (SW41 rotor, Beckman). The virus pellets were resuspended in PBS (pH 7.4) and 
p24 levels determined and equivalent levels of p24 were used in RT assays according to 
manufacturer's instructions. The relative RT activity was plotted with the pcDNA3.1(+) control 
set at 100% activity. The Test principle of in vitro RT activity is shown in figure 70 and the 
procedure is described in figure 71. 
 
Assessment of reverse transcription in the presence of HA-A3 proteins 
                 In order to assess whether incorporation of HA-hA3A [27WVS29] would block virion 
reverse transcriptase, 293 cells in 60 mm dishes were co-transfected with vector pNL4–3 and the 
empty pcDNA3.1(+) vector or one expressing either HA-hA3A, HA-hA3G, or HA-
hA3A[27WVS29]. The virus containing culture medium was harvested at 48 h post-transfection, 









Figure 68. Flowchat for detection of viral integration level in target cells. 293  cells were co-
transfected with various A3A protein or pcDNA3.1(+) as control, and HIV-1Δenv and VSV-G. 
At 48 h post-transfection, supernatants were collected and used to inoculate 293 cells for 48h. 





















Figure 69. Alu-gag nested PCR coupled with quantitative real time PCR for Quantitation. In the 
first step, PCR is performed with primers sets that flank the Alu sequence and the HIV structural 
gene gag to amplify the integrated form of HIV-1 gene sequence. In the second round of qPCR, 













Figure 69    Alu-gag nested PCR coupled with quantitative real time PCR for Quantitation 
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sucrose cushion at 35,000 rpm (Beckman SW41 rotor, 210,000 g) for 2 h. The virus containing 
pellet was resuspended in PBS (pH 7.4) and the p24 levels determined. Using equivalent 
amounts of p24, reverse transcriptase activity was determined using the Roche colorimetric 
Reverse Transcriptase Assay kit according to the manufacturer's instructions. The reverse 
transcriptase activity was plotted with the RT activity of the pcDNA3.1(+)/NL4–3 virus set at 
100%. For these experiments, 293 cells were transfected with plasmid with the pNL4–3 genome 
and either the empty pcDNA3.1(+) vector or vectors expressing HA-hA3A, HA-hA3G, or HA-
hA3A[27WVS29]. At 48 h the virus stocks were harvested and the p24 levels in stocks 
determined. Using equivalent levels of p24, viruses were used to inoculate C8166 cells for 24 h. 
Total cellular DNA was purified using DNeasy Blood & Tissue Kit from Qiagen. The R/U5 and 
U5/Gag levels were detected as previously described (Suzuki et al., 2003). Real-time PCR was 
performed using the following oligonucleotide primers: for R/U5, forward primer: M667-5’-
GGCTAACTAGGGAACCCACTGC-3’; reverse primer: AA55-5’ 
CTGCTAGAGATTTTCCACACTGAC-3’) and probe (HIV FAM-5’- 
TAGTGTGTGCCCGTCTGTTGTGTGAC-TAM; for U5/gag, forward primer: LG564-
5’CCGTCTGTTGTGTGACTCTGGT-3’ reverse primer: LG699-
5’GAGTCCTGCGTCGAGAGATCT-3’ and probe: LG-FAM-5’- (FAM)-
CCCGAACAGGGACTTGAAAGCGAA-(TAMRA)-3’. For β-actin, forward primer: ES2474-  
5’CTGGCATCGTGATGGACTCC-3’; reverse primer: ES2476-5′GGAGCTGGAAGCAGCCG-
3’ and β-actin probe: 5’ (6FAM)GATCCTCACCGAGCGC-(TAMRA)-3’. A standard curve of 
the amplification being measured was run ranging from 1 to 1 1011 copies. Reactions containing 
1x premix (Takara), 0.5 µM forward primer, 0.5µM reverse primer, 250 nM probe and 1X 








Figure 70. The principle behind detection of in vitro RT activity. The microplate is precoated 
with streptavidin. The biotin-labeled DNA then is bound to the streptavidin on the plate. Next, an 
antibody to digoxigenin, conjugated to peroxidase (anti-DIG-POD), is bound to the digoxigenin-
labeled DNA. Finally, the peroxidase substrate ABTS is added and catalyzes the cleavage of the 
substrate, resulting in a colored reaction. The absorbance of the reaction is determined by a 


















Figure 71. Procedure for preparation of virus for in vitro RT assay. 293 cells were co-transfected 
with a plasmid with the HIV-1 (pNL4–3) and either the empty pcDNA3.1(+) vector or vectors 
expressing either HA-hA3A, HA-hA3G, or HA-hA3A[27WVS29]. At 48 h, the viral culture 
medium was collected, centrifuged at low speed to removed cellular debris and the virus 
containing supernatants layered onto a 20% sucrose cushion. The virus was pelleted for 2 h at 
35,000 rpm (SW41 rotor, Beckman). The virus pellets were resuspended in PBS (pH 7.4) and 














amplification at 5 s at 95 °C and 34 s at 60 °C. Reactions were analyzed using the 7500 Real 
Time PCR System (ABI). The experiment was repeated three times, the mean determined, and 
the results plotted as the percent product with the pcDNA3.1(+)/NL4– 3 control set at 100%. The 














Figure 72. Reverse transcription in target cell. 293 cells were transfected with plasmid with the 
pNL4–3 genome and either the empty pcDNA3.1( þ ) vector or vectors expressing HA-hA3A, 
HA-hA3G, or HA-hA3A [27WVS29]. At 48 h the virus stocks were harvested and the p24 levels 
in stocks determined. Using equivalent levels of p24, viruses were used to inoculate C8166 cells 
for 24 h. Total cellular DNA was purified using DNeasy Blood & Tissue Kit from Qiagen. The 













Chapter VI : Conclusions  
                 HIV-1 is the causative agent of AIDS, which causes depletion of CD4+ T cells 
and profound immunodeficiency in infected humans. Current therapy focuses on drugs in 
HAART (highly active antiretroviral therapy) or cART (combined antiretroviral therapy), 
which was introduced in 1996. The introduction of HAART therapy has changed HIV-1 
infection from a fatal disease into a chronic disease. However, current therapies focusing 
on antiretroviral drugs suffers from the rapid emergence of resistant viral strains resulting 
from high mutation rate during reverse transcription and the fact that these drugs do not 
eradicate viral reservoirs from the body. Thus, novel treatment strategies are needed to 
eliminate these viral reservoirs and eventually eliminate AIDS. 
                 Recent efforts aimed at enhancing the activity of innate host factors are 
promising. Currently known host restriction factors against HIV-1 include tripartite 
motif-containing protein 5 alpha isoform (TRIM5α), bone marrow stromal antigen 2 
(BST-2), sterile alpha motif (SAM) and histidine-aspartic domain (HD) containing 
protein 1 (SAMHD1), and apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3 (APOBEC3). These restriction factors have been shown to exhibit a 
positive selection signature (Laguette et al., 2012; Ortiz et al., 2009). The human 
APOBEC3 family is comprised of seven members that includes hA3A, hA3B, hA3C, 
hA3D, hA3F, hA3G, hA3H that are tandemly arranged on chromosome 22 (Jarmuz et al., 
2002). They are cytidine deaminases that restrict various retroviruses, other viruses and 
the transposition of endogenous retroelements. Human A3G was the first identified hA3 
protein that restricted HIV-1Δvif by both deaminase-dependent and independent 
mechanisms (Chiu & Greene, 2009). However, HIV-1 circumvents the restriction of A3 
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proteins by encoding for a Vif protein that binds to certain A3 proteins and shunts them 
to the proteasome for degradation. Human A3A (hA3A) is generally expressed in 
myeloid cells such as monocyte-derived macrophages (MDM) and monocyte-derived 
dendritic cells (MDDC). The expression of A3A in these cells is boosted in response to 
type I interferon, which suggests that hA3A might be a important player in the antiviral 
response (Berger et al., 2011). While hA3A has little activity against HIV-1, it can 
restrict many other viruses including parvoviruses, adeno-associated virus (AAV), minute 
virus of mice (MVM), papillomavirus, human T-lymphotropic virus type I (HTLV-1) and 
some endogenous retroelements (H. Chen et al., 2006; Kinomoto et al., 2007; Kondo et 
al., 2016; Narvaiza et al., 2009; Ooms et al., 2012) Select A3 genes (A3B, A3D, A3F, 
A3G, and A3H) have also undergone positive selection (Cagliani et al., 2011; Ortiz et al., 
2009; Sawyer, Emerman, & Malik, 2004). In contrast, A3A was shown to be under 
purifying selection, consistent with the notion that it may not have played a significant 
role in retrovirus restriction (Sawyer et al., 2004). However, our group and in a recent 
study have indicated that A3A genes have evolved rapidly under diversifying selection in 
primates. (McLaughlin et al., 2016; Wang, Schmitt, et al., 2016; Wang, Wang, et al., 
2016). The Malik/ Emerman groups found that this rapid evolution has not been driven 
by long interspersed elements-1 (LINE-1) but rather through the gain of antiviral 
specificity against other pathogens. We concur with this conclusion as our follow-up 
experiments on LINE-1 (Schmitt et al., 2011) did not reveal a substantial difference (2-
fold or less) in the anti-LINE-1 restriction activity of rhesus macaque A3A versus human 
A3A.  
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                 While HIV-1 infection of humans leads to massive CD4+ T cell loss and 
collapse of immune system, many Old World monkeys are naturally infected with simian 
immunodeficiency viruses and maintained high plasma viremia but do not develop 
disease. The interaction between host proteins and pathogens may leave positive-
selection signature on host proteins. Previous work from our laboratory revealed the A3A 
protein from rhesus macaques restricted SHIVΔvif (Schmitt et al., 2011). The purpose of 
my research was to determine why rhA3A could restrict SHIVΔvif and why the hA3A 
could not restrict HIVΔvif. 
                 The sequence of human A3A (hA3A) and rhesus macaque A3A (rhA3A) have 
approximately 81% identity at the amino acid level. Studies have shown that human A3A 
(hA3A) lacks activity against HIV-1Δvif activity. However, we previously showed that 
rhA3A potently restricted the replication of SHIVΔvif and HIV-1Δvif to a much greater 
extent than hA3A (hA3A generally doesn’t restriction HIV-1 or HIV-1Δvif) (Schmitt et 
al., 2011). Since the rhA3A had a different restriction pattern than hA3A, it raised the 
possibility that A3A from other Old World monkeys might also restrict primate 
lentiviruses. Additional experiments with two other Old World monkey (OWM) A3A 
proteins from the African Green monkey A3A (agmA3A), colobus monkey A3A 
(colA3A), and another hominid A3A (gibA3A) confirmed that OWM A3A proteins 
restricted SHIV Δvif and HIV-1 Δvif more potently than hominid A3A proteins. Notably, 
colA3A not only restrict SHIVΔvif and HIVΔvif, but also restricted wild type HIV-1 
(expressing intact Vif proteins). We also determined if the A3A proteins from other 
OWM species also restricted HIV-1 in producer cells and if we could modify the hA3A 
protein with a few amino acid substitutions mimicking to potently inhibit HIV-1. 
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Analysis of amino acids sequence from hA3A and colA3A revealed significant 
variability in N-terminal domain sequences, especially within the AC (Active Center) 
loop 1 region located near the N-terminus. AC loop 1 region is responsible for substrate 
binding (AC loop 1 is also known as recognition loop 1, or RL1). Additional support for 
the importance of this region in restriction has come from a recent study using 
oligonucleotide substrates with a single deamination site (Logue et al., 2014). These 
investigators found that A3A preferentially deaminated at TC followed by an A or G 
residue. Further, using chimeric hA3A/hA3G proteins these investigators found that 
amino acids GI25-26 of AC-Loop 1 region of hA3A (referred to as the recognition loop 
1; RL1) specified the 5’ nucleotide of the recognition motif and that a chimeric 
A3A/A3G with the RL1 of A3G was more flexible with respect to the 5’ nucleotide (AC, 
CC, GC all used with equal frequency) (Logue et al., 2014). To test the hypothesis that 
AC loop 1 region was important in retrovirus restriction, we analyzed the A3A sequences 
of other OWM with AC Loop1 sequences similar to colA3A (25KPWVSGQRE33). We 
found that the A3A proteins from both Cercopithecus neglectus (debA3A; 
25KPWVSGQRE33) and Mandrillus sphinx (mndA3A; 25KLWVSGQHE33) were identical 
or nearly identical to colA3A in this region. We observed that both mndA3A and 
debA3A not only restrict the replication of HIV-1Δvif but also intact HIV-1, with 
mndA3A consistently being more restrictive than colA3A and debA3A. The restriction of 
HIV-1 by these A3A proteins appears to be specific since mndA3A did not restrict Friend 
MuLV, gammaretrovirus. The Old World monkeys (Family Cercopithecidae) are 
composed of two subfamilies (Cercopithecinae and Colobinae). The Cercopithecinae are 
further classified into two tribes, the Cercopithecini, and the Papionini. The Colobiniae 
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are generally classified into the African and Asian colobines. Our findings indicate that 
restriction of wild type HIV-1 by A3A is represented by species in two tribes of the 
Cercopithecinae (Cercopithecini, debA3A; and Papionini, mndA3A) and by the African 
group of the Colobinae. These results also reinforced our previous findings that the 
sequence of the AC Loop1 region was critical for restriction of wild type HIV-1 by 
OWM A3A proteins. Notably, while these three monkey species express an A3A that 
restricts HIV-1, all three monkeys are known to harbor endemic SIV infections (SIVcol, 
SIVmnd, and SIVdeb) (Courgnaud et al., 2001; Souquiere et al., 2001; Bibollet-Ruche et 
al., 2004).  
                 In a recent study, investigators found that the sequences of the colobus 
monkey, mandrill and DeBrazza's monkey were most likely an artifacts of the 
oligonucleotides used in the PCR process and likely an exon of colA3G (the 
oligonucleotides primers also matched the intronic sequence on either side of exon 5 of 
A3G (Henry et al., 2012). Thus, it is likely that the studies with the colA3A were most 
likely a colA3A/G chimeric protein (McLaughlin et al., 2016). The actual colA3A of the 
colobus monkey doesn’t contain the WVS motif in the AC loop 1 gene. Although the 
correct A3A sequence for mandrill and De Brazza’s monkey were not examined, it is 
very possible that the mndA3A and debA3A we used are also mndA3A/G and debA3A/G 
chimeras. Investigators have used the correct sequence of colA3A and observed no 
restriction of HIV-1. While unexpected, this error provided clues to the amino acid 
determinants necessary for restriction of HIV-1. Moreover, it led us to identify two 
additional monkey A3A and A3G chimeras (mndA3A/G, and debA3A/G) that possessed 
similar restriction capacities towards HIV-1. It is amazing that this unexpected artifact 
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led to a unique finding that the AC loop 1, especially the WVS motif, was critical in 
restoring hA3A’s antiviral activity.  
                 We previously used a chimeric protein approach to show that substitution of 
AC loop 1 of hA3A with that of rhA3A restored the ability to hA3A to restrict HIV-1Δvif 
(Schmitt et al., 2013). We hypothesized that the three amino acid insertion in AC loop 1 
of rhA3A could result in a AC-Loop1 with a greater molecular surface compared to 
hA3A. Due to its predicted solvent-accessibility, this additional molecular surface may be 
an important region for protein–protein interactions (Schmitt et al., 2013). Next, we took 
advantage of chimeric protein approach and hypothesized that the amino acids within the 
N-terminal domain (i.e. the first 100 amino acids) which include the AC Loop-1 region of 
colA3A/G were likely involved in the restriction of HIV-1. 
                 We first asked whether the N-terminal, C-terminal or both were essential for 
retaining the restriction. Both hA3A and colA3A/G contains approximately 200 amino 
acids in length. Thus, we constructed chimeras that either have the first 100 amino acids 
of hA3A and the last 100 amino acids of colA3A (h1-100colA3A), or the first 100 amino 
acids of colA3A and the last 100 amino acids of hA3A (col1–100hA3A). By comparing the 
restrictive abilities of h1-100colA3A and col1–100hA3A with wild type hA3A and colA3A, 
we could speculate the relative importance of the N-terminal and C-terminal. If the 
restriction determinants were in the N-terminal region, then the h1-100colA3A should 
behave similarly to hA3A (no restriction towards HIV-1), and col1–100hA3A should act 
like colA3A/G (strong restriction towards HIV-1). Conversely, if the restriction 
determinant lies completely in the C-terminal region, then the h1-100colA3A should 
behave similarly to colA3A (strong restriction towards HIV-1), and col1–100hA3A should 
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act like hA3A (no restriction towards HIV-1). If both N-terminal and C-terminal of A3A 
proteins contributed to restriction of HIV-1, then both chimeric proteins (h1-100colA3A 
and col1–100hA3A) should restrict HIV-1 at levels higher than hA3A and lower than 
colA3A/G. The result of our restriction assays showed that col1–100hA3A restricted at 
levels similar to full length colA3A/G while h1-100colA3A did not restrict HIV-1. This 
revealed that the first 100 amino acids in the N-terminal contain the key determinants for 
HIV-1 restriction. In addition, to further confirm this conclusion, we truncated the C-
terminal off from all three OWM A3As that possess anti-HIV-1 activity. All three 
truncated A3A proteins (colA3A1–100, mndA3A1–100, and debA3A1–100) retained the 
restrictive ability similar to the full-length A3A proteins. These results represent the first 
demonstration that a single deaminase A3 protein could be significantly truncated (i.e., 
50%) without loss of restriction activity and further support the idea that N-terminal 
region of colA3A, mndA3A and debA3A had the determinants for HIV-1 restriction 
(Katuwal et al., 2014). 
                 Although we determined that the first half (N-terminal) was the key to HIV-1 
restriction, we want to further determine if we could narrow down the amino acids in 
colA3A/G that were required for restriction. Next, we constructed chimeras with the first 
75, 50, 33 amino acids from colA3A/G fused to hA3A resulting in three additional 
chimeric proteins: col1–75hA3A, col1–50hA3A, col1–33hA3A. Our results indicated that 
col1–75hA3A, col1–50hA3A, col1–33hA3A restricted HIV-1, although not at the same level 
as col1–100hA3A. Additionally, we showed that the introduction of the AC-Loop1 region 
from mndA3A into hA3A (a total of six amino acid substitutions/insertions; now 
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designated as HA-hA3A [25KLWVSGQHE33]) resulted in a protein gained the ability to 
restrict HIV-1 (Katuwal et al., 2014).  
                 This confirmed our hypothesis that AC loop 1 region in the N-terminal of A3A 
was the key determinants of HIV-1 restriction. Since the OWM A3A that restricted HIV-
1 (colA3A/G, mndA3A/G, and debA3A/G) contained WVS at this site, we introduced 
27WVS29 motif into hA3A (hA3A[27WVS29]). By insertion of these three amino acids, we 
were able to enable hA3A to restrict both HIV-1Δvif and HIV-1. While HA-
hA3A[27WVS29] restricted HIV-1, restriction appeared to occur through a different 
mechanism than with HA- hA3A[25KLWVSGQHE33] as the latter significantly reduced 
the levels of viral p24 released from cells compared to cultures transfected with HA-
hA3A,HA-hA3G, and HA-hA3A[27WVS29].  
                 We next explored the importance of each of the three amino acids in the 
27WVS29 motif in HIV-1 restriction. We first substituted each amino acid in the WVS 
motif with the ones owing differing charge and polarity, resulting in hA3A[27FVS29], 
hA3A[27YVS29], hA3A[27HVS29], hA3A[27WLS29] hA3A[27WTS29], hA3A[27WDS29], 
hA3A[27WVT29], hA3A[27WVA29], and hA3A[27WVD29]. We found that all single amino 
acid substitutions retained the ability to restrict HIV-1 to some level. The results 
indicated that the nature of the amino acids in the 27WVS29 motif did not appear to be 
important. To investigate the role of the length of the motif, we deleted either one or two 
of the amino acids in the WVS motif, resulting in hA3A[28VS29], hA3A[27WS29], 
hA3A[27WV28], hA3A[W27], hA3A[V28], and hA3A[S29]. While deletion of one amino 
acid still resulted in restriction of HIV-1, deletion of two amino acids resulted in 
restriction that was not statistically significant when compared to hA3A. Taken together, 
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these results indicate that the length and not necessarily the nature of the amino acid was 
most important for defining HIV-1 restriction. Our results indicated that substitution of 
one amino acid of the WVS motif with either a conservative, non-conservative or charged 
amino acid was inconsequential in the restriction of HIV-1. In the final two constructs, 
we substituted the 27WVS29 with 27AAA29 or 27GGG29. Similar to our other amino acid 
substitutions, these constructs also restricted HIV-1. These results confirmed that the 
nature of the amino acids in this region did not seem to be critical for HIV-1 restriction.  
                 Next, we explored the mechanism through which hA3A[27WVS29] restricted 
HIV-1. Deciphering the mechanism of hA3A[27WVS29] restriction could be instrumental 
in designing novel antiviral strategies against HIV- 1. As our restriction assays showed 
that the infectivity of virions produced from hA3A[27WVS29] transfected cells were 
decreased as evidenced titers in TZM.b1 cells, the level of Gag released from cells were 
not significantly lowered using ELISA p24 antigen caption/WB. Thus, in the presence of 
hA3A[27WVS29], the virions were successfully released but were impaired for replication 
in the next round of infection. This suggested that the site of restriction was likely in the 
target cells. Additional evidence comes from our results from pulse-chase experiments 
that indicated that viral protein synthesis and processing was similar in producer cells 
transfected with vectors expressing HA-hA3A or HA-hA3A[27WVS29]. We further 
showed that HA- hA3A and HA-hA3A[27WVS29] both had a nucleocytoplasmic 
localization in producer cells. Therefore, the cellular localization wasn’t responsible for 
the divergence in restriction capacities of HA- hA3A and HA-hA3A[27WVS29]. 
                 We also examined several parameters on the virus released from the producer 
cells. We determined if the RNA packaged into virions was decreased. Our results 
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indicate the presence of HA-hA3A[27WVS29] did not affect RNA packaging. We also 
analyzed the activity of reverse transcriptase (RT) in the progeny virions using an 
exogenous template. Our results indicate that RT activity was similar for HA-hA3A, HA-
hA3A[27WVS29], and HA-hA3G. These results suggest that incorporated HA-
hA3A[27WVS29] did not directly interact with reverse transcriptase to block its activity. 
Alternatively, it is also possible that HA-hA3A[27WVS29] may interact weakly with the 
reverse transcriptase but that the conditions of the reverse transcriptase assay disrupted 
this interaction.  
                 We next focused on target cells to explore the inhibition mechanism involved. 
First we excluded the possibility of hA3A[27WVS29] restricts viral replication through 
canonical hypermutation pathway. As the truncation disrupted the Z domain of this 
protein, it indicated that deamination is not required for colA3A or mndA3A restriction 
of HIV-1 (Katuwal et al., 2014). Furthermore, our hypermutation experiment confirmed 
that HA-hA3A[27WVS29] did not cause cytidine hypermutation of the HIV-1 nef gene.  
                 However, when virus grown in the presence of HA-hA3A[27WVS29] was used 
to inoculate target cells, we observed a significant decrease in the levels of early (R-U5) 
and late (U5-gag) reverse transcriptase products. Since the RT activity of virus grown in 
the presence of HA-hA3A[27WVS29] was not significantly decreased, it suggests that HA-
hA3A[27WVS29] may interact with the viral RNA to decrease levels of early and late RT 
products. This would explain the deaminase-independent restriction by HA-
hA3A[27WVS29]. As a result of decreased reverse transcription in target cells, we also 
observed a subsequent decrease in integration, transcription, virion production and 
release from target cells. 
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                 In summary, our results suggested that hA3A[27WVS29] restricted viral 
replication at the level of reverse transcription in target cells. As we previously showed 
that the reverse transcriptase activity of budding virions from producer cells was not 
inhibited, it is possible that hA3A[27WVS29] may directly interfere with the interaction 
with viral RNA/DNA or tRNAlys3 in the target cells. Although we have not provided 
direct evidence disclosing the exact viral RNA/DNA sequence that is targeted by 
hA3A[27WVS29], we have previous structural and experimental data to support this 
hypothesis. Both the NMR and crystal structures of hA3A have been solved (Byeon et 
al., 2013; Bohn et al., 2015). The crystal structure of A3A-E72A-C171A, which was 
solved at 2.85 Å resolution, showed that hA3A exists as a homo-dimer (Bohn et al., 
2015). These investigators found that A3A dimerization formed a highly positive groove 
that connects the active site of both monomers. These investigators identified two sets of 
residues that might contribute to dimerization, H11/H56 and H16/K30. Substitution of 
these residues showed that both sets of interactions were critical to cooperative DNA 
binding. Our results could have implications for the structure of A3A proteins from Old 
World monkey species as K30 is part of the AC Loop 1 region and that the insertion of 
27WVS29 could possibly alter the interface and perhaps dimer formation and substrate 
binding. In a previous study, the binding efficiency of hA3A to a 40 nucleotide ssRNA 
was reported to be approximately 3-fold higher than for the corresponding 40 nt ssDNA 
(Byeon et al., 2013). More recently, it was shown that hA3A binds single stranded RNA 
(ssRNA) but no deamination of ssRNA occurs (Mitra et al., 2014). Thus, it is possible 
that hA3A[27WVS29] with its different AC-loop-1 region may have a slight change in its 
structure to permit altered binding to regions of the viral RNA or DNA, therefore 
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inhibiting virus replication by interfering in the initiation of reverse transcription and 
elongation. The specific sequence of RNA was not determined but could be possibly 
located in the 5’ end of viral RNA or the newly synthesized DNA fragment (R-U5) as the 
presence of HA-hA3A[27WVS29] inhibits reverse transcription at the very early stage. 
Another possibility is that HA-hA3A[27WVS29] might have altered binding affinity with 
the primer tRNAlys3 as it is a key player in initiating reverse transcription. The possible 
model of restriction is summarized in Figure 73. 
                 In addition, human A3A has been reported to restrict autonomous parvoviruses 
and adeno-associated virus type 2 (AAV-2), papillomaviruses, and HTLV-I (Ahasan et 
al., 2015; Bulliard et al., 2011; Chen et al., 2006; Muckenfuss et al., 2006; Narvaiza et al., 
2009; Ooms et al., 2012; Vartanian et al., 2008; Warren et al., 2015). Human A3A 
restricts AAV-2 DNA replication and was initially thought to be due to cytidine 
deamination since an E72A mutant of hA3A did not restrict AAV-2 replication (Chen et 
al., 2006). However, a subsequent study found that the mechanism of restriction was 
likely deamination-independent (Narvaiza et al., 2009). More recently, we found that 
unlike hA3A, rhA3A did not restrict AAV-2 (Schmitt et al., 2011). In a previous study, 
several residues in hA3A were substituted to assess the effect on retro- transposition and 
restriction of AAV-2 (Bulliard et al., 2011). These investigators showed that substitution 
of residues such as N57, Y130, and D133 abolished AAV-2 restriction while substitution 
of residues R28, H29, or K30F had modest effects (50% to 85% restriction compared to 
unmodified hA3A) on AAV-2 restriction (Bulliard et al., 2011). These results are similar 
to our observations with HA-hA3A[27WVS29] (Wang et al., 2016), which restricted 









Figure 73. Proposed model of restriction by hA3A[27WVS29]. 1.hA3A[27WVS29] might 
have altered binding affinity for viral RNA template that prevents the binding of primer 
tRNA or initiation of RT; 2.hA3A[27WVS29] might interact with newly synthesized DNA 
and prevents the initiation & elongation of RT; 3.hA3A[27WVS29] might binds to the 













replacement of the entire AC Loop 1 region with the analogous region from mndA3A/G 
essentially abolished restriction (Wang et al., 2016). These results shown for the first time 
that the sequence (and structure) of the AC Loop1 region is crucial to hA3A-mediated 
parvovirus restriction. It also suggests that hA3A with its three amino acid indel (and 
possibly A3A proteins from other primates) may have been under positive selection to 
combat parvoviruses and perhaps DNA viruses in general. Since the available data 
indicates that hA3A does not restrict parvovirus or papillomavirus replication by cytidine 
deamination, perhaps it can interact with the single stranded DNA of these viruses or 
interact with proteins involved in DNA replication such as the NS-1 protein of AAV-2. It 
will be of interest to determine if this region is important for the restriction of human 
autonomous parvoviruses such as B-19 virus and human bocavirus (HBoV). 
                 In summary, inserting three amino acids in AC loop 1 region can either restore 
the anti-HIV-1 activity of hA3A or make it lost the ability to restrict AAV-2. These direct 
evidences confirmed that the key determinants of hA3A for retroviruses and parvoviruses 
lie in the AC loop 1 region. 
                 As we identified the minimal modification that are required for HIV-1 
restriction and constructed a powerful chimeric protein, hA3A[27WVS29], that is able to 
restrict HIV-1 replication though interfering with reverse transcription, it would be 
interesting to investigate generating a non-immunogenic hA3A (with domains involved 
in possible cytidine deamination deleted) for potential gene therapy in HIV-1 patients in 
the future studies. Current HAART therapy based on anti-retroviral drug cocktail 
improved the life expectancy of HIV-1 patients by converting AIDS from a deadly 
disease into a manageable chronic infection. However, HAART is not without its side 
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effects and can result in drug resistance in many cases. Novel therapeutic approaches 
taking advantage of natural anti-HIV restriction factors inhibiting HIV might offer some 
effective alternative and should be a booster when combined into current regimen. A 
distinguished advantage of our chimera protein hA3A[27WVS29] is that it prevents the 
initiation and completion of reverse transcription possibly through altered binding to viral 
RNA/DNA or to other essential players in the reverse transcription such as tRNA, but 
don’t directly interfere with reverse transcriptase enzymatic activity. This is very 
important because current reverse transcription drugs are either nucleoside analog 
reverse-transcriptase inhibitors (NRTIs), nucleotide analog reverse-transcriptase 
inhibitors (NtRTIs) that can prevent the growing of viral DNA chain resulting in chain 
termination, or Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) that binds to 
the catalytic groove of reverse transcriptase. The differences in inhibition mechanisms of 
hA3A[27WVS29] and current RT drugs indicate that the possibility of resistance is 
minimized if we introduced this novel hA3A[27WVS29] into current drug cocktail. 
Moreover, gene therapy is known for precision and direct therapeutic effects on its 
targets. However, cell toxicity, immunogenicity, insertional mutagenesis needs to be 
tested before introducing hA3A[27WVS29]  into infected individuals. Currently, effects on 
modifying effector cells to specifically kill HIV-1 infected cells has been evaluated in 
phase I and II clinical trials (Deeks et al., 2002; Mitsuyasu et al., 2000). Other promising 
attempts have also been made to altering susceptible cells to be resistant to HIV-1 entry 
and integration (Holt et al., 2010; Maier et al., 2013). These preliminary results from 
clinical trials and previous experiments have provided feasibility of engineering cells in 
vivo based on safety and efficacy data. It would be very encouraging if we could express 
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our chimeric protein hA3A[27WVS29] into a HIV-1 susceptible primary cells using 
lentiviral vectors and determine how it behaves in vivo.   
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